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In this dissertation I use a variety of methods to study the effect of and choice to 
use long-acting reversible contraceptives (LARCs) using data from the National Survey 
of Family Growth. Effective contraception may increase women’s welfare by allowing 
better control of the timing of fertility. However, many contraceptives rely on consistent 
use to achieve low failure rates, potentially leaving benefits of fertility control forgone 
due to user error. As LARCs do not rely on contraceptive adherence, they may be welfare 
improving through eliminating the gap between the “perfect use” and “typical use” 
failure rates. 
How much LARCs can reduce the risk of unintended pregnancies depends on the 
degree to which LARC users would have used other methods consistently and correctly, 
how sensitive the other methods would be to inconsistent use, and how long LARCs are 
used. In my first essay, I implement survival analysis techniques to analyze which 
reversible methods women used before transitioning to a long-acting method and the 
duration of LARC use. Consistent with the literature, I find that LARC use is associated 
with high continuation rates. I also find that contraceptive spells of methods that are more 
sensitive to inconsistent use are not at a greater risk of ending due to switching into 
LARC use, which may dampen the effect of increased LARC use on pregnancies among 
contracepting women. 
 
 
 
 
Evaluating the additional effectiveness of using a LARC compared to other 
methods on pregnancy is difficult as women may select into LARC use due to their risk 
of pregnancy. In my second essay, I use an exogenous change in provider 
recommendations to get around the selection issue and evaluate the causal effect of 
LARC use on pregnancies and births using an instrumental variables approach. First, I 
show that the release of the recommendation had a differential effect for younger mothers 
of one child compared to older mothers of one child. Then using this exogenous 
variation, I find that LARC use decreases the probability of pregnancies in the current 
year, in the following year, and births in the following year compared to other methods, 
at least among young mothers who were affected by the recommendation. Using a 
correlated random coefficients model, I find evidence that women who choose LARCS 
would have been more likely to experience pregnancy in the following year. 
Finally, LARCs can only be welfare improving if women choose them over other 
alternatives. As with any product, each contraceptive can be thought of as a bundle of its 
different characteristics such as its maximum duration of use, its effectiveness, if it is 
hormonal, and if the method requires the insertion of a device. In my third essay, I use 
discrete choice models to estimate how attributes of contraceptives affect method choice. 
I find that the LARC-specific attribute of being a physical device may discourage some 
women from choosing a LARC method.  
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CHAPTER I 
INTRODUCTION 
 
 
Effective contraception has been shown to improve women’s welfare by 
increasing educational attainment, wages, and labor market attachment (Bailey & Lindo, 
2018; Bailey, 2006; Goldin & Katz, 2002). Many contraceptives rely on correct and 
consistent use for maximum effectiveness. Because individuals may make mistakes, the 
actual failure rates of contraceptives tend to be much higher than their “perfect use” 
failure rates (Trussell, 2011). Thus, due to user error, some benefits of fertility control 
may be lost. 
My dissertation contains three essays on long-acting reversible contraceptives 
(LARCs). LARCs are physical devices that are highly effective at preventing pregnancy 
for 3 to 10 years, depending on the type chosen. One of the important features of LARC 
methods is that they require little (if any) effort on the part of the woman during their 
duration of use. Thus, they reduce the probability of mistakes. If LARCs increase fertility 
control compared to other methods by removing user error, then increased use of LARCs 
may be welfare improving. 
The usefulness of LARC methods in increasing control over fertility depends on 
how long they are used, what method woman would have used otherwise, and how 
consistently she would have used the other method. The first two essays of my 
dissertation address these three factors using contraceptive histories from the National
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Survey of Family Growth. In my first essay, I use Kaplan-Meier survival probabilities 
and a discrete-time hazard model to study the duration of LARC use and a competing risk 
model to assess which reversible method spells are more at risk of ending due to 
switching to a LARC.  
It is possible that LARCs are more attractive to women who struggle to use 
contraceptive methods consistently. It is also possible that women who choose LARCs 
tend to be more cautious and would have correctly used other potentially effective 
methods had they not had access to a LARC. In my second essay, I use contraceptive 
histories from the National Survey of Family Growth to study the causal effect of LARC 
use on pregnancies and births among young mothers using exogenous variation in LARC 
use due to the release of provider recommendations.  
Finally, in order for LARCs to make a difference on the rates of unintended 
pregnancies, women need to find IUDs and implants as an attractive contraceptive option. 
As physical devices, LARCs have unique barriers to use compared to other contraceptive 
methods, such as high upfront costs, yet LARC use has grown considerably since the 
early 2000s (Kavanaugh & Jerman, 2018). Despite this growth, LARCs were still used by 
less than 16% of contracepting women between the ages of 15-49 in 2016 (Daniels & 
Abma, 2018). It is likely that the proportion of women currently using a LARC is 
influence by continued barriers to use, however it is also likely that some women do not 
choose LARCs simply because they do not like various characteristics of LARC 
methods. In my third essay, I use data from the National Survey of Family Growth and 
information on birth control prices from the literature to estimate a set of models of 
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contraceptive choice to assess how the characteristics of contraceptive methods 
(including the LARC-specific attribute of being a device) affect the likelihood that a 
woman chooses that method. 
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CHAPTER II 
WHO CHOSES LONG-ACTING REVERSIBLE CONTRACEPTION AND FOR HOW 
LONG? 
 
 
2.1 Introduction 
The United States has a relatively high rate of unintended pregnancies compared 
to other developed nations (Singh et al., 2010). It was estimated that 45% of pregnancies 
were unintended in 2011(Finer & Zolna, 2016). Such unintended fertility can be costly. 
For example, public expenditures on unplanned pregnancies in 2010 were estimated to be 
$21 billion (Sonfield & Kost, 2015). This cost does not take into the account the effect of 
mistimed fertility on women’s lifetime utility. Women who experience unintended 
pregnancies may not be able to make their preferred decisions regarding education, 
careers, or in the marriage market, which may lead to poorer economic outcomes (Bailey 
& Lindo, 2018; Bailey, 2006; Goldin & Katz, 2002). 
While over half of unintended pregnancies are due to not using a contraceptive 
method (54%), a large minority (41%) are due to inconsistent method use. Only 5% of 
unintended pregnancies occur due to a “true” failure of the contraceptive method, in 
which a correctly used method still results in pregnancy (Sonfield et al., 2014). Because 
non-adherence with contraceptive regimens accounts for such a large proportion of 
unintended pregnancies among contraceptive users, one potential avenue for 
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decreasing the rate of unplanned pregnancies is reducing the proportion of women who 
depend on methods that are sensitive to user adherence. Increasing the use of long-acting 
reversible contraceptives would accomplish this goal, as long-acting reversible 
contraceptives (or LARCs) are physical devices that do not rely on regular effort to 
maintain effectiveness (American College of Obstetricians and Gynecologists, 2015).  
Public health advocates, physicians, and professional organizations such as the 
American College of Obstetricians and Gynecologists have called for increased access to 
long-acting reversible contraceptives, which can have unique barriers compared to other 
methods and high out-of-pocket expenses (Committee on Adolescence, 2014; Foster et 
al., 2015; American College of Obstetricians and Gynecologists, 2015). Because LARCs 
can be used for multiple years, increased LARC use has the potential to provide cost-
savings despite frequently high upfront costs (Trussell et al., 2013, 2015). In a 2015 
study, Trussell et al. estimate how long a LARC would need to be used before its use 
would be considered “cost-neutral” compared to other methods, in which the calculations 
consider both the cost of the methods and their effectiveness. The authors’ estimates 
suggest that it could take 1.7 years before the cost and benefits of using LARC would be 
equal to using no method at all, or 2.1 years of LARC use to achieve cost-neutrality 
compared to other hormonal methods (Trussell et al., 2015). Switching from barrier 
methods would require an even longer duration of use to reach this point—around 3 
years. Thus, in order to consider increasing access to LARCs for the purpose of reducing 
expenditures on unintended fertility, policy makers need to consider not only the 
effectiveness of LARCs, but also the duration of LARC use. 
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There are two important factors that determine the benefits of using a LARC 
compared to other methods, at least regarding pregnancy prevention. The first is how 
long LARCs are used, and the second is what method the woman would have used 
otherwise. While the literature on the duration of LARC use has grown considerably in 
the past 20 years, there is a lack of studies using recent US data on what methods women 
were using before choosing a LARC.  
In this paper I use data from the National Survey of Family Growth to study the 
duration of LARC use and to explore what methods women were using before switching 
to a LARC method. While studying what women were using previously is not a perfect 
measure of what she would have used had she not had access to LARCs, knowing who is 
more likely to switch to a long-acting method may shine some light on the benefits of 
LARC use.  
I first estimate the Kaplan-Meier survival probabilities. Since Kaplan-Meier 
analysis does not allow for the inclusion of (many) covariates, I next estimate a 
discrete-choice hazard model with random effects. Finally, I estimate a competing risk 
model that allows me to look at the likelihood that contraceptive users exit their 
non-LARC contraceptive spells to switch to a LARC while allowing for other exits such 
as to pregnancy or sterilization.  
My results confirm that long-acting reversible methods exhibit high continuation 
rates with 77%, 65%, and nearly 54% of LARC spells continuing out to one, two, and 
three years respectively. My estimates from a discrete time hazard model of contraceptive 
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discontinuation indicate that spells of LARC use have reduced odds of discontinuation 
compared to spells of short-acting reversible contraceptive (or SARCs) use such as birth 
control pills, even after accounting for spurious duration dependence. Finally, my 
competing risk results imply that spells of contraceptive use of methods with higher 
typical use failure rates (such as barrier and traditional methods) are not at greater risk of 
ending in LARC use than spells of moderately effective SARC methods, which may 
dampen the effect of LARC use and increase the time needed to achieve cost-neutrality. 
Taken together, these results imply that long-acting reversible contraception is used 
longer than other methods. However, it is unclear if the methods are used long enough to 
offset the upfront costs of their provision for the purpose of lowering expenditures on 
pregnancies, as over one third of LARC spells are discontinued by two years of use.  
2.2 Background 
Since the early 2000s, there has been increased use of long-acting reversible 
contraceptives in the United States (Branum & Jones, 2015). Long-acting reversible 
contraception includes subdermal implants and intrauterine devices (IUD). These 
contraceptives can be used for 3 to 10 years, depending which method is chosen 
(American College of Obstetricians and Gynecologists, 2015). Over the lifespan of the 
device, LARCs offer low failure rates (>1%) without requiring frequent effort from those 
using them (American College of Obstetricians and Gynecologists, 2015; Trussell, 2011).  
The modern history of LARC use in the US began in the 1960s with the 
introduction of several IUDs to the US market (Hubacher & Cheng, 2004). By 1973, 
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close to 10% of married contracepting women reported relying on an IUD (Mosher & 
Westoff, 1982). However, factors including negative and dangerous experiences with a 
poorly designed IUD in the 1970s diminished the use of LARCs in subsequent decades, 
and use of LARCs by American women fell below 2% by 1988 and remained low until 
the 2000s (Branum & Jones, 2015; Hubacher & Cheng, 2004; Hubacher et al., 2011). It 
was not until the release of new IUDs and changes in views of professionals in the early 
2000s that LARCs began to regain traction (Hubacher et al., 2011). The proportion of 
LARC users has increased to nearly 16% of contracepting women in 2016 (Daniels & 
Abma, 2018).  
Researchers, physicians, and professional organizations have encouraged the use 
of LARCs and have advocated for the removal of barriers to LARC use (Committee on 
Adolescence, 2014; Hubacher, 2002; The American College of Obstetricians and 
Gynecologists, 2015). Some of these barriers include demand-side issues such as patient 
misinformation or a lack of knowledge and supply-side issues such as misinformation 
among providers and difficulties keeping the devices in stock (Beeson et al. 2014; Foster 
et al., 2015; Luchowski et al., 2014; Phillips & Sandhu, 2018). LARCs are also costly, 
with out-of-pocket expenses up to $1,000 (Planned Parenthood, n.d.). However, when 
considering these costs spread out over the lifespan of LARCs, LARCs can be less 
expensive compared to other methods (Mavranezouli, 2008; Trussell et al., 2013, 2015). 
Researchers have studied the duration of LARC use, often by estimating Kaplan-
Meier survival probabilities or the hazard of discontinuation of LARCs compared to other 
contraceptives using Cox proportional hazard models or other similar approaches. 
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Consistently, LARCs have high continuation rates. While there is some variation in 
survival probabilities based on which type of LARC is used, the continuation rates are 
substantially higher for LARCs they are for short-acting methods. IUDs and implants 
have continuation rates from 81 to 88% at one year, compared to 41 to 61% for short-
acting reversible contraceptives (SARCs), such as pills and patches (Abraham et al., 
2015; Aoun et al., 2014; Chiles et al., 2016; Diedrich, Madden, et al., 2015; Diedrich, 
Zhao, et al., 2015; Grunloh et al., 2013; Peipert et al., 2011; Romano et al., 2018).  
O’Neil-Callahan et al. (2013) estimated 24-month continuation rates of 77% for 
LARC users. Diedrich, Madden, et al. (2015) found that the continuation of IUDs was 
63.2% at four years, and 53.9 at five years, with older women having higher rates of 
continuation. Similarly, the hazards for discontinuing the use of LARC methods are much 
lower than they are for other methods (Berenson et al., 2015; Grunloh et al., 2013; 
Peipert et al., 2011). 
One primary source of data for studying the duration of LARCs and related 
outcomes is the St. Louis Contraceptive CHOICE Project (Abraham et al., 2015; Grunloh 
et al., 2013; OʼNeil-Callahan et al., 2013; Peipert et al., 2011). The CHOICE Project was 
an initiative aimed at removing barriers to LARC use by providing contraceptive 
counseling and the method of choice free of charge. With cost and information barriers 
removed, 75% of participants chose LARCs (Birgisson et al., 2015; McNicholas et al., 
2014). Women who participated in the CHOICE Project were followed up with every 6 
months for two to three years, providing rich data on failure rates, satisfaction, and 
continuation. At one year, LARC continuation ranged from 82 to 88%, depending on 
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method (Abraham et al., 2015; Diedrich, Zhao, et al., 2015; OʼNeil-Callahan et al., 2013; 
Peipert et al., 2011). At two years, continuation remained high ranging from 66 to 79%, 
with IUD users having higher continuation rates. LARC users also had low failure rates 
and were more likely to report being satisfied with their method compared to other 
contraceptive users (Peipert et al., 2011). 
Other papers have used a variety of data sources to study the duration of LARC 
use, including insurance claims (Berenson et al., 2015; Romano et al., 2018), records 
from Tricare enrollees (Chiles et al., 2016), and electronic records from healthcare 
systems (Aoun et al., 2014). Results are similar across studies, leading to continuation 
rates of 75 to 80% in at one year, and lower hazards of discontinuation when compared to 
short-acting methods. Chiles, Roberts, and Klein (2016) found IUD continuation to be 
61.2% at 36 months for IUDs and 45.8% for implants at 33 months. 
In Huchbacher et al (2017), the authors offered the option to be randomized to a 
LARC or SARC to women seeking short-acting methods from Planned Parenthood 
clinics in North Carolina. If a woman chose to randomize, she would have her 
contraceptive provided free of cost for the duration of the study. She could freely 
discontinue LARC use, however she would need to pay for her new method if she did 
switch. The results showed that among women who originally requested a SARC, 
LARCs were acceptable and continuation was 77.8% at one year. Interestingly, a lower 
proportion of women who were randomized planned to have children in the future, 
implying that women who were willing to potentially be given a LARC method may have 
been more interested in limiting their family size (Hubacher et al., 2017).  
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The results from previous studies have found that long-acting reversible 
contraceptives are associated with high continuation rates, which is intuitive. A woman 
can easily discontinue her other reversible methods if she is unsatisfied, no longer wishes 
to use contraception or is not currently sexually active. Most reversible methods require 
active continuation of the method. If an individual is relying on condoms or SARCs, she 
will have to go to the store, pharmacy, or doctor’s office to continue use and may have 
reoccurring out-of-pocket expenses. These factors could lead to more frequent 
discontinuation and switching, especially if there is no cost to stopping the method.  
The only reversible methods that have discontinuation costs are LARCs. To stop 
using a LARC, the woman must at least go to the doctor’s office to get the device 
removed. She may also face other costs and barriers to removal, including out-of-pocket 
expenses (Amico et al. 2020; Gomez et al. 2014). Her desire to discontinue use would 
have to be greater than the cost to stop using the method and she may also have to more 
carefully consider discontinuation as it could be costly to resume LARC use. Though 
they are one-time costs, the presence of initiation and discontinuation costs may make 
discontinuing a LARC more difficult compared to other methods. 
As discussed above, the how much LARCs can reduce unintended pregnancies 
depends in part on what contraceptives women would have used had they not had access 
to LARCs. Using data from the 2006-2010, 2011-2013, and 2013-2015 National Survey 
of Family Growth, Kavanaugh and Jerman (2018) compare the proportions of 
contraceptive methods used in 2008, 2012, and 2014. They find that the use of LARCs 
increased by 8.3 percentage points between 2008 and 2014, while the use of sterilization 
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decreased by 8.4 percentage points. The use of pills and condoms also fell by 2.1 and 1.8 
percentage points, respectively, while the use of traditional methods increased. While 
Kavanaugh and Jerman’s results exhibit some interesting patterns, the authors did not 
examine switching patterns between methods. 
It is not possible to know the counterfactual of what women would have used, but 
one way to attempt to gain some information is to examine the methods women were 
using prior to LARC use. To my knowledge, there has been little work discussing what 
method women were using before switching to LARCs among American women using 
recent US data1. In one study, the authors use the 1995 NSFG to estimate a competing 
risk model of the hazard of switching methods within a two-year period (Grady et al., 
2002). Due to few unmarried women relying on LARCs and sterilization, the authors 
combined the switching to sterilization and LARC methods outcomes. Thus, it is not 
possible to learn about switching into LARC use among unmarried women. Another 
study examines contraceptive use patterns (including switching behaviors) in 2004, but 
the authors grouped together all hormonal and long-acting methods (Frost et al., 2007). 
Neither of these studies focused primarily on transitions into LARC use. By grouping 
LARC use with other methods for some or all women, it becomes impossible to 
 
1 The mix of available LARCs has changed considerably since 2000. While copper IUDs have been 
available for decades, one of the most popular LARCs—a hormonal IUD called Mirena—was not approved 
by the FDA until 2000. As noted in Hubacher et al. (2011), the approval and marketing of Mirena may 
have increased the use of LARCs. There are now multiple hormonal IUDs available in the US (Planned 
Parenthood, n.d.). The first contraceptive implant in the US was Norplant, which stopped being inserted 
during the early 2000s and Implanon (the precursor to Nexplanon) was not available until 2006 (The Henry 
J. Kaiser Family Foundation, 2019b). Additionally, professional organizations such as ACOG now 
encourage increased LARC access and use in a wide population of women (American College of 
Obstetricians and Gynecologists, 2015).  
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disentangle which types of contraceptive spells are at a greater risk for ending due to 
transitions into LARC use.  
In this paper, I expand upon the current literature by estimating a hazard model 
that includes random effects to account for the possibility of spurious duration 
dependence. I also analyze what flexible methods (SARCs, barrier methods, or traditional 
methods) women were using before switching to a LARC by estimating a competing risk 
model. Estimating a single model with contraceptive indicators allows me to detect 
significant differences in the hazard of a spell ending due to switching into LARC use 
depending on method. 
2.3 Data 
I use data from the 2006-2010, 2011-2013, and 2013-2015 public file releases of 
the female respondent questionnaires from the National Survey of Family Growth 
(NSFG) with some supplementation from the corresponding NSFG pregnancy interval 
files.2 The NSFG is a nationally representative sample of the non-institutionalized 
civilian population of the United States when properly weighted and uses a stratified 
multistage area probability sampling design, with oversampling of Black and Hispanic 
women and teenagers between the ages of 15-19. 
The survey was designed to collect information on fertility, contraception, 
marriages, and cohabitation from male and female respondents. The female respondent 
 
2 Because the female respondent file does not included information on the number of births resulting from a 
pregnancy, the pregnancy interval files are used to obtain information on non-singleton births.  
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questionnaire records demographic and socioeconomic information on women in the 
sample, information on their fertility, current work and education, and other factors 
deemed significant regarding reproductive well-being such as age of first intercourse and 
mother’s education. The pregnancy interval files are pregnancy-level datasets and contain 
information on the number of live births, pregnancy intentions, contraceptive use 
surrounding the pregnancies, and both prenatal and post-partum behaviors. Importantly, 
the NSFG contains a life-history calendar and records important events such as 
marriages, whether the respondent was sexually active, pregnancies, and contraceptive 
use month-by-month for up to four years.  
As I am conducting my analyses based on the duration of contraceptive use, it is 
important that I know when the woman initiated use of a method. I choose to exclude 
left-censored spells where the start month is not within the months covered in the NSFG 
calendar.3 I also exclude all spells in which the woman was less than 20 years old at the 
start of the spell, as teenagers may face different choices than adults. In total, there were 
77,695 spells and 19,784 spells were removed due to the age restriction. Among women 
who were at least 20 years old, 16,258 spells were left censored (or both left and right 
censored). A breakdown of the number of spells that are censored by method for women 
ages 20 and older can be found in Appendix A. 
 
3 The NSFG does include a variable for the start month of a method prior to the start of the calendar, but 
out of concerns that there may be misreporting of the dates due to recall bias and missing values for nonuse 
spells, I only include spells that start during the contraceptive calendar.  
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Because women may report multiple methods used in a month, I construct my 
spells based on the “main method” used, where “main method” is determined based on 
the effectiveness and duration of the method.4 Women can rely on female or male 
sterilization, LARCs, SARCs, barrier methods, traditional methods, emergency 
contraception, other methods, and no method.5 More details about the hierarchy used in 
spell construction are available in Appendix A.  
The number of months without contraceptive use may be overstated because a 
woman is pregnant. To correct for this, I reassigned her contraceptive status to pregnancy 
if she reports being pregnant and not using a method during a given month.6 Women also 
sometimes report switching to another method after being sterilized even though 
sterilization is permanent method. These occurrences could reflect legitimate reversals of 
sterilization or data errors. As the NSFG includes the presence of perturbed data to 
protect the confidentiality of the respondents, some of these switches could also be 
related to the perturbation process. To address this issue, I replace the method used in any 
month after the woman becomes sterilized by sterilization if she did not report a reversal. 
I take a similar approach to male sterilization. All months past the first mention of male 
sterilization were recoded to male sterilization if the marriage did not end and the 
respondent did not report her partner having a reversal.7  
 
4 The coding of my main method hierarchy is similar (but not exactly) like that of the NSFG’s 
“CONSTAT1” variable. For an example of a paper that uses a similar hierarchy (with some differences) see 
Sundaram et al. (2017). 
5 An example of “other method” includes the use of the lactational amenorrhea method among 
breastfeeding mothers or sterility of the woman or her partner. 
6 I also assigned women to this category if she had given birth that month. 
7 I am also assuming that she is monogamous.  
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Some women may report nonuse of contraception during months when she is 
sexually inactive, even if she is using a method that cannot be easily discontinued. If the 
woman reports using a LARC both before and after a period of sexual inactivity and that 
she is not using a method during the sexually inactive period, then I reassign her main 
method during her sexually inactive months from “no method” to “LARC” as she may 
still be using a LARC during these months, even if she does not currently need protection 
from pregnancy. 
My analysis sample includes 41,653 spells covering 294,551 months from 10,814 
women. In Table 1, I report the descriptive statistics for the cross-section of individual 
women at time of survey. I do not use the weights from the NSFG and thus my 
descriptive statics reflect the oversampling by race and ethnicity.8 Nearly 70% of the 
sample has children and slightly under 8% are using a LARC. Despite female sterilization 
being one of the most popular contraceptive methods (Kavanaugh & Jerman, 2018), only 
8.2% of women in my sample are using female sterilization. This disparity likely reflects 
the removal of left-censored spells, as many women relying on sterilization would have 
become sterilized prior to the first month of the contraceptive calendar. On average, each 
woman contributes slightly more than 5 spells. 
  
 
8 The survey weights of the NSFG are constructed to create a dataset that is nationally representative of the 
midpoint of the survey. These weights were not constructed to be used with month-by-month contraceptive 
data; thus, I do not use weights in my primary analysis. Weighted results of select estimates are available in 
Appendix B.  
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Table 1. Descriptive Statistics of the 2006-2010, 2011-2013, and 2013-2015 National 
Survey of Family Growth 
 
Variable Mean 
Age during calendar month 29.869 
Respondent is Black 0.243 
Respondent is Hispanic 0.239 
Currently married 0.376 
Has children 0.682 
      Number of children (among mothers) 2.088 
Currently working 0.668 
Household income is below the poverty level 0.305 
Respondent is insured 0.785 
Less than high school education 0.151 
Has high school diploma or equivalent 0.492 
Greater than high school education (any level) 0.356 
Number of spells 5.121  
Unweighted data from the 2006-2010, 2011-2013, and 2013-2015 NSFG. N = 10,814 (7,373 mothers) 
ages 20-45. 
 
 
In Table 2 I report descriptive information about the spells. The median spell 
length (including spells of nonuse and pregnancy) is 4 months. Nearly half of spells are 
of some type of contraceptive use, while 14.1% are spells of pregnancy. Over 35% of 
spells are among women who are not pregnant and not using a method. The high 
proportion of barrier method spells likely indicates that women often switch in and out of 
barrier method use, resulting in many short spells. Methods that are longer lasting such as 
sterilization and LARCs make up a much smaller proportion of the spells.  
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Table 2. Descriptive Statistics of Contraceptive Spells in the National Survey of 
Family Growth 
 
Variable Median 
Median spell length (in months) 4 
Variable Mean 
Pregnant 0.141 
Using contraception 0.496 
Female sterilization 0.022 
Male sterilization 0.013 
LARC  0.028 
SARC  0.118 
Condoms 0.227 
Traditional  0.089 
EC 0.004 
Other Method 0.005 
Data from the 2006-2010, 2011-2013, and 2013-2015 NSFG. Data are 
unweighted. N = 41,653 spells. EC is Emergency Contraception.  
 
 
2.4 Empirical Approach 
To analyze the duration of LARC use, I use a number of different hazard rate 
methods. I first estimate the Kaplan-Meier survival probabilities. The Kaplan-Meier 
(KM) survival estimator is a natural starting point to assess the duration of LARC use as 
it is frequently used in studies on LARC use. The KM estimator does not make any 
parametric assumptions and is specified as the following (Cleves et al., 2016): 
 
𝑆(𝑡) =  ∏ |   (1) 
 
 
where 𝑛  is the number of contraceptive spells at time 𝑗 and 𝑑  is the number of spells 
that end at time 𝑗. I can use this estimate of the survivor function to compare the survival 
probabilities for different contraceptive methods. However, a limitation of the KM 
 
19 
 
estimator is that other than stratifying by a limited number of characteristics, it does not 
allow me to adjust for other important factors that may influence the duration of 
contraceptive use (Etikan, 2017).  
Another approach to assessing the duration of contraceptive use is estimating a 
discrete-time hazard model. A discrete-time approach is more appropriate than 
continuous-time methods since the data is recorded in months (Allison, 1982). My 
outcome variable is the hazard of discontinuing a contraceptive. Unlike in the KM 
estimator, I can include a broad set of observed characteristics that may influence the 
duration of contraceptive use. Additionally, women may differ in unobserved ways that 
affect their duration of using a contraceptive. To allow for this, I include a random effect 
at the woman-level (Zorn, 2000). I define the hazard of a contraceptive spell ending at 
duration 𝑡 as (Allison, 1982): 
 
ℎ(𝑡) =
exp {ψν(𝑡) + 𝛿 𝑥(𝑡) + 𝛾}
1 + exp {ψν(𝑡) + 𝛿 𝑥(𝑡) + 𝛾}
 
(2) 
 
 
In which 𝛾 is the woman-level random effect which is normally distributed with variance 
𝜎 . 𝜈(𝑡) is a set of duration dummies indicating the number of months that the woman 
has been using the method, which are quarterly for the first year, in 6-month intervals for 
the second year, and then grouped together for any month greater than 24 months. 𝜓 are 
the parameters to be estimated on the duration dummies, which make up the baseline 
hazard that the spell will end. 𝑥 (𝑡) is a (𝑘𝑥1) vector of covariates which includes 
indicators of the main method a woman is using that month (LARC, SARC, barrier, 
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traditional, no method9), an indicator of the woman’s age group at the beginning of the 
contraceptive spell (20-24, 25-29, 30-34, 35-39, and 40-45), if she is Black, if she is 
Hispanic, the number of children she has (0,1, 2, and 3+), if she is sexually active, 
marriage duration (unmarried, 1-3 years, 4-6 years, and 7+ years) and a set of year 
controls. I also include an indicator for if the woman is postpartum (Steele et al., 2004). 
𝛿 is the (𝑘 × 1) vector capturing the effect of the covariates on the hazard of the spell 
ending. I select SARC as the omitted contraceptive category. I estimate this model using 
the xtlogit command in Stata16 and cluster my standard errors at the woman-level.  
To investigate which contraceptive spells are at greatest risk of ending due to 
switching into LARC, I use a competing risk model. A competing risk model is used 
when there is more than one way that a spell – in this case a contraceptive spell – can 
end. I estimate the model for women who are currently using a flexible contraceptive 
method. This “flexible” category includes the use of SARCs, barrier methods, and 
traditional methods. I do not estimate the results for women who are relying on 
sterilization (male or female) as no one transitions out of female sterilization due to my 
data construction and very few individuals transition out of male sterilization in my data. 
I also do not include women relying on emergency contraception or “other method” as 
very few spells fall within in these categories. Finally, I exclude women who are 
currently using LARCs as they cannot transition into LARC use. As I am interested in 
 
9 As emergency contraception is meant to be used temporarily, I do not include an EC indicator when 
assessing the hazard of discontinuation. 
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how spells of contraceptive use end, I also exclude women who are currently pregnant 
and women who are not currently using a method.  
My primary interest is the hazard of ending a contraceptive spell by switching to 
LARC use. I designate four other competing risks that could cause a spell to end. These 
include switching into no method, switching to another flexible method, becoming 
pregnant, or switching to sterilization (either male or female). As some of the benefits of 
using a LARC for pregnancy prevention are due to long-acting methods not relying on 
adherence for their effectiveness, women switching from methods with a large gap 
between the perfect use and typical use failure rates such as barrier methods and 
traditional methods could experience a greater reduction in the risk of pregnancy 
compared to women switching from hormonal methods. If women who are using SARCs 
are more likely to switch to LARCs, then the effect of increasing access to LARCs on 
unintended pregnancies might be dampened as the typical use failure rates for SARCs 
range from 4 to 9%, compared to over 12% for male condoms (the most popular barrier 
method) and 19.9% or greater for traditional methods (Kavanaugh & Jerman, 2018; 
Sundaram et al., 2017; Trussell, 2011).  
The approach to implementing the discrete-time competing risk hazard model is 
similar to that of the binary discrete-time hazard model. Instead of estimating a model of 
the hazard of discontinuation for any reason, I can break out different hazards for 
different causes for the end of the spell (Allison, 1982). I denote the cause-specific hazard 
as ℎ (𝑡). Summing up all cause specific hazards gives the hazard of a contraceptive spell 
ending for any reason (ℎ(𝑡)) (Allison, 1982). I allow the hazard of discontinuing a 
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contraceptive spell due to cause 𝑘 = (1 … 4) to depend on the same set of covariates, 
𝑥(𝑡): 
 
ℎ (𝑡) =
exp{𝜔 𝛼 (𝑡) + 𝛽 𝑥(𝑡)}
[1 + ∑ exp {𝜔 𝛼 (𝑡) + 𝛽 𝑥(𝑡)} 
 
(3) 
 
 
As there are five ways that a spell can end, there are five (𝑘 × 1) vectors of coefficients, 
𝛽 . 𝛼 (𝑡) is the set of duration dummies as defined previously, and 𝜔  gives the baseline 
hazard for the spell to end for a specific reason, 𝑘. 
By estimating my results for all women in a flexible contraceptive state and 
including the indicators of contraceptive use, I can compare how the type of flexible 
contraceptive used affects the hazard of switching into LARC use. I use SARC as the 
omitted category, and thus the coefficients on the included contraceptive variables 
indicate proportional shifts in the baseline hazard of using a barrier or traditional method 
versus a SARC. I estimate all coefficients using maximum likelihood estimation. The 
log-likelihood function is (Schmidheiny, 2007): 
 
𝐿𝐿 =  ∑ ∑ 𝑑 log(ℎ (𝑡)). (4) 
 
 
I use the 𝑚𝑙𝑜𝑔𝑖𝑡 command in Stata 16 to estimate the results, with standard errors 
clustered at the woman-level. 
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2.5 Results 
In Table 3 I report the Kaplan-Meier survival estimates for all LARCs and 
separately for IUDs and implants. I also present the estimated survival probabilities for 
SARCs for comparison. 
 
Table 3. Kaplan-Meier Survival Probabilities of Long-Acting Reversible 
Contraceptives 
 
Method 6 months 
12 
months 
18 
months 
24 
months 
30 
months 
36 
months 
All LARC 87.45 77.43 70.90 65.56 62.60 53.69 
     IUD 86.67 77.64 70.64 66.31 63.62 56.18 
     Implant 91.75 75.82 72.49 60.81 56.23 36.90 
SARC 63.90 46.33 36.45 29.74 24.61 21.15 
Unweighted data from the 2006-2010, 2011-2013, and 2013-2015 National Survey of Family Growth. 
Number of spells when t=1: 1,097 (LARC), 923 (IUD), 174 (implant), 4,225 (SARC).  
 
 
By 12 months, the survival probabilities for a spell of LARC use is 77.43%. By 24 
months this number has fallen by only 12 percentage points to 65.56%, and by 36 months 
the survival probability is 53.69%. The estimated survival probabilities for IUDs (and 
thus LARCs overall, as IUDs make up a large proportion of LARC use) are on the low 
end compared to other recent studies, possibly due to excluding left-censored spells, but 
the pattern of LARC methods having high survival probabilities compared to other 
methods remains. Fewer than half of SARC spells are continued through 12 months. This 
number falls to 29.74% at 24 months. The estimated survival probabilities for SARCs are 
also low compared to the results of other studies (Hubacher et al., 2017; OʼNeil-Callahan 
et al., 2013; Peipert et al., 2011).  
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In Table 4 I report the results of the discrete-time hazard model with and without 
random effects. Coefficients indicate a proportional change in the hazard of 
discontinuation. Positive coefficients imply an increased risk of the contraceptive spell 
ending, and negative coefficients imply a decrease in the risk.  
 
Table 4. Discrete-Time Hazard of Contraceptive Spell Ending Results 
 
 (1) 
Logit 
(2) 
Random Effects Logit 
Variable Discontinuation of 
Contraception 
Discontinuation of 
Contraception 
Contraceptive variables   
       SARC Omitted Omitted 
 - - 
       LARC -1.017*** -1.182*** 
 (0.0626) (0.0679) 
       Barrier 0.928*** 0.982*** 
 (0.0277) (0.0318) 
       Traditional 0.858*** 0.804*** 
 (0.0361) (0.0406) 
       Other method 0.712*** 0.897*** 
 (0.0689) (0.0845) 
       No method 0.638*** 0.760*** 
 (0.0256) (0.0300) 
Demographic variables   
       Respondent is Black 0.0894*** 0.0993*** 
 (0.0249) (0.0259) 
       Respondent is Hispanic -0.0286 -0.0372 
 (0.0274) (0.0272) 
       Age group   
          20 - 24 0.0104 0.0330 
 (0.0233) (0.0246) 
          25 - 29  Omitted Omitted 
 - - 
          30 - 34 -0.0121 -0.0478* 
 (0.0289) (0.0286) 
   
         35 - 39 0.0172 -0.0753** 
 (0.0366) (0.0371) 
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Table 4 Continued   
         40 - 45 -0.0129 -0.220*** 
 (0.0590) (0.0558) 
   
   
      Number of children   
          0 Omitted Omitted 
 - - 
          1 -0.0461* -0.0828*** 
 (0.0263) (0.0266) 
          2 -0.102*** -0.158*** 
 (0.0307) (0.0319) 
          3+ -0.173*** -0.265*** 
 (0.0374) (0.0377) 
     Marriage duration   
          0 Omitted Omitted 
 - - 
          1 - 3 years -0.135*** -0.143*** 
 (0.0308) (0.0314) 
          4 - 6 years -0.0816** -0.129*** 
 (0.0329) (0.0320) 
          7+ years -0.0261 -0.0465 
 (0.0547) (0.0523) 
Postpartum -0.0723 0.167*** 
 (0.0443) (0.0459) 
Sexually active -0.146*** 0.0535* 
 (0.0234) (0.0275) 
Intraclass correlation  0.1305*** 
  (0.0050) 
𝜎   0.7027*** 
  (0.0153) 
Unweighted data from the 2006-2010, 2011-2013, and 2013-2015 National Survey of Family Growth. 
N = 218,880 months. Includes controls for duration and year. Standard errors are clustered at the woman 
level and are in parentheses. 
* p<0.10, ** p<0.05, *** p<0.010 
 
 
The coefficient on LARC use in the random effects model is -1.182. Another way to 
interpret results from a logit model is to report exponentiated coefficients or odds ratios 
(OR) (Hosmer et al., 2013). The OR for LARC use is 0.307, meaning that the odds of 
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discontinuation for a spell of LARC use are nearly 70 percentage points lower than they 
are for the reference category of SARC use. This implies that LARC use is associated 
with higher contraceptive persistence, even with the inclusion of random effects. Spells 
of other methods increase the hazard of discontinuation compared to SARCs spells.  
Having children, being postpartum, and being older are associated with a decrease 
in the hazard of discontinuation. Interestingly, in the random effects model, sexual 
activity is associated with an increased hazard of discontinuing a contraceptive spell. This 
could possibly reflect short spells of barrier method use and traditional method use, as 
traditional and barrier methods are used while the woman is sexually active. This could 
also reflect the adjustments to spells of LARCs and sterilization, in that more women will 
still be in a LARC spell or a spell of sterilization even if they are not sexually active. 
I now turn to switches among contraceptive methods. I first calculate the 
transition probabilities of switching from one method to another contraceptive for all 
methods. Table 5 presents the monthly transition probabilities. Consistent with the 
duration results, LARCs have lower monthly transition probabilities verses SARCS 
(2.04% versus 6.78%). Less effective methods such as traditional methods have a greater 
probability of transitioning into pregnancy than more effective methods, such as LARCs.  
The transition probabilities are helpful for both looking at patterns of how LARC 
spells end and also which methods have higher month-to-month probabilities of moving 
into LARC use. But as some methods are much more prevalent than others (e.g., a much 
greater proportion of women rely on SARCs than emergency contraception), analyzing 
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what women were using prior to switching to a LARC is also useful. As a simple first 
pass to understanding what methods women use prior to LARC use, I tabulate the 
contraceptive status in the month before the first month of a LARC spell. From the results 
in Table 6 below, nearly one third women initiating LARC use do so after pregnancy, and 
over 30% third switch from no method. Only a small proportion of the LARC users were 
relying on traditional methods. A similar proportion of LARC users were previously 
SARC and barrier method users (14.19% versus 14.76%, respectively). 
Next, I turn to the competing risk model. Table 7 summarizes the outcome 
variable. Over one quarter of the spells transition into nonuse, and over 35% result in 
switches to another flexible method. Over 12% of spells among women using flexible 
contraceptive methods end due to pregnancy. A much smaller proportion of spells end in 
the use of LARCs (1.63%) or sterilization (1.39%). Almost 23% of spells are censored. 
Table 8 presents the coefficients for the competing risk models. The sign of the 
coefficient indicates direction of the effect of an increase in that variable on the cause 
specific hazard, compared to the hazard of the spell not ending during the month. Larger 
coefficients imply a greater shift. 
 
 
 
 
Table 5. Contraceptive Method Monthly Transition Probabilities 
 
 Method Used This Month 
Method Used 
Last Month 
Sterilization 
(F) LARC SARC Barrier Traditional 
Sterilization 
(M) 
Other 
method EC 
No 
method Pregnancy 
Sterilization (F) 100 0 0 0 0 0 0 0 0 0 
LARC 0.06 97.88 0.43 0.27 0.14 0.05 0.07 0 0.9 0.19 
SARC 0.09 0.27 93.22 1.49 0.72 0.1 0.05 0.03 3.36 0.68 
Barrier 0.08 0.27 1.56 83.02 1.51 0.16 0.07 0.04 11.81 1.49 
Traditional 0.08 0.2 1.29 2.28 84.83 0.14 0.05 0.08 8.68 2.37 
Sterilization (M) 0.1 0.01 0 0.01 0 99.86 0 0 0.01 0.01 
Other method 0 1.07 4.03 3.37 1.32 0.41 84.54 0 3.87 1.4 
EC 0.47 1.4 9.77 10.7 9.3 0 0.47 27.44 33.49 6.98 
No method 0.12 0.34 1.91 6.82 2.14 0.17 0.04 0.1 85.35 3.02 
Pregnancy 0.91 0.7 2.41 1.76 0.73 0.08 0.04 0.03 6.05 87.27 
Unweighted data from 2006-2010, 2011-2013, and 2013-2015 NSFG. N = 281,737 months.20-45. EC is emergency contraception. 
28 
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Table 6. Method Used Prior to LARC Use 
 
Prior Method Proportion 
SARC 14.19 
Barrier 14.76 
Traditional 4.73 
Male sterilization 0.12 
Other 1.50 
Emergency contraception 0.35 
No Method 31.60 
Pregnancy 32.76 
Unweighted data from 2006-2010, 2011-2013, and 2013-2015 
NSFG. N = 867 LARC spells. 
 
 
Table 7. Competing Risk Contraceptive Spell Exit Outcomes 
 
Outcome Proportion (How Spells End) 
Censored 22.93 
LARC 1.63 
No method 26.34 
Other flexible method* 35.32 
Pregnancy 12.39 
Sterilization 1.39 
Unweighted data from 2006-2001, 2011-2013, and 2013-2015 NSFG. N = 32,743 
spells. 
*Includes SARCs, barrier method, and traditional method.  
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Table 8. Competing Risk Contraceptive Spell Exit Results 
 
 (1) (2) (3) (4) (5) 
Variable LARC No Method 
Other 
Flexible 
Method Pregnancy Sterilization 
     
Baseline hazard 
(SARC use) 
months 
     
     1 - 3 -5.980*** -2.198*** -3.939*** -5.367*** -6.371*** 
      (0.365)      (0.079)      (0.161)      (0.193)      (0.381) 
     4 - 6 -6.193*** -3.227*** -4.734*** -5.858*** -6.465*** 
      (0.364)      (0.084)      (0.167)      (0.198)      (0.378) 
     7 - 9 -6.845*** -3.625*** -5.177*** -6.071*** -6.688*** 
      (0.396)      (0.091)      (0.174)      (0.202)      (0.393) 
     10 - 12 -6.304*** -3.620*** -5.002*** -6.011*** -6.914*** 
      (0.396)      (0.095)      (0.174)      (0.206)      (0.423) 
     13 - 18 -6.710*** -3.870*** -5.457*** -6.146*** -6.872*** 
      (0.402)      (0.095)      (0.177)      (0.207)      (0.414) 
     19 - 24 -7.010*** -4.291*** -5.534*** -6.143*** -6.806*** 
      (0.458)      (0.114)      (0.191)      (0.217)      (0.428) 
     25 + -7.293*** -4.263*** -5.667*** -6.425*** -7.307*** 
      (0.522)      (0.118)      (0.206)      (0.234)      (0.480) 
      
Method      
     SARC Omitted Omitted Omitted Omitted Omitted 
      
     Barrier 0.148 1.174*** 0.101** 0.945*** 0.347** 
      (0.146)      (0.042)      (0.051)      (0.074)      (0.160) 
     Traditional -0.325 0.940*** 0.286*** 1.435*** 0.102 
      (0.213)      (0.054)      (0.065)      (0.079)      (0.207) 
      
Black -0.364** 0.227*** 0.111 0.254*** -0.516*** 
      (0.184)      (0.041)      (0.088)      (0.069)      (0.193) 
Hispanic -0.331** -0.0662 0.221** 0.0242 -0.841*** 
      (0.161)      (0.046)      (0.104)      (0.069)      (0.184) 
      
Age Group      
     20 - 24 0.104 -0.0971** -0.0198 0.275*** -0.409* 
      (0.172)      (0.041)      (0.071)      (0.068)      (0.241) 
     25 - 29 Omitted Omitted Omitted Omitted Omitted 
      
     30 - 34 -0.183 0.174*** -0.0976 -0.0772 0.083 
      (0.181)      (0.051)      (0.091)      (0.078)      (0.196) 
     35 - 39 -0.403 0.450*** -0.289** -0.543*** 0.709*** 
      (0.259)      (0.059)      (0.133)      (0.118)      (0.197) 
     40 - 45 -1.151** 0.593*** 0.0191 -1.353*** 0.904*** 
      (0.499)      (0.087)      (0.205)      (0.224)      (0.265) 
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Parity      
     0 Omitted Omitted Omitted Omitted Omitted 
      
     1  0.759*** -0.214*** -0.151* 0.523*** 0.534* 
      (0.200)      (0.045)      (0.080)      (0.075)      (0.277) 
     2  1.242*** -0.454*** -0.221** 0.506*** 1.604*** 
      (0.206)      (0.055)      (0.092)      (0.089)      (0.248) 
     3+ 1.124*** -0.491*** -0.356*** 0.633*** 1.991*** 
      (0.224)      (0.067)      (0.129)      (0.098)      (0.259) 
      
Marriage 
duration in 
years 
     
     Not married Omitted Omitted Omitted Omitted Omitted 
      
     1-3 0.317* -0.479*** -0.287*** 0.230*** -0.215 
      (0.190)      (0.058)      (0.072)      (0.076)      (0.268) 
     4-6 -0.0197 -0.358*** -0.173 -0.0626 0.274 
      (0.177)      (0.061)      (0.110)      (0.085)      (0.172) 
     7+  0.203 -0.366*** 0.0381 -0.452** 0.152 
      (0.297)      (0.095)      (0.156)      (0.199)      (0.230) 
      
Postpartum 1.038*** -0.928*** -0.328** 0.134 0.411 
      (0.224)      (0.105)      (0.128)      (0.136)      (0.302) 
Sexually active 0.0815 -0.193*** 1.318*** 0.450** -0.528** 
      (0.265)      (0.068)      (0.140)      (0.179)      (0.256) 
Unweighted data from 2006-2010, 2011-2013, and 2013-2015 NSFG. Includes 120,485 months of 
data from spells of SARC, barrier, or traditional method use. “Other flexible” includes SARCs, 
barrier, and traditional. Standard errors are in parenthesis and clustered at the woman-level.  
* p<.10, ** p<.05, *** p<.01 
 
 
The first two rows of Table 8 show the proportional shift in the cause specific 
hazards for barrier methods and traditional methods compared to SARC use. The risk of 
switching to a LARC is not statistically different for spells of traditional and barrier 
method use compared to SARC use. Consistent with higher failure rates for both 
traditional and barrier methods versus short-acting hormonal methods, use of barrier 
methods and traditional methods increases the chance that the spell will end in a 
pregnancy. Condom and barrier spells are also more likely to end due to switching into 
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another flexible method or into nonuse. Barrier method spells are at an increased risk of 
the spell ending due to switching to sterilization. 
Consistent with research on contraceptive preferences (Jackson et al., 2016), 
spells of use among Black and Hispanic women have a lower hazard of switching to the 
use of long-lasting methods, including sterilization. The hazard of a spell ending due to 
switching into nonuse or becoming pregnant is greater for Black women. Young age 
increases the hazard of a spell ending in pregnancy compared to women ages 25-29, 
though young age is also associated in a decreased hazard of the spell ending due to the 
woman discontinuing use of any method. The positive effect of young age on the risk of 
pregnancy is consistent with younger women having more unintended pregnancies (Finer 
& Zolna, 2016).   
Being older than 29 is associated with a reduced risk of a spell ending due to 
pregnancy, which is consistent with reduced fecundity with age. The increased hazard of 
switching into no method use with age could also reflect this reduced fecundity. The 
increased hazard of becoming sterilized for spells of use among older women could be 
related to increased access to permanent methods for women over the age of 30.10 The 
hazard of switching to a LARC is similar for spells of use among women ages 20-39. 
 
10 A 1999 study found that women who were sterilized before 30 were more likely to express regret (Hillis 
et al., 1999). In a 2017 Committee Opinion, the American College of Obstetricians and Gynecologists note 
that physicians sometimes wish to prevent “sterilization regret” among their patients. It should be noted 
that the Committee Opinion recommends that physicians avoid paternalism when working with young 
patients (American College of Obstetricians and Gynecologists, 2007b). 
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Women over 40 are at a reduced risk of spell exit due to use of an IUD or implant, 
perhaps due to increased access to sterilization or reduced fecundity.  
Having children is associated with an increased risk of switching into a LARC 
method. The positive effect on LARC use for women with children could partially reflect 
the barriers to the use of IUDs that women without children sometimes face, in that some 
providers do not consider nulliparous women as suitable candidates for IUD use 
(Luchowski et al., 2014). Spells among women with children are also more at risk of 
ending due to the woman becoming sterilized. The effect is much larger for women with 
at least two children. Mothers have a greater hazard of a contraceptive spell ending due to 
pregnancy but also have reduced hazard of switching into nonuse or into another flexible 
method. Spells of contraceptive use among women who are postpartum but are currently 
relying on flexible methods have a greater chance of ending due to the woman switching 
to more effective methods, such as LARCs or sterilization. 
In the specification from Table 8, I am assuming that the effect of using a 
traditional method or a barrier method follow the same baseline hazard as SARC users, 
other than the hazard being shifted up or down. Under this specification I do not find 
evidence that the hazard of a spell ending due to switching into LARC use is statistically 
significantly different for traditional or barrier spells verses SARC spells. It is possible 
that the baseline hazards of these methods take on a different shape and that time-
dependent differences are being obscured. For example, becoming a SARC user may 
require more planning and thus women deciding to use SARCs may plan to use the 
methods for an extended period of time. On the other hand, some women may use barrier 
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methods or traditional methods as bridge methods between other, more effective 
methods, or they may use these methods due to sporadic sexual activity, which could 
result in more switching into nonuse and other methods early in a spell.  
To explore this possibility, I re-estimate the competing risk model described by 
Equation 4 and allow each method to have a different baseline hazard. This is done by 
including a set of interactions of the method and the duration dummies in place of the 
contraceptive indicators. I show these results in Table 9 and discuss the differences in the 
baseline hazards below. I restrict the coefficients of the other covariates to be the same 
across flexible methods and do not allow the effect of the other variables to depend on the 
duration of the spell. Due to these restrictions, the rest of the results in Table 9 are similar 
to those in Table 8. 
 
Table 9. Competing Risk Contraceptive Spell Exit Results: Time-Method 
Interactions 
 
 (1) (2) (3) (4) (5) 
Variable LARC No Method 
Other 
Flexible 
Method Pregnancy Sterilization 
     
Baseline hazard 
(SARC use) 
months 
     
     1 - 3 -6.641*** -2.455*** -4.125*** -5.521*** -6.393*** 
      (0.418)      (0.083)      (0.170)      (0.204)      (0.416) 
     4 - 6 -5.786*** -3.155*** -4.587*** -5.696*** -6.735*** 
      (0.356)      (0.104)      (0.169)      (0.220)      (0.448) 
     7 - 9 -6.677*** -3.267*** -5.017*** -6.191*** -6.749*** 
      (0.441)      (0.112)      (0.185)      (0.255)      (0.458) 
     10 - 12 -6.031*** -3.274*** -4.830*** -5.786*** -6.856*** 
      (0.424)      (0.121)      (0.186)      (0.242)      (0.499) 
     13 - 18 -6.286*** -3.457*** -5.338*** -5.988*** -6.629*** 
      (0.409)      (0.115)      (0.191)      (0.244)      (0.462) 
     19 - 24 -6.743*** -3.931*** -5.232*** -6.171*** -6.529*** 
      (0.509)      (0.156)      (0.208)      (0.293)      (0.465) 
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     25 + -6.648*** -3.938*** -5.472*** -6.295*** -7.455*** 
      (0.526)      (0.165)      (0.232)      (0.317)      (0.655) 
      
Barrier  
×Time 
months 
     
     1 - 3 1.126*** 1.481*** 0.393*** 1.120*** 0.454* 
      (0.245)      (0.066)      (0.078)      (0.116)      (0.253) 
     4 - 6 -0.713** 1.145*** -0.233** 0.750*** 0.621* 
      (0.327)      (0.080)      (0.108)      (0.150)      (0.357) 
     7 - 9 -0.3 0.747*** -0.105 1.257*** 0.515 
      (0.519)      (0.102)      (0.150)      (0.207)      (0.421) 
     10 - 12 -0.348 0.713*** -0.201 0.715*** 0.21 
      (0.441)      (0.116)      (0.161)      (0.216)      (0.540) 
     13 - 18 -0.489 0.623*** -0.158 0.723*** -0.199 
      (0.454)      (0.117)      (0.185)      (0.212)      (0.458) 
     19 - 24 -0.351 0.486** -0.401 0.864*** -0.346 
      (0.710)      (0.190)      (0.244)      (0.295)      (0.582) 
     25 + -1.503 0.730*** -0.646** 0.814** 0.463 
      (1.086)      (0.195)      (0.320)      (0.345)      (0.742) 
      
Traditional 
×Time  
months 
     
     1 - 3 0.544* 1.303*** 0.499*** 1.680*** -0.126 
      (0.321)      (0.078)      (0.101)      (0.123)      (0.348) 
     4 -6 -0.727* 0.711*** 0.260** 1.245*** 0.721* 
      (0.420)      (0.104)      (0.123)      (0.159)      (0.409) 
     7 - 9 -0.0563 0.323** -0.0766 1.336*** -0.0709 
      (0.593)      (0.142)      (0.195)      (0.234)      (0.600) 
    10 - 12 -0.692 0.450*** 0.016 1.046*** 0.0448 
      (0.635)      (0.160)      (0.200)      (0.237)      (0.695) 
    13 - 18 -15.85*** 0.234 0.185 1.251*** -0.146 
      (0.265)      (0.167)      (0.211)      (0.227)      (0.586) 
    19 - 24 -0.712 0.796*** -0.53 1.645*** -0.0127 
      (1.087)      (0.220)      (0.347)      (0.298)      (0.691) 
     25 + -15.59*** 0.399 0.418 1.222*** 0.543 
      (0.435)      (0.269)      (0.302)      (0.384)      (0.919) 
      
Black -0.358* 0.229*** 0.114 0.255*** -0.518*** 
      (0.184)      (0.040)      (0.089)      (0.069)      (0.193) 
Hispanic -0.309* -0.0565 0.230** 0.0269 -0.834*** 
      (0.161)      (0.046)      (0.104)      (0.069)      (0.185) 
      
Age Group      
     20 - 24 0.116 -0.0936** -0.0158 0.277*** -0.401* 
      (0.172)      (0.041)      (0.071)      (0.068)      (0.241) 
     25 - 29 Omitted Omitted Omitted Omitted Omitted 
      
      
 
36 
 
Table 9 Continued 
    
     30 - 34 -0.179 0.173*** -0.0993 -0.0774 0.0786 
      (0.181)      (0.051)      (0.091)      (0.078)      (0.196) 
     35 - 39 -0.391 0.446*** -0.291** -0.543*** 0.714*** 
      (0.257)      (0.059)      (0.133)      (0.118)      (0.196) 
     40 - 45 -1.122** 0.591*** 0.0222 -1.352*** 0.916*** 
      (0.499)      (0.086)      (0.205)      (0.224)      (0.264) 
      
Parity      
     0 Omitted Omitted Omitted Omitted Omitted 
      
     1  0.759*** -0.214*** -0.151* 0.523*** 0.534* 
      (0.200)      (0.045)      (0.080)      (0.075)      (0.277) 
     2  1.242*** -0.454*** -0.221** 0.506*** 1.604*** 
      (0.206)      (0.055)      (0.092)      (0.089)      (0.248) 
     3+  1.124*** -0.491*** -0.356*** 0.633*** 1.991*** 
      (0.224)      (0.067)      (0.129)      (0.098)      (0.259) 
      
Marriage 
duration in 
years 
     
     Not married Omitted Omitted Omitted Omitted Omitted 
      
     1 - 3 0.340* -0.468*** -0.277*** 0.234*** -0.207 
      (0.191)      (0.057)      (0.072)      (0.076)      (0.268) 
     4-6 -5.786*** -3.155*** -4.587*** -5.696*** -6.735*** 
      (0.356)      (0.104)      (0.169)      (0.220)      (0.448) 
     7+ -6.677*** -3.267*** -5.017*** -6.191*** -6.749*** 
      (0.441)      (0.112)      (0.185)      (0.255)      (0.458) 
      
Postpartum 1.296*** -0.854*** -0.255** 0.177 0.417 
      (0.231)      (0.106)      (0.128)      (0.138)      (0.313) 
Sexually active -0.0121 -0.218*** 1.296*** 0.429** -0.537** 
      (0.261)      (0.069)      (0.140)      (0.179)      (0.254) 
Unweighted data from 2006-2010, 2011-2013, and 2013-2015 NSFG. Includes 120,485 months 
of data from spells of SARC, barrier, or traditional method use. “Other flexible” includes 
SARCs, barrier, and traditional. Standard errors are in parenthesis and clustered at the woman-
level.  
* p<.10, ** p<.05, *** p<.01 
 
 
The first set of coefficients is the baseline hazard for SARC users. The next two 
sets of coefficients are the interaction of barrier methods and traditional methods with 
duration dummies. For women using barrier methods, there is no difference in the 
baseline hazard of switching to LARCs versus SARCs other than within the first six 
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months. During the first three months, barrier method spells have an increased hazard of 
spell exit for all causes compared to spells of SARC use. This result is consistent with 
barrier methods being used in short spells as a bridge method or due to sporadic sexual 
activity. Barrier methods have a decrease risk of ending due to a switch to LARCs during 
the 4-6 month interval, though this result may reflect an increase in the risk of switching 
to LARCs for SARC spells. Consistent with higher failure rates, barrier methods spells 
are associated with greater chance of a spell ending due to pregnancy. Despite higher 
failure rates, barrier method spells have a similar risk of ending due to switches into 
LARC use as spells of the more effective SARC methods after the first 6 months. 
Similar to the results for barrier methods, spells of traditional method use have a 
higher hazard of ending due to pregnancy compared to spells of SARC use. Spells of 
traditional methods have a greater risk of ending due to switching into nonuse of a 
method, except in the 13-18 month and 25+ month intervals. The hazard to switching to a 
LARC follows a similar pattern as barrier method spells during the first year. For the first 
few months of a spell, traditional method spells have a higher hazard of switching into 
LARC use, followed by a lower hazard compared to SARC spells during the 4-6 month 
interval. After the first year, few traditional method spells end due to LARC use, as 
evidenced in the baseline hazard of essentially 0 during the 13-18 month and 25+ month 
intervals. Other than during the first three months, the coefficients on the traditional 
method interactions are negative, but the coefficients are not always statistically different 
from zero.  
 
38 
 
Taken together, these results imply that despite being more sensitive to incorrect 
and inconsistent use, traditional method spells are not at a greater risk (and may actually 
be at a lower risk) of ending due to a switch into LARC use compared to SARC spells.  
2.6 Discussion 
The results from the KM estimator demonstrate that LARCs have high rates of 
continuation, with 77% of LARC spells continuing at 12 months, 65% continuing at 24 
months, and around 53.69% of continuing at 36 months. This is particularly salient as it 
has been estimated that LARCs become cost-neutral at 1.7 to 3 years. The discrete-time 
hazard model results show that the hazard of discontinuation during a given month is 
much lower in spells of LARC use compared to SARC use, while other methods 
increased the hazards of the spell ending. When interpreted as an odds ratio, the odds of a 
LARC spell ending is roughly 70 percentage points lower than that of SARC spells.  
The results from the competing risk models imply that overall, the risk of a spell 
ending due to switching to a LARC is similar for spells of SARC use and barrier method 
use, other than during the first 6 months. The pattern is similar for traditional method 
spells, other than that very few spells of traditional method use end due to switches into 
LARC use after the first year. This implies that spells of contraceptive use of methods 
with gaps greater than 10 percentage points between the perfect use and typical use 
failure rates are not more likely to switch to adherence-free LARC methods. This may 
dampen some of the potential impact of LARC use for pregnancy prevention. 
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It has been estimated that it takes between 1.7 to 3 years to reach cost-neutrality 
of LARC use, depending on if the woman is using no method, a SARC method, or a 
barrier method. To my knowledge, there has not been a formal calculation of how long a 
LARC would need to be used compared traditional methods. Traditional methods have 
higher failure rates, which would increase the benefits of switching to LARCs in terms of 
pregnancy-related costs avoided compared to SARCs and barrier methods; however, 
traditional methods are also often free to implement, which makes them less expensive 
than SARCs and barrier methods.11 It should be noted that even traditional methods such 
as withdrawal have much lower failure rates compared to nonuse, with typical use failure 
rates of 19.9% compared to 85%, respectively (Sundaram et al., 2017; Trussell, 2011). 
Given the substantial decrease in failure rates compared to nonuse of any contraception, it 
seems likely that the time needed to achieve cost-neutrality for traditional methods could 
still tend towards the middle to upper range of the 1.7 to 3 year estimate.  
Cost-neutrality is not the only concern regarding if women should use LARCs and 
whether or not policies to increase LARC access should be implemented. Implants and 
IUDs may still be beneficial for women who wish to use very effective methods, are 
using a method for birth spacing, or who prefer the convenience of a method that does 
not require constant effort, even when the LARC is use for less than its full duration. The 
analyses in Trussell et al. (2015) only account for direct medical costs associated with 
unintended pregnancies such as the cost of a birth or an abortion, however not being able 
 
11 Some natural family planning methods include using thermometers and other devices or apps.  
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to time fertility may have other costs over the course of a woman’s life (Bailey, 2006). 
Thus, increasing access to LARC methods so that women who would benefit from long-
acting options can use them may still be welfare improving, even if the methods are not 
used long enough to become “cost-neutral.” 
2.6.1 Limitations 
This paper has some important limitations to consider. I find that one-third of 
LARC spells are discontinued at the two years needed to achieve cost-neutrality for 
SARCs and that nearly half of spells are discontinued at three years of use, but have not 
addressed what proportion of women would need to continue LARC use before a 
program providing LARCs would generate more savings than costs. A formal cost-
benefit or cost-effectiveness analysis of LARC use which includes comparisons to barrier 
method use and traditional method use in the US may be needed, but it is beyond the 
scope of this study.12 
By not allowing for correlations between cause-specific hazards in my competing 
risk models, I am making the strong assumption that the risks are independent from each 
other. An approach like that in Steele et al. (2004), in which models for switching within 
contraceptive use and between using a method and nonuse are estimated jointly may 
provide additional insights. Also, while I allow the effect of methods to have different 
 
12 Trussell et al. (2014) studies the cost-effectiveness of a specific IUD in the US compared to SARC 
methods. A 2008 UK study also assesses the cost-effectiveness of LARCs compared to various hormonal 
options (Mavranezouli, 2008). 
 
41 
 
baseline hazards in my second specification of the competing risk model, I do not allow 
this flexibility for other covariates.   
What women were using previously is not a perfect measure of what she would 
have used if she had not switched to a LARC, as some women would have still ended 
their contraceptive spells without access to LARCs. LARC use has increased 
substantially during a time where sterilization has decreased, thus it is also possible that 
some LARC use is crowding out sterilization. In this case, increased LARC use would 
not result in large differences in unintended pregnancies. Studies of the substitution 
patterns between LARCs and sterilization are needed. 
LARC use may have a greater effect on pregnancies among special populations 
such as teenagers. Analyses using data from the Colorado Family Planning Initiative find 
that increased LARC access lowered teen pregnancy rates and abortions (Kelly et al., 
2019; Lindo & Packham, 2017). It is also possible that women who choose to switch to 
LARCs do so because they struggle to use their methods consistently. In this case, 
increased LARC access could still provide a large reduction in the probability of 
pregnancy even among women who are switching from moderately effective methods. In 
order to better understand the benefits of long-acting methods, studies are needed to 
investigate if women choosing LARC methods are more likely to have higher failure 
rates when using other methods.  
Using the National Survey of Family Growth also has its limitations. The 
contraceptive calendar is relatively short (a maximum of four years) and collected 
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retrospectively, thus there may be concerns with the reliability of reporting.13,14 
Additionally, the NSFG was shortened after the 1995 survey by omitting questions 
regarding work and education over the span of the calendar. The user guide of the NSFG 
datasets also note that the data have been perturbed to prevent individuals from being 
identified, but no details regarding the perturbation are given. 
2.7 Conclusion 
More than 40% of pregnancies that occur in the United States are unintended, 
with 41% of these pregnancies occurring due to inconsistent and incorrect use of 
contraception. Long-acting reversible contraceptives do not rely on user compliance and 
are very effective, thus increased LARC access could be an important part of a strategy to 
reduce unintended pregnancies. Because LARCs can have high up-front costs and unique 
barriers, policy interventions may be needed to increase access to LARCs.  
 
13 A paper assessing potential errors in the 1995 found inconsistencies within roughly 10% of the NSFG 
data (Martin & Wu, 1998). However, it should be noted that the 1995 NSFG was conducted with the 
interviewer using pencil and paper, collected information on sexual activity differently, and had a much 
longer questionnaire than the ones used in more recent versions of the NSFG. The paper assessing the 
quality of the 1995 NSFG recommended shortening the survey and rephrasing the sexual activities 
questions improve the quality of the survey; both of these changes were implemented by the next survey, 
with the survey time reduced from 100 minutes to 80.   
14 Approaches similar to the calendar method in the NSFG have been used in some of the Demographic and 
Health Surveys (DHS). DHS are administered in developing countries and include 5-year calendars of 
contraceptive use if the prevalence of contraceptive use in the country is not below a certain threshold. 
Some DHS surveys with life-history calendars have interviewed the same women multiple times and have 
some overlap between the latter survey and the earlier survey, allowing for researchers to study 
inconsistencies between current use in the first wave and reports of use at that time in the second wave. 
Tabulating the results revealed some inconsistencies between the two waves at the individual level 
(Callahan & Becker, 2012; Strickler et al. 1997). It was also found that women with more complicated 
histories of fertility and contraception tend to have more inconsistencies in their responses (Callahan & 
Becker, 2012; Strickler et al. 1997).  
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In this paper I analyze the duration of LARC use and what women were using 
before they switched to a LARC. My results indicate that continuation of LARC use is 
high relative to the continuation rates of other contraceptives. Among contracepting 
women, spells of contraceptive use of moderately effective and less effective methods are 
at a similar risk of ending due to switching to a LARC—and perhaps even a reduced 
chance in the case of traditional method spells. This may dampen the effect of increased 
LARC use on pregnancy prevention.  
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CHAPTER III 
OF IVS AND IUDS: ASSESSING THE EFFECT OF LONG-ACTING REVERSIBLE 
CONTRACEPTION ON PREGNANCIES USING AN INSTRUMENTAL 
VARIABLES APPROACH 
 
 
3.1 Introduction 
Correct use of effective contraception allows women to control their fertility, 
which enables them to pursue higher levels of education, increase labor market 
attachment, and delay marriage (Bailey & Lindo, 2018; Bailey, 2006; Goldin & Katz, 
2002). Many contraceptive methods are difficult to use, resulting in typical use failure 
rates that are higher than the “perfect use” failure rates (Sundaram et al., 2017). Higher 
failure rates imply that there are unrealized welfare gains from reducing the gap between 
typical and perfect use, which can be filled by contraception that does not require regular 
user action. Subdermal contraceptive implants and intrauterine devices (IUDs) are very 
effective at preventing pregnancies with little to no user involvement for a period of 3 to 
10 years, depending on the type of device chosen (American College of Obstetricians and 
Gynecologists, 2015). Due to their long-acting nature, contraceptive implants and IUDs 
are collectively known as long-acting reversible contraception (LARC). By reducing the 
potential for user error, LARC use may improve women’s economic outcomes, 
particularly among women who are more likely to have contraceptive failures. 
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Identifying the causal effect of LARCs on pregnancies and births is difficult 
because the decision to use a long-acting method may be related to a women’s probability 
of becoming pregnant when she uses other contraceptive methods. If the decision to use a 
LARC is endogenous, then estimates of the impact of LARC use on pregnancies and 
births from approaches that do not account for this endogeneity will be biased. In this 
paper, I overcome this problem by using exogenous variation in LARC use due to a 
change in contraceptive recommendations from the American College of Obstetricians 
and Gynecologists (ACOG). The new recommendation encouraged providers to counsel 
patients on all contraceptive options, including IUDs and implants, and to encourage 
LARC use among women for whom it is appropriate. Using data from the National 
Survey of Family Growth, I demonstrate that the change in ACOG’s recommendation 
increased LARC use by roughly 9 percentage points for younger women with one child 
compared to older women with one child. The ACOG publication also reduced the 
probability of pregnancy among younger women in this cohort by over 5 percentage 
points.  
I combine these estimates to yield an estimate of the causal effect of LARC use 
on the probability of pregnancy and birth. My instrumental variables results indicate that 
LARC use reduced the probability of becoming pregnant in the subsequent year by 58.7 
percentage points and the probability of giving birth in the subsequent year by 44.3 
percentage points, compared to OLS estimates of 7.5 and 6.9 percentage points, 
respectively. These results imply that the marginal woman who was induced to use a 
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LARC would have had a relatively high failure rate if she used an alternative 
contraceptive method.  
Women who are poorer compliers with other contraceptive methods may select 
into LARC use because they find the compliance-free aspect of IUDs and implants to be 
particularly beneficial. To investigate the possibility that unobserved heterogeneity is 
driving some of my results, I estimate a correlated random coefficients model using a 
control function approach (Wooldridge, 2015). My results indicate that among current 
contraceptive users, women who select into LARC use would have been more likely to 
become pregnant in the subsequent year than the average woman had she not used a 
LARC. These results provide evidence that women who choose LARCs do so because 
they will experience a greater reduction in their probability of becoming pregnant 
compared to women who do not choose long-acting methods.  
The rest of the paper is organized as follows: In Section 3.2, I summarize relevant 
literature connecting contraceptive effectiveness to economic outcomes and relating 
LARCs to contraceptive effectiveness. In Section 3.3, I discuss the factors associated 
with LARC use, including ACOG guidelines and recommendations, such as the one I use 
for identification. In Section 3.4, I describe my data and sample selection and in Section 
3.5, I define my methods. In Section 3.6, I report the results of my difference-in-
differences estimation of the effect of the ACOG recommendations on LARC use and the 
reduced form estimates. In Section 3.7, I present my main results of the effect of LARCs 
on pregnancies and births. In section 3.8 I discuss various robustness checks. Section 3.9 
concludes. 
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3.2 Literature 
3.2.1 Contraceptive Effectiveness and Economic Outcomes 
Bailey and Lindo (2018) summarize the effect of fertility control on economic 
outcomes. Because many societal changes were occurring around the introduction of 
effective contraception in the 1960s and 1970s, it is difficult to disentangle the effect of 
birth control on economic outcomes from changes in women’s opportunities increasing 
the demand for contraception (Bailey, 2006; Bailey & Lindo, 2018). Much of the relevant 
literature uses exogenous variation in access to the pill for identification to estimate the 
causal effect of contraceptives on economic outcomes (Bailey, 2006; Bailey & Lindo, 
2018; Bailey et al., 2018; Beauchamp & Pakaluk, 2019; Goldin & Katz, 2002).  
Goldin and Katz (2002) use the introduction of the pill to younger, unmarried 
women in the 1970s to find that contraception allowed women to pursue higher levels of 
education and to delay marriage. Using the overturning of anti-obscenity statutes which 
had banned contraceptives, Bailey (2006) finds that while birth control does not explain 
the declines in fertility, it allowed women to control the timing of their pregnancies, 
leading to greater labor market attachment. Bailey et al. (2018) use the rollout of Title X 
to find that children born in households in which mothers had access to effective 
contraception were more likely to have greater economic resources. This literature 
implies that access to modern contraception has had positive effects on the economic 
outcomes of women and their children (Bailey & Lindo, 2018; Bailey et al. 2018). 
There may have been heterogeneous effects of the pill. Using changes in access 
due to the overturning of anti-obscenity laws, Beauchamp and Pakaluk (2019) find that 
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the introduction of the pill actually led to more nonmarital births and a lower probability 
of obtaining a high school diploma for some women, particularly among women of color 
and working-class women. The authors suggest that the mechanism of the “paradox of 
the pill” is through increased nonmarital sexual activity and subsequent contraceptive 
behavior and failures, which may be related to differential failure rates (Musick et al., 
2009). Access to a contraceptive that does not require user adherence could be 
particularly welfare improving for women who are more likely to experience 
contraceptive failures with other methods. 
3.2.2 Effectiveness of LARCs and Other Contraceptives 
LARC methods include intrauterine devices and subdermal contraceptive 
implants. LARCs are placed in the uterus or the arm by a medical professional and are 
approved to prevent pregnancy for 3 to 10 years, unless they are removed early 
(American College of Obstetricians and Gynecologists, 2015). The contraceptive 
effectiveness of these devices has been well established through clinical trials (Stoddard 
et al., 2011).  
Table 10 compares the perfect use and typical use failure rates for various 
contraceptive methods. LARCs, short-acting reversible contraceptives (SARCs), 
permanent methods, and condoms all have perfect use failure rates of 2% or less. The 
more substantial differences in effectiveness are seen in the typical use failure rates, in 
which LARCs are considerably more effective than methods that are less forgiving of 
user error (Sundaram et al., 2017; Trussell, 2011).
 
 
 
Table 10. Contraceptive Method Perfect and Typical Use Failure Rates 
 
Method Type Methods Perfect Use Failure Rate Typical Use Failure Rate 
No method N/A 85% 85% 
Traditional Withdrawal, fertility-awareness and 
calendar-based methods 
0.4% - 4% 19.9+% 
Barrier Male condoms, female condoms, 
diaphragms, creams, jellies 
2 – 20 % 12.6+% 
SARC Pills, patches, rings, shots 0.3% 4 - 9% 
LARC Implant, hormonal IUD, copper IUD 0.05% – 0.6% 0.05% - 0.8% 
Sterilization Male, female (including Essure, 
tubal ligation, hysterectomy) 
0.1% – 0.5% 0.15% – 0.5% 
Source: Trussell (2011) and Sundaram et al. (2017). Failure rates denote the probability of a couple becoming pregnant during the first year of use. 
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The low failure rates of LARCs are also demonstrated in observational and 
prospective studies. The St. Louis Contraceptive CHOICE Project aimed to remove 
barriers to LARC use by offering contraceptive counseling and covering the cost of 
contraception for two to three years. Telephone surveys of participants occurred every six 
months during this time (McNicholas et al., 2014). Results based on data from the 
CHOICE Project show that the failure rates for LARC users were less than 1% at years 
1,2, and 3, respectively, and that these rates were considerably lower than those of 
women using non-LARC reversible contraception (McNicholas et al., 2014).  
There are two papers in the economics literature, both using data from the 
Colorado Family Planning Initiative (CFPI), that identify causal effects of LARC access 
on outcomes such as unintended pregnancies and abortions. The CFPI increased access to 
LARCs by providing IUDs and implants without cost to patients and implementing 
informational campaigns to increase awareness of Title X clinics (Ricketts et al., 2014). 
Lindo and Packham (2017) use a difference-in-differences approach by defining counties 
near or with Title X clinics as the treatment group and find that increased LARC access 
decreases teen pregnancies and abortion. In a recent paper, Kelly et al. (2019) refine the 
2017 difference-in-differences approach by using ZIP codes to gauge the distance from 
Title X clinics and defining the treatment group as ZIP codes that were close to clinics. 
The Kelly et al. (2019) results indicate that LARC use decreases pregnancies among both 
teens and young adults and also decreases the abortion rate. 
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3.3 Background 
3.3.1 Contraceptive Use in the United States 
Before the creation of the pill, contraceptive options in the United States included 
barrier methods such as condoms and diaphragms and traditional methods such as 
withdrawal (Tietze, 1965). The 1960s brought in new types of modern contraception 
(Bailey & Lindo, 2018; Hubacher & Cheng, 2004). The first pill was approved as a form 
of birth control in 1960 and women quickly began adopting the method, with nearly 24% 
of married contracepting women using the pill by 1965 (Bailey & Lindo, 2018; Mosher 
& Westoff, 1982). The modern history of LARC use in the US started in the 1960s with 
the introduction of several IUDs (Hubacher & Cheng, 2004).15 IUDs became the method 
of choice for close to 10% of married contracepting women by 1973 (Hubacher & Cheng, 
2004; Mosher & Westoff, 1982). Due to a poorly designed device called the Dalkon 
Shield and concerns that IUDs increased the probability of pelvic inflammatory disease, 
IUDs fell out of favor in the United States and their use remained very low through the 
1990s (Branum & Jones, 2015; Hubacher, 2002; Hubacher & Cheng, 2004). 
The pill continues to be one of the most popular forms of reversible contraception, 
used by nearly 20% of contracepting women (Daniels & Abma, 2018). Other short-acting 
reversible methods have been introduced in the past few decades, including injectable 
contraception (Depo-Provera), rings, and patches. Additionally, women can also choose 
to use barrier and traditional methods. LARC use has increased in recent years, with pills, 
 
15 Hubacher and Cheng (2004) note that IUD access in the US prior to 1960 was “extremely limited.” 
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LARCs, and male condoms being the most frequently used reversible methods (Daniels 
& Abma, 2018).  
3.3.2 Factors Associated with LARC Use 
Variation in LARC use depends on age, with a higher prevalence among women 
in their 20s and 30s compared to teens and women in their 40s (Branum & Jones, 2015; 
Daniels & Abma, 2018). In earlier studies, Hispanic women and non-Hispanic White 
women are more likely to use LARCs than Black women (Branum & Jones, 2015). While 
this pattern of LARC use by race and ethnicity is still present in the most recent 
estimates, the differences in use by race and ethnicity are no longer statistically 
significant (Daniels & Abma, 2018). LARC use is similar across types of insurance and 
does not vary significantly by education level (Daniels et al., 2015). LARC prevalence 
has historically been greater among mothers than women without children, but LARC use 
has increased among women without children in recent years (Branum & Jones, 2015).   
Less than 2% of women were using a LARC method in the late 1980s through the 
early 2000s (Branum & Jones, 2015). The use of long-acting methods began to rise in the 
mid-2000s and soon made up over 11% of contraceptive use by 2012 (Kavanaugh & 
Jerman, 2018).This upward trend has continued, with nearly 16% of contraceptive users 
ages 14-49 reporting using an implant or IUD in 2016 (Daniels & Abma, 2018). Thus, 
after decades of nearly negligible LARC use, the US has seen a considerable increase in 
LARC use in less than two decades.  
There are issues on both the supply and demand side of the market for LARCs 
that can explain some of the previously low prevalence of use and the recent increases in 
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utilization. Demand-side issues that have affected LARC uptake include a lack of 
familiarity with the methods, concerns over side effects, misinformation, and 
prohibitively high costs of insertion (Foster et al., 2015), though the implementation of 
the Affordable Care Act’s contraceptive mandate in August 2012 has made LARCs more 
affordable for some women (Becker & Polsky, 2015). Supply-side issues preventing 
wider use of LARCs have included misinformation and reluctance from providers to 
insert LARCs into women who are adolescents, do not have children, or who have a 
history of sexually transmitted infections (Luchowski et al., 2014). Additional supply-
side barriers include difficulty keeping the devices in stock and a lack of trained 
providers (Beeson, et al. 2014; Foster et al., 2015; Phillips & Sandhu, 2018).  
Hubacher et al. (2011) discuss factors that could contribute to the recent rapid rise 
in LARC use, breaking up the potential explanations into three categories. The first 
category is patient factors, such as direct-to-consumer marketing, increased affordability, 
and positive word-of-mouth. The second category is product factors, such as new devices 
(e.g. Mirena) and changes in labeling of the devices. Finally, the third category is 
provider factors, which includes greater training and familiarity with LARCs, recognition 
of their non-contraceptive benefits, awareness of LARC use outside the US, and 
organizations working to help providers become better informed about long-acting 
methods (Hubacher et al., 2011).  
Hubacher et al. (2011) also point to changes in provider recommendations from 
the American College of Obstetricians and Gynecologists (ACOG) as a reason that 
LARC use has increased. The authors focus on the release of two publications. The first 
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publication is Practice Bulletin 59, which was released in January 2005 (American 
College of Obstetricians and Gynecologists, 2005). This bulletin endorsed LARC use in a 
broad population of women, including some women without children. The second 
publication mentioned was a 2007 committee opinion supporting the use of LARCs as 
“front-line” contraceptives for some adolescents (American College of Obstetricians and 
Gynecologists, 2007a.; Hubacher et al., 2011).  
In December 2009, ACOG released a new opinion, Committee Opinion 450 
(“Increasing Use of Contraceptive Implants and Intrauterine Devices to Reduce 
Unintended Pregnancy”), which may have had a larger effect on women in their 20s than 
women in their 30s. This committee opinion differed from the previous ACOG 
publications in that it actively encouraged providers to increase LARC use to prevent 
unintended pregnancies, encouraged providers to discuss all contraceptive options (even 
if the woman had a preferred option), detailed potential barriers to LARC use, and 
described how providers could help overcome these barriers (American College of 
Obstetricians and Gynecologists, 2009). 
Medical professionals have been wary of IUD use in young women, women 
without children, or women at risk of sexually transmitted infections (STI) (Luchowski et 
al., 2014). In the early 1990s, ACOG released a bulletin noting that IUDs were best 
suited for older mothers in monogamous relationships (American College of 
Obstetricians and Gynecologists, 1992). Because women in their 20s may not have been 
seen ideal candidates for LARCs previously and because they have historically had the 
highest rates of unintended pregnancies (Finer & Zolna, 2016), providers may have 
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responded more strongly to CO 450 when counseling younger women. This response 
could have led to increased LARC use in this population compared to older women. It is 
this variation in LARC use that I use as an instrument in my main analysis.  
3.4 Data 
3.4.1 The National Survey of Family Growth 
I use data from the 2006-2010, 2011-2013, and 2013-2015 female respondent 
files of the National Survey of Family Growth (NSFG). The female respondent 
questionnaire records demographic and socioeconomic information and other factors 
regarding reproductive well-being. Importantly, the NSFG contains a life-history 
calendar and records events such as marriages, sexual activity, pregnancies, and 
contraceptive use month-by-month for up to four years preceding the interview. After 
combining the datasets, there were observations from 23,579 women. After removing 
observations that were missing pertinent information, there were 23,362 woman-level 
observations.  
In Table 11, column 1, I report summary statistics from the NSFG. Slightly under 
half of the women in my sample have not had children. The high proportion of women 
without children reflects the NSFG’s oversampling of women under 20. The proportion 
Black and proportion Hispanic also reflect the NSFG’s sampling scheme. Over half of the 
women used private insurance in the past year, and 62% of women are currently working 
at the time of the interview.  
 
 
 
 
Table 11. Summary Statistics from 2006-2010, 2011-2013, and 2013-2015 National Survey of Family Growth 
 
 (1)  (2) (3) (4) (5) (6) 
Women-Level 
Variables 
NSFG Time Varying NSFG Ages 21-27: 
Pre-Period 
Ages 21-27: 
Post-Period 
Ages 31-35: 
Pre-Period 
Ages 31-35: 
Post-Period 
Age at interview  28.639 Age during year 27.136 24.015 24.036 32.935 32.928 
Black 0.227 Pregnant this year 0.080 0.197 0.176 0.095 0.124 
Hispanic 0.236 Pregnant next year 0.076 0.174 0.143 0.086 0.106 
Currently married 0.313 Birth next year 0.060 0.138 0.116 0.070 0.085 
No children 0.455 Black 0.227 0.320 0.289 0.207 0.208 
Parity b 2.162 Hispanic 0.236 0.242 0.280 0.200 0.210 
Private insurance 0.563 LARC use 0.058 0.096 0.237 0.089 0.142 
Public insurance 0.257 SARC use 0.267 0.498 0.420 0.397 0.390 
No insurance  0.143 Condom use 0.193 0.380 0.292 0.296 0.277 
Currently working 0.623 Traditional 0.071 0.138 0.161 0.136 0.192 
  Sexually active 0.736 0.979 0.972 0.958 0.943 
  Married 0.350 0.358 0.337 0.609 0.570 
  LTHS 0.060 0.183 0.118 0.119 0.071 
  Any contraception a 0.683 0.782 0.800 0.708 0.733 
Number of women: 23,362 Number of woman-years 93,233 1,641 1,375 818 718 
Notes: Unweighted data from the 2006-2010, 2011-2013, and 2013-2015 NSFG. Data used from non-survey years only. Columns 3-6 includes 
contraceptive users only (except for the “Any contraception” row, which includes both contracepting and non-contracepting women). Women in the 
treatment group are between the ages of 21 to 27 with one child, and women in the control group are between the ages of 31 and 35 with one child. 
LTHS indicates that the respondent has less than a high school education. 
a Number of women years (Any contraception):  2,666, 2,223, 1,514, and 1,225 for columns 3-6, respectively. 
b Among women with at least one child. 
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Using the month-by-month contraceptive and sexual history calendars, I construct 
retrospective panel data of contraceptive use. Women were interviewed in different 
months and were asked about their contraceptive use during the current year and the three 
years before the survey. Because of this, some women contributed 37 months of data 
while others contributed up to 48 months. I consider the implications of this issue in a 
sensitivity analysis in which I restrict my sample to non-survey years. My final dataset 
contains information on race, ethnicity, age, sexual activity, pregnancy, births, and 
contraceptive use. 
The reliability of retrospective contraceptive histories from life table calendars 
may be questionable as recall is not completely accurate, especially among women with 
more complicated contraceptive histories (Callahan & Becker, 2012; Martin & Wu, 
1998.; Strickler et al., 1997). Due to evidence of heaping of the month of contraceptive 
initiation, I aggregate the monthly data into years.16 A woman is considered sexually 
active if she was sexually active at any time during the year and married if she reported 
being married for any of the months. Similarly, if the woman reports a new pregnancy 
during any month, then she has had a pregnancy that year. A woman’s contraceptive 
status depends on the most effective method used during any month of the year.17 The 
year-level indicators are not exclusive. For example, if a woman used a SARC and 
condoms from January-March, she will be considered a SARC user for those months. At 
 
16 Appendix C, Table C.1 reports the proportion of new contraceptive spells initiated in each month. The 
proportion beginning in January is 13.48% compared to a range of 6.76-8.73% in other months.  
17 Appendix C, Table C.2 lists the criteria used to rank the “main contraceptive method” in a particular 
month. 
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the year level, she will be considered a SARC user. If she switched to using a LARC 
method from April-December, then she will be a LARC user for those months, and at the 
year level she will also be considered a LARC user.  
In Table 11, column 2, I provide descriptive statistics of the time-varying 
variables. Women report using some form of contraception during 68% of the years, with 
SARCs being the most common method. Women also reported being sexually active in 
74% of the years and married during 35% of the years. 
3.4.2 Sample Restrictions 
To analyze the effect of CO 450, I designate contracepting women between the 
ages of 21 to 27 with one child as the treatment group and contracepting women between 
the ages of 31 to 35 with one child as the control group. I define the pre-period as years 
2005-2009 and the post-period as the years 2010-2013. Because I am interested in the 
additional effectiveness of LARCs compared to other methods, I restrict my sample to 
contraceptive users only. In order to make this restriction, increased LARC use must not 
affect contraceptive use on the extensive margin differently for younger women 
compared to older women.18 
I only include women with one child for two reasons. First, though LARC use 
among nulliparous women was slowly increasing during this time frame, many providers 
were hesitant to insert IUDs (which make up a large majority of LARC use) in women 
without children (Branum & Jones, 2015; Luchowski et al., 2014). This likely dampened 
 
18 I test this assumption by assessing the impact of CO 450 on the decision to use any contraceptive 
(reported in Table 12). I also report my main results without this sample restriction in Appendix E. 
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the effect of CO 450 in this population. Second, young women with two or more children 
may be fundamentally different than others in my treatment and control groups and 
women in their 30s with more than one child may be more likely to be considered 
candidates for sterilization. 
I exclude women under the age of 20 as adolescents may face different 
circumstances regarding their reproductive care than older women. Because I am using 
an estimated age based on the woman's age at time of survey, I do not include women 
who are 20 as they may have been 19 for the majority of the year. I also do not include 
women between the ages of 28 and 30 to prevent women from aging out of my treatment 
group and into my control group as each woman can contribute up to 4 years of 
information.  
Practice Bulletin 59 was released in January 2005 and may have affected 
providers’ attitudes towards LARCs; thus, I begin my pre-period in 2005 and continue it 
through 2009. I define my post-period as the years 2010-2013. These cutoffs are sensible 
as 2010 was the first year after the release of CO 450, and various changes from the 
Affordable Care Act (ACA) were implemented in 2014, such as the rollout of Medicaid 
Expansion for many of the participating states (U.S. Department of Health and Human 
Services, 2014, as cited in Forum on Medical and Public Health Preparedness for 
Catastrophic Events et al., 2014, Appendix F). 
In Table 11, columns 3 through 6, I report summary statistics for women in my 
treatment and control groups during the pre- and- post periods. In the pre-period, younger 
women and older women have a similar prevalence of LARC use (9.6% and 8.9% for 
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younger and older women, respectively), but in the post-period the difference has grown 
considerably, with 23.7% of younger women using a LARC compared to 14.2% of older 
women. Despite the large gap in LARC use, the use of any contraception increases 
slightly but similarly in both groups (from 78.2% to 80.0% for young women and 70.8% 
to 73.3% for older women). There are changes in the proportion of women with less than 
high school education in the pre- and post- periods, which are also quite different when 
comparing the two groups of women. There are also differences in both groups regarding 
marital status, but these differences are similar in both periods.  
3.5 Methods 
3.5.1 The Effect of CO 450 
I use a difference-in-differences (DID) design to estimate the effect of ACOG’s 
Committee Opinion 450 on the LARC use of younger women versus older women. I 
specify the DID as: 
 
 𝐿𝐴𝑅𝐶 = 𝛾𝑝𝑜𝑠𝑡 × 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 + 𝑥 𝜂 + 𝛿  (5) 
 
 
In which 𝑝𝑜𝑠𝑡  indicates years 2010-2013 and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  indicates that the woman is 
between the ages of 21 and 27. 𝑥  is a vector of regressors that includes indicators for if 
the respondent is Black, of Hispanic ethnicity, married, and sexually active and a set of 
age and year controls. 19 𝛿  is an error term. I do not include the main effects for 𝑝𝑜𝑠𝑡  
and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  as the age and year controls subsume them. Because I am using 
 
19 I include women who are not sexually active in my analysis for both the LARC and the pregnancy 
equations as some women may choose abstinence as a contraceptive method. I report results excluding 
sexually inactive women in Appendix E. 
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retrospective histories and most of the socioeconomic information was collected for the 
time of the survey, I do not include variables such as income or insurance status in my 
analyses.20  
To be valid as an instrument, CO 450 needs to satisfy the conditions of relevance, 
independence, excludability and monotonicity (Lousdal, 2018). As a committee opinion 
actively aiming to increase LARC use, CO 450 should have an effect on the probability 
of using a LARC (relevance); as a supply-side shock, the committee opinion should be 
unrelated to unobserved woman-level factors that would affect the probability of 
becoming pregnant (independence); CO 450 should only have affected the probability of 
pregnancy through changes in contraceptive use (excludability) and should have not 
caused women to choose to not use a LARC (monotonicity). 
3.5.2 The Effect of LARC Use on Pregnancy 
I use an instrumental variables approach to estimate the effect of LARC use, in 
which the previously described difference-in-differences model is the first stage. I 
consider three outcomes in my second stage. First, I consider the probability of becoming 
pregnant in the current year. This outcome introduces timing issues, as I cannot 
differentiate between pregnancies that occur before and after the initiation of a 
contraceptive method. Second, I estimate the effect of LARCs on the probability of 
becoming pregnant in the following year. This relationship may be of interest, as LARC 
methods are long-acting and have continuation rates of greater than 80% for the first year 
 
20 Analyses including controls for income and insurance are included in Appendix E. 
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(Diedrich, Zhao, et al., 2015). This outcome also does not face the same timing issue as 
the current year pregnancy variable. Finally, I consider the effect of LARCs on the 
probability of giving birth in the following year, in which the pregnancy could have 
started in the current year. The outcomes related to the future can only be estimated in 
years when there is information on the following year, and thus observations from the 
survey year are removed during estimation. 
My estimating equation for the second stage is as follows: 
 
 𝑦 = 𝛼𝐶𝑜𝑛𝑡𝑟𝑎 + 𝑥 𝛽 + 𝜖   (6) 
 
 
Where 𝑦 is whether or not a woman reports a pregnancy during the current year, whether 
or not a woman reports a pregnancy in the following year, or whether or not a woman 
reports a birth in the following year. 𝐶𝑜𝑛𝑡𝑟𝑎  is a set of indicators for contraceptive use, 
including LARC and non-LARC methods, 𝑥  is defined as it was in equation 1, and 𝜖  is 
an error term. 
If the decision to use contraception (including LARCs) is exogenous, then I can 
use OLS to estimate the causal relationship between LARC use and fertility. It seems 
likely, however, that due to factors such as differences in fecundity, difficulty complying 
with contraceptive regimens, sexual activity, or openness to unintended pregnancy, the 
decision to use any particular method may be related to 𝜖 . That is: 
 
 𝑐𝑜𝑣(𝑒 , 𝑐𝑜𝑛𝑡𝑟𝑎 ) ≠ 0 (7) 
 
 
 
63 
 
I am interested in estimating the causal effect of LARC use on a woman’s 
probability of becoming pregnant or giving birth. I designate this effect as: 
 
 𝜃 = 𝑦 − 𝑦  (8) 
 
 
In the above, 𝑦  indicates a woman’s probability of becoming pregnant or giving birth 
while using a LARC and 𝑦  indicates her probability of becoming pregnant or giving 
birth when not using a LARC. In practice, I can only observe either 𝑦  or 𝑦 , thus I must 
estimate the average causal effect of LARC use, which can be expressed as (Cerulli, 
2015): 
 
 𝜃 = 𝐸[𝑌 |𝐿𝐴𝑅𝐶 = 1] − 𝐸[𝑌 |𝐿𝐴𝑅𝐶 = 0] (9) 
 
 
Based on the clinical effectiveness of LARCs, 𝐸[𝑌 |𝐿𝐴𝑅𝐶 = 1] should be close to zero. 
If the decision to choose a LARC is randomly assigned, then the difference between the 
terms in equation 9 will give an unbiased estimate of the average effect of LARCs on 
pregnancies and births. As noted, 𝜖  and the decision to use a long-acting method may 
not be independent for the reasons listed previously.  
If women who are more likely to become pregnant choose LARCS, then women 
who do not use LARCs are less likely on average to become pregnant. In this case, the 
estimated difference between the probability of becoming pregnant for LARC users and 
non-LARC users will be too small and OLS will understate the effect of LARCs. It is 
also possible that there is a negative correlation between 𝜖  and the decision to use a 
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LARC. For example, if women who use IUDs and implants would correctly use other 
methods but prefer LARCs as a matter of convenience or because they are very averse to 
pregnancy, then it is unlikely that they would have become pregnant while using a short-
acting method. In this case, women who choose LARCs would have a lower probability 
of pregnancy and birth on average compared to women who remain in the non-LARC 
group. Thus, the difference between the probability of becoming pregnant for LARC 
users and non-LARC users will be too large and OLS will overstate the effect of LARCs. 
Because of this, it is necessary to use an alternative method (such as 2SLS) to estimate 𝜃.  
A benefit of 2SLS is that it is fairly robust and that it can produce good 
approximations of local average treatment effects when the probability of the outcome 
equation is not too close to zero or one (Angrist, 2001; Chiburis et al., 2012). A drawback 
of 2SLS is that the standard errors are often larger than that of OLS (Wooldridge, 2010). 
Ignoring the binary nature of the LARC variable can lead to less efficient estimation of 
the LARC equation (Cerulli, 2015). To gain efficiency, I estimate a probit model of 
LARC use on the exogenous variables and the interaction of 𝑝𝑜𝑠𝑡  and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  and 
use the predicted propensity score from the probit regression as the instrument in the 
2SLS estimation.21 This procedure increases efficiency in the first stage, as the predicted 
propensity score should be more strongly related to LARC use than just the DID 
 
21 The procedure is as follows: 1.) Use probit regression to estimate a model of LARC use on the 𝑥’s and 
the 𝑃𝑜𝑠𝑡 × 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  interaction and obtain the predicted probabilities from this model. 2.) Estimate 
the LPM first stage of 𝐿𝐴𝑅𝐶  on the 𝑥 variables and the predicted probabilities from the probit model. 3.) 
Run an LPM of 𝑦 on the 𝑥 variables and the predicted values from the 𝐿𝐴𝑅𝐶  equation. Note that the 
standard errors do not need to be corrected for the presence of a generated instrument. See Cerulli (2015) p. 
170-171. 
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interaction term on its own (Cerulli, 2015). Following Cerulli (2015), I will refer to the 
traditional 2SLS procedure as “direct 2SLS” and the 2SLS using the predicted propensity 
score as an instrument as “probit 2SLS.”  
Another common way to estimate the average causal effect when both the 
outcome and endogenous variables are binary is by estimating a recursive bivariate probit 
model using maximum likelihood estimation (Chiburis et al., 2012; Heckman, 1978). In 
my current application, this requires specifying the LARC and pregnancy equations as: 
 
 𝑦 = 𝑰(𝜃𝐿𝐴𝑅𝐶 + 𝑥 𝛽 + 𝜖 > 0)  (10) 
 
 
 𝐿𝐴𝑅𝐶 = 𝑰(𝛼𝑃𝑜𝑠𝑡 × 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 + 𝑥 𝛽 + 𝛿 > 0) (11) 
 
 
And assuming joint normality of the error terms, 𝛿  and 𝜖 . A criticism of this approach 
is that it requires strong assumptions about the functional form (Angrist, 2001). In 
column 5 of Table 14, I report the marginal effects from the recursive bivariate probit 
specification.  
3.6 First Stage and Reduced Form Results 
3.6.1 Difference-in-Differences Estimates 
In the top row of Table 12, I report the first stage results for women with one 
child, regardless of contraceptive status. The release of CO 450 did not affect the use of 
any contraception among young women compared to older women, but it did increase the 
use of LARCs and decrease the use of short-acting methods (such as pills) and condoms. 
It also did not affect the use of traditional methods. The impact on the use of SARCs and 
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condoms implies that women who use IUDs and implants may have used other 
potentially effective methods. Thus, increases in contraceptive effectiveness should be 
through LARC methods reducing the possibility of user error. 
In the bottom row of Table 12, columns 2 through 5, I re-estimate the difference-
in-difference results for the four method categories among contraceptive users only. 
There is a slightly stronger effect of CO 450 on both LARC use and SARC use while the 
effect on traditional method use remains insignificant. The coefficient from the condom 
use model is no longer statistically different from zero. Column 6 reports the results from 
the LARC use equation during non-survey years, and column 7 reports the average 
marginal effect from the probit model used to generate the instrument in the probit 2SLS 
results. 
I also estimate the reduced form results using the specification listed in equation 
5, but with the three outcomes of interest as the left-hand variables. I report these results 
in Table 13. The coefficient on the difference-in-differences interaction term is 
statistically significant and negative across outcomes, indicating that the release of CO 
450 had a negative impact on pregnancies and births. 
  
 
 
 
Table 12. Difference-in-Differences Results: The Effect of CO450 on LARC Use 
 
 (1) (2) (3) (4) (5) (6) (7) 
 
Any 
Contraceptives LARC SARC Condoms Traditional 
LARC  
(Non-Survey 
Years) 
LARC  
(Probit)a 
Any Contraceptive 
Status 
       
PostxTreatment -0.021 0.078*** -0.060** -0.053** -0.032 0.071*** 0.060** 
 (0.025) (0.020) (0.029) (0.026) (0.021) (0.022) (0.025) 
N 7,628 (3,647) 7,628 (3,647) 5,891(3,261) 7,628 (3,647) 
Contraceptive Users 
Only 
       
PostxTreatment  0.096*** -0.069* -0.055 -0.039 0.089*** 0.083*** 
  (0.026) (0.036) (0.033) (0.027) (0.028) (0.031) 
N 5,832 (2,958) 5,832 (2,958) 4,552 (2,629) 5,832 (2,958) 
Number of woman-years (number of women). Unweighted data. Pre-period is 2005-2009; post-period is 2010-2013. Treatment indicates women 
ages 21-27 with one child while control group includes women ages 31-35 with one child. All specifications include indicators for if the woman is 
Black, Hispanic, married, sexually active, has less than a high school education and year and age controls. Standard errors are clustered on the 
woman level.  
*, **, and *** indicate significance at the 0.10, 0.05, and 0.01 levels, respectively. 
a Average marginal effect. 
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Table 13. Reduced Form Results: The Effect of CO450 on Pregnancies 
 
 (1) (2) (3) 
 Pregnant This 
Year 
(OLS) 
Pregnant next 
year 
(OLS) 
Birth next year 
(OLS) 
PostxTreatment -0.052*** -0.052*** -0.039** 
 (0.018) (0.020) (0.018) 
N 5,832 (2,958) 4,552 (2,629) 4,552 (2,629) 
Number of woman-years (number of women). Unweighted data from the 2006-2010, 
2011-2013, and 2013-2015 National Survey of Family Growth. Contraceptive users 
only. N indicates the number of woman-years (number of women). Pre-period is 
2005-2009; post-period is 2010-2013. Columns 2 and 3 do not include observations 
from the survey year. Treatment indicates women ages 21-27 while control group 
includes women ages 31-35. All models include indicators for if the woman is Black, 
Hispanic, married, sexually active, has less than a high school education and year and 
age controls. Standard errors are clustered on the woman-level. 
 *, **, and *** indicate significance at the 0.10, 0.05, and 0.01 levels, respectively. 
 
 
3.6.2 Threats to Validity 
CO 450 was released in December 2009, when the economy was in the midst of 
the Great Recession and right before the Affordable Care Act was signed into law. A 
discussion of how these factors may affect my results is warranted. 
The recession may have increased the relative cost of childbearing (Stone, 2018) 
and thus increased the demand for more reliable contraception. There was growth in the 
popularity of long-acting reversible methods among most groups of women during this 
time (Branum & Jones, 2015). It seems unlikely, however, that LARC use would 
experience a sudden jump in 2010 compared to 2008 or 2009 due to the recession or that 
there would be such a differential effect on LARC use for mothers in their 20s versus 
mothers in their 30s.  
More concerning is the passage of the Affordable Care Act, which included a 
dependent care coverage provision for children up to the age of 26, a contraceptive 
 
69 
 
mandate which required that private insurance cover all FDA-approved contraceptives at 
100%, and the Medicaid expansions. I discuss each of these pieces of the ACA in turn. 
The dependent care provision was implemented in September 2010. After this 
time, children ages 18-25 could be covered under their parents’ insurance (Sommers et 
al., 2013). For the difference-in-differences results to be valid, the gap in LARC use must 
be explained by CO 450 and not by increased insurance access from the ACA. The initial 
gap in LARC use for younger women compared to older women occurred in 2010, even 
though the increases in coverage did not begin until late that year. If increased insurance 
coverage explained the divergence, then there should have been another substantial 
increase in LARC use in 2011—perhaps more substantial than in the initial jump in 
2010—as the number of young adults insured under the dependent care provision was 
greater in 2011 than in 2010 (Sommers et al., 2013). Such a pattern is not observed in the 
event study (Figure 1). Also, though the dependent care provision did increase insurance 
among young adults, the contraceptive mandate was still not in effect at this time (Becker 
& Polsky, 2015). Thus, the price of LARCs may have still been prohibitively high for 
some. 
The contraceptive mandate was implemented in August 2012, though its effect 
was not felt by many until 2013 (Becker & Polsky, 2015). Because the contraceptive 
mandate went into effect towards the end of the post-period, it cannot explain the gap that 
began in 2010. Similarly, while states were considering Medicaid Expansion during this 
time, the expansions themselves were implemented in 2014 (The Henry J. Kaiser Family 
Foundation, 2019a). 
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Figure 1. Event Study: The Effect of CO450 on LARC Use Among Mothers with 
One Child 
 
 
Unweighted data from the 2006-2010, 2011-2013, and 2013-2015 National Survey of Family Growth. 
Sample includes 5,838 woman-years from 2,561 women between the ages of 21 and 27, and 2,744 woman-
years from 1,328 women between the ages of 31 and 35. Dotted line indicates the release of Committee 
Opinion 450 in December 2009. The base year is 2008. 
 
 
3.7 Main Results 
3.7.1 The Effect of LARC Use 
In Table 14, I report the effect of LARC use on fertility outcomes. The OLS, 
direct 2SLS, probit 2SLS coefficients are in columns 1, 2, and 3, respectively. The 
marginal effects from a probit specification are reported in column 4, and the bivariate 
probit marginal effects are reported in column 5. Because I only have one instrument, I 
include an indicator for LARC use but not for any other form of contraception. The 
coefficient on LARC use can be interpreted as the additional effectiveness of using an 
IUD or implant compared to other methods. The three rows correspond with the three 
outcomes: Pregnant this year, pregnant next year, and birth next year.
 
 
 
Table 14. Instrumental Variables Results: The Effect of LARC Use on Pregnancies 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate Probita  
Pregnant this year      
LARC use -0.106*** -0.536** -0.389** -0.104*** -0.240*** 
 (0.010) (0.226) (0.160) (0.009) (0.061) 
Confidence set b  [-1.274, -0.173]    
Pregnant next year      
LARC use -0.075*** -0.587** -0.395** -0.074*** -0.080 
 (0.012) (0.278) (0.186) (0.012) (0.164) 
Confidence set b  [-1.66, -0.175]    
Birth next year      
LARC use -0.069*** -0.443* -0.246 -0.067*** -0.043 
 (0.011) (0.241) (0.156) (0.010) (0.203) 
Confidence set b  [-1.34, -0.057]    
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-
period is 2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while control group includes 
women ages 31-35. All models include indicators for if the woman is Black, Hispanic, married, sexually active, has less 
than a high school education and year and age controls. Standard errors are clustered on the woman-level. 
N: 5,832 woman-years from 2,958 women (row 1) and 4,552 woman-years from 2,629 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 13.32 (row 1); 9.86 (row 2 and 3) 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. Standard 
a Average marginal effects 
b Weak instrument-robust Anderson-Rubin confidence set computed using the ‘weakiv’ command in Stata. 
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Across specifications, LARC use has a negative and statistically significant effect 
on the probability of becoming pregnant in the current year. The OLS results indicate that 
LARC use decreases the probability of becoming pregnant among contraceptive users by 
10.6 percentage points. The 2SLS results are much larger but less precise, with an 
estimated 56.3 percentage point decline in the probability of becoming pregnant. The 
probit 2SLS results are smaller than the direct 2SLS results, but still indicate a larger 
effect on becoming pregnant in the current year than the OLS estimates. The bivariate 
probit results are smaller than either of the 2SLS results, but still more negative than 
those of OLS, with an estimated 24 percentage point decrease in the probability of 
becoming pregnant.  
The pattern for the “pregnancy next year” results is similar to that of the current 
year pregnancy results, with an exception of the estimates reported in column 5. The 
marginal effect from the bivariate probit model is similar to that of the OLS coefficient 
(-0.08 vs. -0.075, respectively), though the results are imprecise and not statistically 
different from zero. The birth equations also exhibit a similar pattern to the next year 
pregnancy results, only now the probit 2SLS results are no longer statistically significant. 
The bivariate probit results—while not different from zero—are smaller in magnitude 
than the OLS results. The estimates across the three outcomes indicate that LARC use 
has a large negative effect on the probability of pregnancy and subsequent birth among 
women who chose a LARC due to the release of CO 450. Given that women in their early 
20s have the highest rates of unintended pregnancies (Finer & Zolna, 2016), this implies 
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that increased access to LARCs could have a substantial impact on unintended 
pregnancies in the United States.  
Table 14 reports the F-statistics for the first stage of the direct 2SLS results. 
Because the F-statistics are fairly low (Andrews et al., 2019; Stock & Yogo, 2005), I also 
estimate Anderson-Rubin confidence sets for each of the outcomes (Anderson & Rubin, 
1949). The sets are wide and imprecise, but only contain negative values. These results 
provide further evidence that LARCs decrease the probability of pregnancy and births 
compared to other contraceptive methods. 
3.7.2 Possible Explanations 
To place the estimates into context, it is important to characterize what the mean 
of pregnancy would have been without any LARC use. In Table 11, I report that roughly 
18% of women in my treatment group experience a pregnancy. Assuming that LARC 
users do not become pregnant, the proportion of non-LARC users experiencing a 
pregnancy should be close to 24%.22  
The results vary by model and the coefficients on LARC use in the 2SLS results 
are quite large. There are multiple reasons why this may be the case. One explanation is 
that the 2SLS estimates reflect a local average treatment effect (LATE) (Angrist, Imbens, 
& Rubin, 1996) for women who were induced to use a LARC by the release of CO 450, 
 
22 In the post period, nearly 24% of young women used a LARC method. Using a back of the envelope 
calculation which assumes that pregnancies occur only among women who did not use LARCs, I find that 
the proportion of pregnancies among women not using a LARC should be approximately 0.18 ×
.
≈
0.237. 
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and that these women were particularly poor compliers with other methods and thus 
experienced a large reduction in their probability of pregnancy. This could explain the 
divergence between the 2SLS and bivariate probit results, as the bivariate probit is 
measuring the average treatment effect (Chiburis et al., 2012). Another explanation of the 
difference between the results more generally is that the sample sizes are less than 5,000, 
and it is expected that the 2SLS and bivariate probit models would produce different 
results, even if I had estimated the LATE from the bivariate probit (Chiburis et al., 2012). 
A second consideration when assessing the magnitudes of the coefficients is that 
LARC methods are difficult to discontinue. The coefficients may reflect decreases in the 
probability of pregnancies due to both the elimination of user error and less frequent 
discontinuation of contraceptive use. I explore this explanation in Table 15 in which I 
consider the importance of discontinuation and the intensity of contraceptive use by 
reestimating the results among women who have used contraception for at least nine 
months of the year. The direct 2SLS results are still quite large, ranging from -0.484 
to -0.500. The probit 2SLS coefficients are smaller (ranging from -0.226 to -0.331), but 
still larger than those of OLS. The marginal effects in column 5 range from -0.117 
to -0.136, though the results for becoming pregnant in the following year are not 
statistically significant from zero. Taken together, these results imply that using a LARC 
provides contraceptive effectiveness over other methods, but the magnitudes of the 
coefficients in the main results are affected partially by women with sporadic 
contraceptive use. 
 
 
 
Table 15. Instrumental Variables Results: The Effect of LARC Use on Pregnancies Among Women Who Use 
Contraception 9+ Months of Year 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate Probita  
Pregnant this year      
LARC use -0.064*** -0.484** -0.226* -0.062*** -0.117*** 
 (0.009) (0.239) (0.131) (0.008) (0.031) 
Confidence set b  [-1.773, -0.158]    
Pregnant next year      
LARC use -0.082*** -0.492* -0.331* -0.079*** -0.136 
 (0.014) (0.292) (0.187) (0.013) (0.121) 
Confidence set b  [-2.07, -0.024]    
Birth next year      
LARC use -0.038*** -0.500** -0.305** -0.038*** -0.132** 
 (0.008) (0.243) (0.137) (0.008) (0.054) 
Confidence set b  [-2.059, -0.173]    
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child who 
have used contraception for at least 9 months of a year. Pre-period is 2005-2009; post-period is 2010-2013. 
Treatment indicates women ages 21-27 while control group includes women ages 31-35. All models include 
indicators for if the woman is Black, Hispanic, married, sexually active, has less than a high school education and 
year and age controls. Standard errors are clustered on the woman-level.  
N: 3,121 woman-years from 1,816 women (row 1); 2,877 woman -years from 1,734 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 7.29 (row 1); 6.76 (rows 2 and 3) 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
a Average marginal effects 
b Weak instrument-robust Anderson-Rubin confidence set computed using the ‘weakiv’ command in Stata.  
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It is also possible the estimated effects of LARCs may be driven by some form of 
unobserved heterogeneity and that the effect of LARC use varies across women. One way 
of characterizing this is by using a correlated random coefficients model, in which the 
treatment effect for an individual depends on both the average treatment effect and a 
mean-zero random component (Wooldridge, 2015). I can use a control function approach 
in which I include an interaction of the potentially endogenous LARC variable and 
generalized residuals to account for the random component (Wooldridge, 2015). 23 In the 
first step, I estimate a probit first stage, regressing LARC use on the instrument and other 
covariates (equation 10) and then use the predicted values to generate generalized 
residuals. In the second step, I estimate the following: 
 
 𝑦 = 𝜃𝐿𝐴𝑅𝐶 + 𝑥 𝛽 + 𝑣 + 𝑣 × 𝐿𝐴𝑅𝐶 +  𝜖    (12) 
 
 
In Table 16, I report the results of this two-step process. In all specifications, I 
include the generalized residual. If the coefficient on the residual is not statistically 
significant, then I cannot reject the null that LARC use is exogenous. In columns 2, 4, 
and 6, I add the interaction of LARC use and the generalized residuals. The coefficient on 
the interaction term is not statistically significant in the “pregnant this year” or “birth next 
year” results. Coupled with the lack of significance on the main effect of the generalized 
 
23 I use generalized residuals because the LARC use variable is binary. Generalized residuals are calculated 
as ν =  D λ(zγ) − (1 − D)(λ(−𝑧𝛾)), where 𝜆(*) is the inverse mills ratio, 𝐷 is a binary indicator for if 
the woman is using a LARC and 𝑧 is the vector of exogenous variables (which includes the instrument). 
See Wooldridge (2015).  
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residual, I do not have evidence of heterogeneous treatment effects of LARCs on either 
of these outcomes.  
The more interesting results come from the pregnant next year outcome, in which 
there is evidence of selection into the use of long-acting methods based on heterogeneous 
treatment effects. The results in Table 16 indicate that women who choose LARCs 
experience a greater decrease in their probability of becoming pregnant in the following 
year. These results are sensible, as the long-acting, compliance-free nature of LARCs are 
likely what draw many women into using them.  
 
 
 
Table 16. Control Function Results: The Effect of LARC Use on Pregnancies 
 
 (1) (2) (3) (4) (5) (6) 
 Pregnant this 
year 
Pregnant this 
year 
Pregnant next 
year 
Pregnant next 
year 
Birth next 
year 
Birth Next 
Year 
LARC Use -0.313*** -0.349*** -0.123 -0.268* -0.106 -0.190 
 (0.117) (0.131) (0.136) (0.156) (0.124) (0.142) 
?̂?  0.115* 0.180 0.027 0.274* 0.020 0.164 
 (0.065) (0.125) (0.075) (0.151) (0.068) (0.137) 
LARC×?̂?  -0.056  -0.202*  -0.117 
  (0.091)  (0.107)  (0.097) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only. N = 5,832 woman-years from 2,958 
women with one child (columns 1 and 2); N = 4,552 woman-years from 2,629 women with one child (columns 3 through 6). Pre-period 
is 2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while control group includes women ages 31-35. ?̂? 
indicates generalized residuals. All specifications include indicators for if the woman is Black, Hispanic, married, sexually active, has 
less than a high school education and year and age controls.  
*, **, and *** indicate significance at the 0.10 ,0.05 and 0.01 levels, respectively.  
Bootstrap standard errors forthcoming. 
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3.8 Other Results and Robustness Checks 
3.8.1 Sample Selection 
In my main analysis, I define my sample as women with one child, however there 
is a possible sample selection issue introduced through this restriction. Women who have 
one child in their late 20s or early 30s may be better at preventing pregnancies than 
women in their early 20s, as women who have additional children—perhaps due to 
repeated contraceptive failures—select out of the sample over time. I re-estimate my 
main results after redefining my sample as women with one child or two same-sex 
children. I make this restriction as women with same-sex children are more likely to have 
a third child than women who have two opposite sex children (Angrist & Evans, 1996).  
As reported in Table 17, LARC use still decreases the probability that a woman will have 
a pregnancy or birth in the following year. The magnitudes of the 2SLS coefficients are 
smaller, and the coefficients in the current year pregnancy direct 2SLS specification is 
not significantly different than zero.
 
 
 
Table 17. Instrumental Variables Results: The Effect of LARC Use on Pregnancies Among Women with One Child or 
Two Children of Same Sex 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.094*** -0.245 -0.188 -0.091*** -0.162*** 
 (0.008) (0.150) (0.121) (0.007) (0.041) 
Confidence set b  [-0.618, 0.034]    
Pregnant next year      
LARC use -0.072*** -0.327* -0.260** -0.069*** -0.108* 
 (0.009) (0.168) (0.130) (0.009) (0.062) 
Confidence set b  [-0.771, -0.028]    
Birth next year      
LARC use -0.067*** -0.268* -0.216* -0.064*** -0.103 
 (0.008) (0.150) (0.115) (0.007) (0.415) 
Confidence set b  [-0.667, -0.001]    
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-
period is 2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while control group includes 
women ages 31-35. All models include year and age controls. Standard errors are clustered on the woman-level. 
N: 8,696 woman-years from 4,164 women (row 1); 6,793 woman -years from 3,731 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 18.72 (Panel A, row 1); 16.25 (Panel A, row 2 and 3) 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
a Average marginal effects 
b Weak instrument-robust Anderson-Rubin confidence set computed using the ‘weakiv’ command in Stata. 
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3.8.2 Other Robustness Checks 
Appendix E includes various sensitivity analyses. In Tables E.1–E.5, I consider 
other variations of my sample. In Table E.1, I report the main results for women 
regardless of contraceptive status while in Table E.2, I report the results for sexually 
active women only. In Tables E.3 through E.5, I vary the age groups and consider women 
ages 18-27 versus 31-35, 23-27 versus 31-35, and 23-27 versus 31-35, respectively. The 
results are overall similar to the main results, though there are some differences in the 23-
27 versus 31-35 estimates.  
Because some women do not contribute a full year of data during the survey year, 
Table AV.6 reports the estimates using only observations from non-survey years. The 
results are identical in the case of the pregnant and birth next year results, as they were 
already estimated without survey year observations, and the pregnant this year results are 
similar to the main results. In Table E.7, I report the results using the weights provided in 
the NSFG and in Table E.8, I reestimate the main results while controlling for insurance 
and income at time of survey. Weighting the data reveals a similar pattern to the main 
results (direct 2SLS results larger than the probit 2SLS results, which are larger than the 
OLS results), but results from the 2SLS models are very large. Including the income and 
insurance controls does not substantially impact the estimates.  
3.9 Conclusion 
In this paper I find that implants and IUDs provide women with better control 
over their fertility than other reversible methods, at least among women in their early 20s 
with one child. Increased ability to control the timing of fertility and number of births due 
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to LARCs may be related to the recent decline in fertility among young women (Buckles 
et al., 2019; Finer & Zolna, 2016). The availability of effective contraception has been 
shown to improve economic outcomes for women (Bailey & Lindo, 2018; Bailey, 2006; 
Goldin & Katz, 2002). Thus, by reducing the possibility of contraceptive failure due to 
use error, LARC use may result in significant economic benefits both to the women 
themselves and to society over the coming decades.24 
One limitation of the paper is the retrospective nature of the data, as such histories 
may be subject to recall bias. Additionally, because retrospective data is only collected 
for contraceptive use and sexual activity, I do not have information on past use of 
insurance, income, or labor force participation. The public-use file of the NSFG also does 
not include state identifiers. 
Another limitation is that these results may not be generalizable to women 
without children or women with larger families. Descriptive estimates of failure rates of 
contraception indicate that women with one child have higher 12-month failure rates than 
women without children (Sundaram et al., 2017). Thus, these results may be an upper 
bound on the effect of LARCs. Nonetheless, future work investigating changes in 
educational attainment and labor market outcomes due to increased LARC use is 
warranted (Bailey and Lindo, 2018). 
 
24 Bailey (2013) finds evidence that access to family planning may have long-run effects on the outcomes 
of children even into adulthood.   
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CHAPTER IV 
THE IMPACT OF LONG-ACTING REVERSIBLE CONTRACEPTIVE  
ATTRIBUTES ON METHOD CHOICE 
 
 
4.1 Introduction 
The United States has a higher rate of unintended pregnancies than other 
developed nations (Singh et al., 2010). It is estimated that 45% of pregnancies in the 
United States in 2011 were unplanned. Estimates from the Guttmacher Institute indicate 
that 41% of unplanned pregnancies occur among women who rely on contraceptives that 
are inconsistently or incorrectly used (Sonfield et al., 2014). Intrauterine devices (IUDs) 
and implants (collectively known as long-active reversible contraceptives or LARCs) do 
not rely on user adherence and thus have failures rates under 1% (Trussell, 2011). Due to 
their effectiveness, increased access and use of LARCs has been suggested as a way to 
decrease the rate of unintended pregnancy in the US (American College of Obstetricians 
and Gynecologists, 2015).  
As physical devices, there may be additional barriers to LARC use compared to 
other contraceptive methods. On the supply-side, a lack of trained providers, 
misinformation among providers, and difficulties keeping the devices in stock may 
prevent women from being able to access these methods (Beeson et al. 2014; Foster et al., 
2015; Luchowski et al., 2014; Phillips & Sandhu, 2018). On the demand-side women 
may be misinformed or unfamiliar with LARCs or may not be able to afford the high 
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out-of-pocket expenses that can be associated with LARC insertion (Foster et al., 2015; 
Kaye et al., 2009).  
LARC use has increased substantially since 2002 (Branum & Jones, 2015), yet a 
large proportion of women do not rely on implants or IUDs. In 2014, the proportion of 
women ages 15-45 using a LARC was still under 15% (Kavanaugh & Jerman, 2018). The 
most recent estimates of LARC use from the 2015-2017 National Survey of Family 
Growth show that just 10.3% of women between 15-49 years old were using either an 
IUD or an implant (Daniels & Abma, 2018). Among contracepting women, less than 16% 
relied on a LARC in 2016 (Daniels & Abma, 2018). 
Barriers to use might partially explain why more than 80% of contracepting 
women are not using either an implant or an IUD, however it is also possible some 
women decide against using a LARC even when they are accessible (Gomez et al., 2014). 
Contraceptive choice depends on a variety of factors, including side effect profiles and 
other considerations (Donnelly et al., 2014; Grady et al., 1999; Jackson et al., 2016; 
Lessard et al., 2012; Madden et al., 2015). Understanding how different attributes of 
contraceptives affect the decision of which contraceptive to use is imperative in 
constructing policies that address the needs of women.  
In this paper I estimate a set of models of contraceptive choice using data from 
the 2011-2013, 2013-2015, and 2015-2017 National Survey of Family Growth (NSFG). 
The results indicate that the LARC-related attribute of being a physical device is 
associated with lower levels of use. In order to increase the use of effective contraception, 
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and thus reduce the rate of unintended pregnancies, it may be necessary to both increase 
access to LARCs and to consider how to better address the needs of women who may 
want the benefits associated with LARC methods without some of their attributes.  
4.2 Background 
Many contraceptives are effective when used consistently and correctly (Trussell, 
2011). However, as women and their partners sometimes make mistakes, there can be 
large gaps between the “perfect use” and “typical use” failure rates for contraceptive 
methods that rely on adherence, including popular methods such as pills and condoms 
(Sundaram et al., 2017; Trussell, 2011). As a familiar example, the perfect use failure rate 
of the contraceptive pill is low (<1%), yet the typical use failure rate of the pill has been 
estimated to be 7.2% (Trussel, 2011; Sundaram et al., 2017). In Table 18, I compare the 
perfect use and typical use failure rates of various contraceptives.  
LARCs are devices that are inserted either in the arm (the contraceptive implant) 
or in the uterus (intrauterine devices or IUDs) and can provide contraceptive benefits for 
up to 3 to 10 years, depending on the specific LARC (American College of Obstetricians 
and Gynecologists, 2015).25 These methods are effective without requiring frequent effort 
from the user and have been advocated as a way to reduce the high rates of unplanned 
pregnancies by both the American College of Obstetricians and Gynecologists and the 
American Academy of Pediatricians (Committee on Adolescence, 2014; American 
College of Obstetricians and Gynecologists, 2015). As illustrated in Table 18, the perfect 
 
25 IUDs are also sometimes referred to as intrauterine systems (IUS) or intrauterine contraception (IUC). 
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use and typical use failure rates are very similar to each other for long-acting methods, 
which reflects their lack of reliance on user adherence. 
 
Table 18. Contraceptive Method Perfect and Typical Use Failure Rates 
 
Category Methods 
Perfect Use Failure 
Rate 
Typical Use Failure 
Rate 
Traditional Withdrawal, fertility-
awareness and calendar-
based methods 
4 - 0.4% 19.9+% 
Barrier Male condoms, female 
condoms, diaphragms, 
creams, jellies 
2 – 20 % 12.6+% 
SARC Pills, patches, rings, shots 0.3% 4 - 9% 
LARC Implant, hormonal IUD, 
copper IUD 
0.6 – 0.05% 0.8 – 0.05% 
Sterilization Male, female (including 
Essure, tubal ligation, 
hysterectomy) 
0.5 – 0.1% 0.5 – 0.15% 
Source: Trussell (2011) and Sundaram et al. (2017). Failure rates denote the probability of a couple 
becoming pregnant during the first year of use. 
 
 
Because LARCs are physical devices that require insertion by trained medical 
professionals, they can have unique barriers to use. On the supply-side, there may be a 
lack of providers trained in insertion, difficulty keeping the devices in stock, or providers 
may be misinformed or following outdated guidelines when determining if a woman is an 
appropriate candidate for LARC use (Beeson et al., 2014; Foster et al., 2015; Luchowski 
et al., 2014; Phillips & Sandhu, 2018). On the demand-side, women may be unfamiliar 
with LARCs, misinformed about their effectiveness or their safety, or they may not be 
able to afford the cost of having a device inserted (Foster et al., 2015; Kaye et al., 2009).  
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In 2002, less than 2% of women relied on a LARC method (Branum & Jones, 
2015). LARC use increased considerably between 2002 and 2014, yet the proportion of 
contracepting women ages 15-44 using a LARC in 2014 was still under 15% (Branum & 
Jones, 2015; Kavanaugh & Jerman, 2018). Hubacher et al (2011) describe factors that 
could explain increases in LARC use during the 2000s, including patient factors (direct-
to-consumer marketing, increased affordability, and positive word-of-mouth), provider 
factors (greater training and familiarity with LARCs, recognition of their non-
contraceptive benefits), product factors (new devices and label changes), and changes in 
provider recommendations.  
Since Hubacher et al (2011), there have been other changes in the landscape of 
LARC use, including the implementation of the Affordable Care Act’s contraceptive 
mandate which required the provision of LARCs with $0 out-of-pocket charges for 
women in private health insurance plans (Becker & Polsky, 2015). Despite these changes, 
the most recent estimate of LARC use from the 2015-2017 National Survey of Family 
Growth shows that just 10.3% of women between 15-49 years old are using LARC 
methods, with slightly under 16% of all contraceptive users relying on these methods 
(Daniels & Abma, 2018). 26  
Foster et al. (2015) surveyed 100 IUD experts on what they believed the largest 
barriers to IUD use were and what they projected the uptake of IUDs to be if these 
barriers were removed. The most common answer was that the experts expected LARC 
 
26 Using data from the NSFG, Daniels & Abma (2018) estimate that 10.3% of women ages 15-49 are 
LARC users and that women using any type contraception make up 64.9% of women in this age range. 
(10.3/64.9) =15.87. 
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adoption among 25-29% of contraceptive users in absence of barriers, implying that there 
may be other factors discouraging women from choosing LARC methods. It is possible 
that many women do not like the features of LARCs, leading to lower uptake. That is, 
some women may not choose LARCs simply because they are not their best 
contraceptive choice.  
4.2.2 Contraceptive Attributes 
Birth control methods are primarily used to prevent pregnancies, but they can also 
provide a range of other medical benefits. For example, certain hormonal birth control 
pills are prescribed to help regulate menstrual cycles, improve acne, and to treat 
conditions such as premenstrual dysphoric disorder (PMDD) and endometriosis (Carey & 
Allen, 2012). Methods vary in price, effectiveness, side effects, and non-contraceptive 
uses. When deciding on a contraceptive method, a woman balances the cost and benefits 
of the methods to find the one that best matches her unique needs (Grady et al., 1999). In 
Table 19 I summarize a number of contraceptive attributes. 
 
 
 
Table 19. Attributes of Contraceptive Methods 
 
Method 
Cost to 
Initiate 
Reoccurring 
Costs 
Cost to 
Discontinue Failure Rates a Hormonal Benefits 
Mode of 
Administration 
Requires 
Doctor’s 
Visit 
Max 
Duration 
of Effect 
No Method No No No 85% 
(85%) 
No No None No None 
Traditional 
Method 
No No No 0.4 – 4% 
(19.9%+) 
No No Episode 
specific/daily 
tracking 
 
No Episode 
specific 
Barrier 
Method 
No Yes No 2 – 12+% 
(12+%) 
No Yes- STI 
protection 
Episode 
specific 
application 
No Episode 
specific 
SARC Yes Yes No 0.2%-0.3% 
(4-9%) 
Yes Yes Daily pill, 
weekly patch, 
monthly ring, 
quarterly shot 
Yes 1 – 3 
Months 
LARCS          
Hormonal IUD Yes No Yes 0.2% 
(0.2%) 
Yes Yes Device placed 
in uterus 
Yes 60 
Months b 
Non-Hormonal 
IUD 
Yes No Yes 0.6% 
(0.8%) 
No No Device placed 
in uterus 
Yes 120 
Months b 
Implant Yes No Yes 0.05% 
(0.05%) 
Yes Yes Device placed 
in arm 
Yes 36 
Months b 
Sterilization Yes No Yes 0.1 – 0.5% 
(0.15 – 0.5%) 
No No Surgical Yes Permanent 
a Sources: Sundaram et al. (2017) and Trussell (2011). b Source: American College of Obstetricians and Gynecologists (2015). Information on 
contraceptive attributes can be found at https://www.plannedparenthood.org/learn/birth-control. Traditional methods include withdrawal and 
fertility-awareness/calendar-based methods. Barrier methods include male and female condoms, diaphragms, foams, jellies, and sponges. Short-
acting reversible contraceptives (SARCs) include pills, patches, rings and shots. Sterilization includes female methods (Essure, tubal ligation) and 
male methods (vasectomies). Benefits indicates that the method provides non-contraceptive benefits. Typical use failure rates in parentheses. 
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Researchers have surveyed women to assess the importance of these contraceptive 
attributes. One attribute that is commonly reported as a “very important” factor is 
effectiveness (Donnelly et al., 2014; Grady et al., 1999; Jackson et al., 2016; Lessard et 
al., 2012; Madden et al., 2015). Some contraceptives are better at protecting women from 
unplanned pregnancies. Permanent methods, LARCs, and short-acting reversible 
contraceptives (SARCs) when used correctly have very low rates of failure (<1%), while 
other methods (in particular, some barrier methods and withdrawal) may still have high 
failure rates even when used perfectly (Trussell, 2011). Methods also vary in how 
sensitive they are to mistakes. Traditional and barrier methods are very sensitive to 
incorrect and inconsistent use, leading to typical use failure rates greater than 12% for 
barrier methods and greater than 19% for traditional methods. SARCs are somewhat 
more “forgiving” and have typical use failure rates ranging from 4 to 9% (Sundaram et 
al., 2017; Trussell, 2011). Because LARCs and sterilization do not depend on user 
adherence, their typical use and perfect use failure rates are very similar (Trussell, 2011).  
Affordability and access are also considered to be important factors. (Jackson et 
al., 2016; Lessard et al., 2012; Madden et al., 2015). The out-of-pocket costs of 
contraceptives can vary substantially, particularly for women who are uninsured. Birth 
control methods may have initiation costs (such as the cost to get a prescription, have a 
LARC inserted, or the procedure to become sterilized), reoccurring costs (buying more 
condoms, the copay for a prescription), and discontinuation costs (removal of LARC 
device, reversal of sterilization), while traditional methods often have zero monetary 
costs.  
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Contraceptives also vary in how they work. Some reversible methods rely on 
synthetic hormones for their contraceptive effect, while others rely on creating a physical 
barrier, or—in the case of the non-hormonal IUD—the negative effect of copper ions on 
sperm and ovum (Grimes, 2008). Hormonal methods can provide non-contraceptive 
benefits, such as improving acne and making conditions such as endometriosis and 
premenstrual dysphoric disorder (PMDD) more bearable. They can also have side effects 
including headaches, effects on mood, weight gain, and unfavorable changes in bleeding 
patterns (Grimes, 2008). Non-hormonal methods also have drawbacks. Non-hormonal 
IUDs can cause adverse effects on bleeding, and some women and their partners may not 
like using a method that requires a physical barrier (Higgins et al., 2009; Hubacher et al., 
2009). On the positive side, the use of physical barriers such as condoms can provide 
protection against sexually transmitted infections (Planned Parenthood, n.d.).  
Traditional methods, barrier methods, and SARCs offer the flexibility to stop 
using the methods at will, but this flexibility comes at the price of having to actively 
continue to use the method and potentially making errors. Among a sample of women 
seeking abortions, Lessard et al 2012 found that 70% of women reported that they valued 
the method being “woman controlled.” In a discussion of LARCs and reproductive 
autonomy, Gomez, Fuentes, and Allina (2014) note: 
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For some women, optimal control may mean choosing a method that will almost 
never fail. For others, optimal control may mean choosing a method that can be 
started or discontinued as they choose, without the assistance of a health care 
provider. 
 
 
Less flexible methods (LARCs and sterilization) do not require constant effort but 
do require that women give up control over their fertility, either permanently in the case 
of sterilization, or temporarily in the case of LARCs. These methods rely on insertion and 
removal by trained professionals or require a surgical procedure. Women who are 
concerned about potential side effects may also prefer to not use a method that cannot be 
easily discontinued in case of a negative experience. Additionally, women may find the 
idea of having a physical device placed in their bodies as unacceptable (Sundstrom et al., 
2016). 
Other considerations when choosing a method include whether the woman plans 
to have children in the future, or if she is spacing the births of her children. Women who 
are trying to space births may prefer long-acting method, while women trying to limit 
their fertility may prefer long-acting or permanent methods. Using questionnaires from 
the Contraceptive CHOICE Project, Madden et al. (2015) found that women value long-
lasting methods and methods that do not require regular effort. These results may reflect 
the eligibility requirements of the CHOICE Project, as a woman had to not want to 
become pregnant for at least one year and be willing to use a new method in order to 
participate (McNicholas et al., 2014).  
Additionally, Black and Hispanic women may value contraceptive features 
differently than non-Hispanic White women, especially regarding LARC-related 
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attributes. Jackson et al (2016) found that non-Hispanic Black women, Latina women and 
Asian/Pacific Islander women were more likely to care about changes in menstrual 
periods, being able to discontinue use at will, and the method being “episode-specific,” 
meaning that is it only used during a sexual encounter. Additionally, non-Hispanic Black 
women and Latina women were more likely to consider a quick return to fertility as very 
important compared to non-Hispanic White women, and non-Hispanic Black women and 
Latina women were more likely to report that “having control over when and whether to 
use the method” was very important. 
Economists have also studied preferences for attributes of contraceptives. 
Delavande (2008) recruited 100 women from a nearby university and community college 
to collect information on the current contraceptive used and subjective beliefs about 
contraceptive attributes and found the largest negative effects on utility from becoming 
pregnant, contracting an STI, and partner disapproval. Fieberg et al. (2011) conducted a 
discrete choice experiment using data collected from 528 women through an online 
platform and found the greatest willingness-to-pay to avoid negative effects on bleeding, 
to have more effective contraception, and to avoid weight gain compared to the base 
alternative of an IUD (Fiebig et al., 2011). Knox et al. (2012) also conducted a discrete-
choice experiment and found that women prefer methods that reduce bleeding and that 
have longer durations of use. Taken together, these results imply that while women do 
value effectiveness, they also consider other factors when choosing a birth control 
method. Thus, even the most effective methods may not be desirable for some women if 
they do not fit their needs along other dimensions.  
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4.3 Data 
I use the 2011-2013, 2013-2015, and 2015-2017 National Survey of Family 
Growth (NSFG) for data on women and their choices. The NSFG collects information on 
current and planned fertility, contraceptive use, and various socioeconomic and 
demographic characteristics. The questionnaires also collect retrospective histories of 
month-by-month contraceptive use for up to four years. Despite this retrospective 
contraceptive information, many important socioeconomic variables are only asked for 
the past twelve months or the past calendar year. For example, a woman is asked about 
her income for the last calendar year and her insurance status for the past twelve months.  
The NSFG surveys women who are of reproductive age, which includes women 
ages 15 to 44 during the 2011-2013 and 2013-2015 surveys and ages 15 to 49 in the 
2015-2017 survey. Because minors may face different contraceptive choices than adults, 
I do not include women under the age of 19. I exclude 18-year-old women as some would 
have been minors during the months prior to the survey. To keep the age groups 
consistent across survey years, I also exclude women over 44.  
In my analysis, I focus on the choice of a single contraceptive method. Some 
women rely on multiple methods per month, but I consider the choice of her “main 
method,” which I determine based on effectiveness, duration of use, and if the method is 
woman controlled.27 I assume that the woman has the opportunity to change methods 
 
27 The “main method” is determined by the following hierarchy: 1.) female sterilization, 2.) implant, 3.) 
non-hormonal IUD, 4.) hormonal IUD, 5.) male sterilization, 6.) SARC method, 7.) condoms, 8.) 
traditional method, 9.) no method. Other examples of hierarchies used to determine a main method of use 
can be found in Sundaram et al. (2017) or in the NSFG’s codebook for the construction of the 
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over the course of a year, even if she chooses to continue the same method that she used 
previously. A woman using a birth control pill must decide every month if she wants to 
refill her prescription and every day if she wants to take her pill, thus I regard her 
decision to continue to use a pill as a new choice. Similar logic applies to episode-
specific contraception, such as withdrawal methods or condoms. A difficulty with this 
assumption comes from long-acting reversible contraceptives and sterilization as women 
must actively decide if they want to discontinue these methods. I assume that this feature 
is captured by constructing a price variable which makes continuing to use the same 
LARC free for women.  
Reversing sterilization can be costly and in some cases impossible, thus I exclude 
women who were relying on either female or male sterilization at the beginning of the 
12-month period. Because so few women and their partners become sterilized during the 
12-month interval that it prevents estimation of some of my models, I do not include the 
choice to become sterilized in my primary specifications.28 A woman can choose to rely 
on an implant, non-hormonal IUD, hormonal IUD, SARC, condoms, traditional methods, 
or nonuse. I restrict my sample to women who have been sexually active at least 3 
months during the 12-month period as pregnancy prevention is a primary use for 
contraception.29 Additionally, as the 2015-2017 public use data files do not include the 
start months of pregnancies, I exclude women who are currently pregnant or 
 
“CONSTAT1” variable. Not included in my hierarchy are other methods such as other barrier methods, 
emergency contraception, use of lactational amenorrhea method, or non-contraceptive sterility.  
28 I estimate the attributes model including women who are sterilized in Appendix F.  
29 I make this restriction as I do not want to include women who have not been sexually active or only 
sporadically sexually active in the prior 12 months. I relax this condition in my sensitivity analyses. 
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postpartum.30 In Table 20, I present the distribution of women choosing each method as 
their main method. 
 
Table 20. Distribution of Contraceptive Method Choice 
 
Method Observed Percentage 
LARC (Any) 16.36 
       Implant 2.93 
       Non-Hormonal IUD 3.82 
       Hormonal IUD 9.62 
SARC 28.33 
Condoms 17.60 
Traditional 8.86 
No Method 28.85 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. 
N = 7,487 women between the ages of 19 and 44 who are not currently 
pregnant, not relying on sterilization, have been sexually active at least 3 
of the past 12 months, and have had private or public insurance or have 
been uninsured for the past 12 months.  
* p<0.10, ** p<0.05, *** p<0.010                        
 
 
As the NSFG does not collect data on out-of-pocket expenditures on 
contraception, I searched the literature to find reasonable estimates for the average out-
of-pocket expenses associated with the use of contraceptives depending on insurance 
status. Table 21 summarizes this information.  
  
 
30 As defined in the NSFG, “postpartum” indicates that the woman gave birth in the past two months. 
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Table 21. Summary of Contraceptive Out-Of-Pocket Costs 
 
 
Uninsured 
($) 
Public 
($) 
Private  
(Pre-ACA)  
($) 
Private  
(Post-ACA)  
($) 
Implant 749.45a 0e 320.31c 91.01c 
Non-Hormonal 
IUD 718a 0e 262.38c 84.3c 
Hormonal IUD 844a 0e 262.38c 84.3c 
SARC 52.81b 0e 16.37c, e 10.19c, e 
Condoms 9a, b 9a, d 9a, d 9a, d 
Traditional 0 0 0 0 
No Method 0 0 0 0 
a Source: Trussell (2010); Source: bTrussell et al. (2009). c  Source: Becker and Polsky (2015); the 
authors note that the out-of-pocket expenses reported from their data are sometimes women filling 2-3 
month prescriptions (Becker & Polsky, 2015), thus I have divided the amount reported by 2; the 
resulting number is in line with 2010 and 2013 estimates from Kim and Look (2018); d Expenses for 1 
month of condoms, assuming couple purchases one 12-count box a month, or uses 9 condoms a month 
at a price of $1 each as in Trussell et al (2009). e Family planning is covered by Medicaid; thus, I have 
assumed $0 out-of-pocket expenses for all methods other than condoms. However, there is variation in 
family planning coverage by state (Walls et al., 2016.). Since the NSFG does not release state 
identifiers in their public use files, I cannot account for these state-by-state differences.  
 
 
I construct a birth control price variable based on information in both the average 
price dataset and the NSFG. I use the survey year and the woman’s insurance status from 
the NSFG to determine which average birth control price she faces. Factoring in the 
survey year allows me to consider whether she was surveyed before or after the 
implementation of the contraceptive mandate in the Affordable Care Act (ACA). I 
consider all years prior to January 2013 as pre-ACA, and all years 2013 and later to be 
post-ACA.31  
 
31 The contraceptive mandate took effect in August 2012 but does not apply to grandfathered plans. Many 
women were not covered by the mandate until they renewed their insurance coverage in January 2013 
(Becker & Polsky, 2015). 
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I also consider the prior method used in determining the price a woman faces. For 
methods with reoccurring costs, the previous method used does not affect the current 
price. A woman using condoms or pills last month will face a similar cost this month. For 
methods with initiation costs but no reoccurring costs (such as LARCs), the cost of the 
LARC depends on if the woman is choosing to continue or initiate a new method. If a 
woman is not using a LARC or is switching from one LARC to another, she may have to 
pay upfront costs for insertion. I assume that the woman is using a LARC that does not 
need to be replaced, and that she does not have to pay to continue using it. The price 
variable is $0 if a woman is choosing to continue a LARC and set to the prices found in 
the literature if she is initiating the use of a LARC. 
For my some of my analyses, I view contraceptives as a bundle of attributes to 
estimate how the choice to use a method depends on its features. To do so, I need 
information on contraceptive attributes, which are not included in the NSFG. I use 
manufacturer the Planned Parenthood website and other sources to construct a dataset of 
contraceptive attributes (Planned Parenthood, n.d.; American College of Obstetricians 
and Gynecologists, 2015; Trussell, 2011). Table 22 summarizes this data.  
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Table 22. Contraceptive Attribute Data Summary 
 
Alternative 
Price* 
($) Hormonal Device 
Reduction of 
Pregnancy 
Risk x 100 
Max 
Duration of 
Use (Years) 
Implant 0 - 749.45 Yes Yes 84.95 3 
Non-Hormonal IUD 0 - 718 No Yes 84.2 10 
Hormonal IUD 0 - 844 Yes Yes 84.8 5 
SARC 0 - 52.81 Yes No 76 0.083 
Condoms 9 No No 67 0.003 
Traditional 0 No No 62 0.003 
No Method 0 No No 0 0 
*Price varies by insurance status (see Table 21) 
 
 
I construct the attributes such that setting all attributes equal to 0 corresponds with the 
non-use alternative. For example, instead of using the typical use failure rate of a method 
(which would be 85% for a no-method option), I convert the failure rate into a measure of 
absolute risk reduction, in which the decision to not use a method results in a risk 
reduction of 0.32 The contraceptive attributes include the price of birth control, if the 
method is hormonal, if the method is a device, the pregnancy risk reduction based on 
typical use failure rates, and the maximum duration of use. 
My contraceptive attribute data does not contain information on protection from 
sexually transmitted infections. As condoms are the only method that offer STI 
protection, the inclusion of such a variable would result in multicollinearity with other 
attributes. Also, though there are SARCs that can be used for 3 months, most SARC 
methods provide roughly one month of contraceptive protection, assuming the woman 
completes the pack of pills or continues to use the ring or patch. Thus, I use one month as 
 
32 I calculate risk reduction from using a method as risk with no method minus risk with method; see 
https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/how-to-calculate-risk/ 
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the maximum duration of use for the SARC category. The typical use failure rates to 
construct the pregnancy risk reduction variable are taken from Trussell (2011). The 
failure rate for the traditional method category is the average of the failure rates for 
withdrawal and fertility awareness methods. 
Because the utility of various contraceptive methods likely depends on a woman’s 
characteristics, I also include a number of socio-demographic variables. These variables 
include her age group (19-23, 24-28, 29-33, 34-38, and 39-44), an indicator of if she is 
married, household income measured in tens of thousands of dollars, an indicator for if 
she is employed, an indicator for if she has greater than high-school education, the 
number of children she has (0,1,2,3+), an indicator for if she is limiting her fertility, and 
an indicator for if she has been diagnosed with an ovulatory or menstrual condition or 
endometriosis. As there may be differences in contraceptive preferences by race and 
ethnicity, I also include indicators for if the respondent is Black and an indicator for if the 
respondent is Hispanic (Jackson et al., 2016). 
In addition to the socio-demographic variables, I also include variables to control 
for access-related factors. These variables include an indicator for if she has a place of 
usual care as a measure of her access to medical care, and variable for if the woman lives 
in a metropolitan area, near a metropolitan area, or in rural area as women living in rural 
areas may have less access to LARC methods (Martins et al., 2016). I also include a set 
of year controls to capture changes in recommendations and access year by year, along 
with changes in attitudes of women and physicians towards LARCs. Insurance status is 
not included as a regressor as it is factored into the price variable.  
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In Table 23, I present the descriptive statistics for the analysis sample. Because 
the weights included in the NSFG are designed to reflect the midpoints of each survey 
rather than at the survey year, the weights may be inappropriate for my analysis. The 
decision to not use the survey weights is reflected in the descriptive statistics below as 
24% percent of respondents are Black and 23% are Hispanic. A majority (55%) of the 
women have children. 
 
Table 23. Descriptive Statistics of 2011-2013, 2013-2015, and 2015-2017 National 
Survey of Family Growth 
 
Variable Mean SD 
Age at interview 29.77        (7.03) 
Black 0.24        (0.43) 
Hispanic 0.23        (0.42) 
Married 0.30        (0.46) 
Employed 0.70        (0.46) 
Has private insurance 0.60 (0.49) 
Has public insurance 0.26 (0.44) 
Household income 4.35      (3.19) 
Greater than HS Education 0.38        (0.49) 
Has kids 0.55        (0.50) 
      Parity (among mothers) 1.94        (1.08) 
      Number of kids in household under 18 1.73        (1.03) 
Limiting fertility 0.32        (0.47) 
Has place of usual care 0.84        (0.37) 
Condition  0.18        (0.38) 
Using contraception 0.61        (0.24) 
N = 9,594 women between ages of 19-44 (5,289 mothers). Household income tens of thousands 
of dollars (nominal). Limiting fertility indicates that the woman does not plan to have more 
children and condition indicates that she has been diagnosed with an ovulatory or menstrual 
condition or endometriosis. Excludes women relying on sterilization.  
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4.4 Empirical Approach 
The analysis begins with a model that focuses on the alternatives themselves 
rather than the attributes and then is extended to explore the relationship between the 
underlying attributes and contraceptive choice. In my first specification, I assume each 
woman can choose from seven contraceptive options. The utility for person 𝑖 choosing 
choice 𝑗 is assumed to be given by 
 
𝑢 = 𝛾 𝑝 + 𝛼 + 𝑋 𝛽 +  𝜖  (13) 
 
 
where, 𝑝  is the price of alternative 𝑗 faced by person 𝑖 and 𝛾  is a scalar that gives the 
effect on utility of this price. 𝛼  is an alternative-specific constant that captures the 
average unobserved effect of the utility of using method 𝑗 (Train, 2009), and the (1 × 𝑘) 
vector 𝑋  includes person-specific characteristics (socio-demographic and access 
variables) for person 𝑖. 𝛽 is a 𝑘𝑥1 vector of coefficients that measures the utility effects 
of these person-specific characteristics on a method, and 𝜖  is the idiosyncratic error 
term which captures the unobserved component of utility from the contraceptive choices. 
I assume that 𝜖  is independent over 𝑖 and 𝑗 and is distributed type I extreme 
value. Assuming the woman has access to all contraceptive methods, the probability of 
her choosing some method 𝑗 is the probability that method 𝑗 maximizes her utility 
(Cameron & Trivedi, 2009) 
 
𝜋 [𝑦 = 𝑗] = Pr 𝑢 ≥ 𝑢 , 𝑎𝑙𝑙 𝑘 ≠ 𝑗 . (14) 
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With the assumption that the error terms are distributed type I extreme value, these 
probabilities have a convenient closed-form solution (Cameron & Trivedi, 2009): 
 
π = Pr(𝑌 = 𝑗) =
exp 𝛾 𝑝 + 𝛼 + 𝑋 𝛽
∑ exp 𝛾 𝑝 + 𝛼 + 𝑋 𝛽
. 
(15) 
 
 
I use non-use of a method as the base alternative (or the “outside good”), which is 
normalized to having a utility of 0. By doing this, the coefficients can be interpreted as 
differences in utility from a contraceptive method compared to not using a method at all. 
The parameters of this model are estimated using maximum-likelihood estimation, with 
log-likelihood (Schmidheiny, 2007): 
 
𝐿𝐿 =  𝑑 log 𝜋  
(16) 
 
 
in which 𝑑  is an indicator equal to 1 if the 𝑗  method is chosen by the 𝑖 woman, and 
𝜋  is given in equation 15. I estimate the results using the asclogit command in Stata16 
with robust standard errors clustered at the woman-level. 
While analyzing the results in models with alternative-specific constants is helpful 
for studying the differences in utility of the contraceptive alternatives, why women 
choose their method could be better explained by studying the features of those methods. 
Viewing a method as a bundle of attributes may be more helpful for understanding why a 
method is a more or less attractive option. Thus, rather than representing the method with 
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a method-specific constant 𝛼 , I model each method as a linear function of a set of its 
attributes and rewrite the utility function as: 
 
𝑈 = 𝛿 𝑝 + 𝑍 𝜃 +  𝜈  (17) 
 
 
In which 𝛿  is a scalar that indicates the effect of price on utility. 𝑍  contains the set of 
non-price attributes (if the method is hormonal, if the method requires the insertion of a 
device, the risk reduction of pregnancy based on the typical use failure rates, and the 
maximum duration of use) and the interactions of those attributes with the characteristics 
of individual women in 𝑋  to allow the utility of the attributes to vary by a woman’s 
characteristics. 𝜈 is the idiosyncratic error term. I again assume that the error terms are 
independent across 𝑖 and 𝑗 and follow a type 1 extreme value distribution and that women 
choose a contraceptive method to maximize their utility. The choice probabilities then 
have a convenient logit form as they did above: 
 
𝜋 (𝑌 = 𝑗) =
exp{𝛿 𝑝 + 𝑍 𝜃}
∑ exp { 𝛿 𝑝 + 𝑍 𝜃}
 
(18) 
 
 
As in the alternative-specific case, I estimate the results using maximum likelihood 
estimation, with log-likelihood: 
 
𝐿𝐿 =  𝑑 log 𝜋  
(19) 
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in which 𝜋  is defined in equation 18. I estimate the results using clogit commands in 
Stata16 with robust standard errors clustered at the woman-level.  
4.5 Results 
Before estimating my main specification of the model with alternative-specific 
constants, I estimate a simplified version without the individual characteristics and report 
the results in Table 24. As there may be differences in how women value contraceptive 
attributes by race and ethnicity (Jackson et al. 2016), I stratify the results in rows 2 
through 4. 
Overall, contraceptives are associated with a negative effect on utility compared 
to not using a method. In the stratified results, the only exceptions to this pattern are that 
women who are not Black or Hispanic find hormonal IUDs and SARCs to have a positive 
effect on utility compared to no method. The coefficient on price is negative across 
specifications, with women who are not Black or Hispanic exhibiting a greater sensitivity 
to price. For most methods, non-Hispanic Black women find disutility of using a method 
compared to no method. The negative results across many contraceptives imply that 
many women would not want to use contraception compared to nonuse. Indeed, nonuse 
of a method is the most common choice observed in the data, with SARC use as a close 
second. However, as many women choose to use other forms of contraception, it is likely 
that there is variation in the utility of methods across women that can be better explored 
by including the effects of women’s socio-demographic characteristics. 
 
 
 
Table 24. Contraceptive Choice Logistic Regression Results 
 
 Price ($10) Implant 
Non-
Hormonal 
IUD 
Hormonal 
IUD SARC Condoms Traditional 
All Women -0.116*** -1.162*** -0.933*** -0.0108 0.191*** -0.390*** -1.181*** 
 (0.009) (0.078) (0.078) (0.060) (0.035) (0.036) (0.044) 
Non-Hispanic Black -0.0781*** -1.458*** -2.110*** -0.923*** -0.121* -0.564*** -1.507*** 
 (0.017) (0.137) (0.187) (0.125) (0.068) (0.073) (0.098) 
Hispanic -0.0753*** -1.123*** -0.738*** -0.237** -0.219*** -0.388*** -1.226*** 
 (0.013) (0.141) (0.126) (0.115) (0.074) (0.069) (0.089) 
Non-Hispanic White or 
Other Race -0.163*** -1.010*** -0.492*** 0.588*** 0.504*** -0.297*** -1.018*** 
 (0.014) (0.126) (0.108) (0.083) (0.048) (0.051) (0.060) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 (row 1), 1,676 (row 2), 1,778 (row 3), and 4,033 (row 4) women 
between the ages of 19 and 44 who are not currently pregnant, not relying on sterilization, have been sexually active at least 3 of the past 12 months, 
and have had private or public insurance or have been uninsured for the past 12 months. Base alternative is no method use. Standard errors 
(clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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In Table 25 I report the results of a model that includes individual characteristics. 
The coefficients on the alternative-specific constants are statistically significant and 
negative, except for SARC use, which remains positive. The magnitudes of the 
alternative-specific constants across LARC methods increase after including the 
individual characteristics. 
The estimates indicate that being young increases the likelihood that a woman 
chooses implants, SARCs, and condoms. Across methods, age is negatively related to the 
utility of contraception compared to nonuse, perhaps due to reduced fecundity with age. 
Women with children receive more utility from LARCs compared to women without 
children. As should be expected, not wanting children in the future increases the utility of 
contraceptive use. Thus, even though the coefficients on many of the alternative-specific 
constants are negative, there are variations in the effect on utility of methods by 
observable characteristics which may result in the observable portion of utility being 
positive for individual women. For example, the alternative-specific coefficient for 
non-hormonal IUD use is negative (as it was in the simple model in Table 24), but a 
working mother of two children who is limiting fertility might find using this method as a 
better option than choosing to forgo contraception. 
 
 
 
Table 25. Contraceptive Choice Logistic Regression Results with Women’s Characteristics 
 
Price ($10) -0.127***      
      (0.011)      
Alternative 
Specific Constant 
Implant Non-hormonal IUD Hormonal IUD SARC Condoms Traditional 
 -1.728*** -1.820*** -1.267*** 0.366* -0.541** -1.936*** 
      (0.595)      (0.484)      (0.351)      (0.213)      (0.240)      (0.312) 
Individual 
Characteristics 
      
Age       
     19-23 0.625*** 0.0672 0.0376 0.435*** 0.207* 0.0706 
      (0.193)      (0.228)      (0.159)      (0.098)      (0.114)      (0.151) 
     29-33 -1.273*** -0.252 -0.432*** -0.350*** -0.276*** -0.194 
 -0.247 -0.188 -0.13 -0.094 -0.104 -0.13 
     34-38 -1.986*** -0.607*** -0.975*** -0.735*** -0.550*** -0.537*** 
 (0.344) (0.216) (0.244) (0.108) (0.116) (0.147) 
     39-44 -1.849*** -0.975*** -1.279*** -1.274*** -0.872*** -0.558*** 
      (0.355)      (0.244)      (0.164)      (0.123)      (0.128)      (0.157) 
Black -0.282 -1.105*** -0.934*** -0.414*** -0.074 -0.410*** 
      (0.175)      (0.198)      (0.127)      (0.082)      (0.089)      (0.122) 
Hispanic 0.299* 0.318** -0.165 -0.335*** 0.0375 -0.240** 
      (0.178)      (0.151)      (0.116)      (0.085)      (0.090)      (0.117) 
Married -0.281 0.0219 -0.0208 -0.405*** 0.095 0.272*** 
      (0.205)      (0.157)      (0.113)      (0.081)      (0.082)      (0.104) 
Income 0.0537* 0.0987*** 0.115*** 0.0615*** 0.0196 0.0373** 
      (0.030)      (0.025)      (0.018)      (0.012)      (0.014)      (0.017) 
Working 0.547*** 0.427*** 0.679*** 0.211*** -0.082 0.191* 
      (0.163)      (0.152)      (0.112)      (0.074)      (0.079)      (0.101) 
Greater than HS 0.0412 0.591*** 0.629*** 0.383*** 0.319*** 0.115 
      (0.228)      (0.170)      (0.116)      (0.077)      (0.085)      (0.110) 
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Table 25 Continued      
Number of 
children 
      
       
     1 0.257 0.390* 0.577*** -0.223*** -0.145 0.296** 
      (0.209)      (0.208)      (0.137)      (0.085)      (0.097)      (0.122) 
     2 0.574** 0.934*** 0.919*** -0.0251 0.0371 0.525*** 
      (0.243)      (0.213)      (0.149)      (0.099)      (0.109)      (0.133) 
     3+ 0.687** 0.690*** 0.688*** -0.253** -0.0469 0.441*** 
      (0.287)      (0.253)      (0.176)      (0.122)      (0.130)      (0.156) 
Limiting fertility 0.636*** 0.793*** 1.019*** 0.677*** 0.606*** 0.256** 
      (0.190)      (0.155)      (0.111)      (0.084)      (0.090)      (0.110) 
Condition -0.185 -1.075*** -0.353*** -0.534*** -0.537*** -0.330*** 
      (0.210)      (0.230)      (0.120)      (0.082)      (0.095)      (0.116) 
Usual care 0.142 0.111 0.148 0.359*** -0.00293 -0.285** 
      (0.211)      (0.191)      (0.137)      (0.093)      (0.093)      (0.115) 
Place of residence       
     Metropolitan  -0.141 0.174 0.112 -0.207** 0.168 0.528*** 
      (0.220)      (0.220)      (0.152)      (0.100)      (0.116)      (0.161) 
     Suburban -0.427* 0.142 0.21 -0.169* 0.125 0.520*** 
      (0.225)      (0.217)      (0.148)      (0.098)      (0.115)      (0.159) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 between the ages of 19 and 44 who are not currently pregnant, not 
relying on sterilization, have been sexually active at least 3 of the past 12 months, and have had private or public insurance or have been uninsured for 
the past 12 months. Greater than HS indicates woman has greater than a high school education, condition indicates woman has a condition that may 
benefit from hormonal contraception. Base alternative is no method use. Includes set of year controls. Base category for age is 24-28, zero for number 
of children, and rural for place of residence. Standard errors (clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.01  
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I next move to models that include specific attributes of the choices rather than 
the alternative-specific constants. In Table 26 I report the results of a simplified model 
without individual characteristics. Like Table 25, the effect of price is negative. Being a 
device has a negative effect on utility, and this result holds when stratified by race and 
ethnicity. Women find being a hormonal method as positive feature, and the effect on 
utility is greater for women who are not Black or Hispanic. Interestingly, reduction in 
pregnancy risk is also negative, perhaps due to the inclusion of non-contracepting women 
who make up over a quarter of the sample. 
Being a device is estimated to have a negative effect on utility compared to not 
using a method. This effect is greater for older women compared to women ages 25-28. 
Women with higher incomes and who are married find less disutility from devices than 
other women. The coefficients on number of children (1, 2, or 3+ compared to none) are 
also positive.  
Again, the coefficient on the reduction of the risk of pregnancy is negative and 
significant. I have included women who are not currently contracepting in my main 
analytical sample as almost half of unintended pregnancies are among women who are 
not contracepting (Sonfield et al., 2014). However, among women who are not using a 
methods may be women who are ambivalent about pregnancy, actively trying to become 
pregnant, and not currently sexually active, and therefore gain no utility or perhaps some 
disutility from increased fertility control, which may explain the negative coefficient. 
Because of these concerns, I reestimate the model on the sample of women who are 
currently using a contraceptive. Table 28 reports these results
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Table 26. Contraceptive Attributes Conditional Logistic Regression Results 
 
 Price Hormonal Device 
Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of 
Use 
All Women -0.109*** 1.084*** -1.169*** -1.157*** 0.138*** 
      (0.008)      (0.036)      (0.068)      (0.050)      (0.011) 
Non-Hispanic Black -0.0709*** 0.996*** -1.126*** -1.452*** 0.0393 
      (0.014)      (0.075)      (0.158)      (0.101)      (0.027) 
Hispanic -0.0721*** 0.679*** -0.802*** -1.146*** 0.113*** 
      (0.011)      (0.076)      (0.142)      (0.098)      (0.021) 
Non-Hispanic White or 
Other Race -0.154*** 1.285*** -1.162*** -1.015*** 0.175*** 
      (0.012)      (0.049)      (0.090)      (0.071)      (0.014) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 (row 1), 1,676 (row 2), 
1,778 (row 3), and 4,033 (row 4) women between the ages of 19 and 44 who are not currently pregnant, 
not relying on sterilization, have been sexually active at least 3 of the past 12 months, and have had 
private or public insurance or have been uninsured for the past 12 months. Standard errors (clustered at 
woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
 
 
In Table 27 I present the results of the attributes with interactions with individual 
characteristics. Like Table 26, contraceptive options that require the insertion of a device 
(i.e., LARCs) have negative effects on utility, as does the reduction in pregnancy risk. 
Hormonal methods have a positive effect, but the coefficient on maximum duration of 
use is no longer statistically significant. 
The lower portion of the table reports the estimates of the relationship between 
utility and the individual characteristics interacted with the attributes. The estimates 
suggest that women who are older, Black, Hispanic, married, or who have large families 
prefer non-hormonal methods if any, while woman with higher income levels find 
hormonal methods more attractive. Women who are Black and married experience 
disutility from methods with longer durations of use.
 
 
 
Table 27. Contraceptive Attributes Conditional Logistic Regression Results with Attribute-Characteristic Interactions 
 
Attributes Birth Control 
Price 
Hormonal 
Method Device 
Reduction in Risk of 
Pregnancy 
Maximum 
Duration of Use 
 -0.119*** 1.342*** -1.692*** -1.458*** 0.0503 
Interactions (0.00851)      (0.235)      (0.376)      (0.334)         (0.066) 
Age group      
    19-23  0.208** 0.0873 0.311* -0.0347 
       (0.106)      (0.233)      (0.165)         (0.038) 
     29-33  -0.0496 -0.572*** -0.403*** 0.0609** 
       (0.102)      (0.198)      (0.148)         (0.029) 
     34-38  -0.103 -0.592** -0.849*** 0.0548 
       (0.117)      (0.230)      (0.166)         (0.034) 
     39-44  -0.397*** -0.228 -1.164*** -5.42E-05 
       (0.132)      (0.261)      (0.180)         (0.039) 
Black  -0.259*** 0.175 -0.216* -0.109*** 
       (0.091)      (0.191)      (0.128)         (0.030) 
Hispanic  -0.302*** 0.329* -0.0443 -0.00314 
       (0.091)      (0.175)      (0.128)         (0.025) 
Married  -0.573*** 0.582*** 0.244** -0.0784*** 
       (0.084)      (0.169)      (0.118)         (0.025) 
Income  0.241*** 0.402** -0.0365 0.0065 
       (0.079)      (0.167)      (0.112)         (0.025) 
Working  0.107 0.000631 0.378*** 0.0356 
       (0.084)      (0.175)      (0.122)         (0.026) 
Greater than HS  0.0333*** 0.0425 0.0366* 0.00364 
       (0.013)      (0.026)      (0.019)         (0.004) 
Number of children      
     1  -0.132 0.671*** -0.0809 -0.00931 
       (0.095)      (0.214)      (0.136)         (0.033) 
     2  -0.137 0.724*** 0.194 0.0142 
       (0.106)      (0.227)      (0.155)         (0.034) 
     3+  -0.271** 0.942*** 0.0808 -0.0215 
       (0.130)      (0.272)      (0.182)         (0.040) 
Limiting fertility  0.149* 0.135 0.724*** 0.0131 
       (0.087)      (0.167)      (0.129)         (0.024) 
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Condition  0.0426 0.655*** -0.746*** -0.0855*** 
       (0.097)      (0.191)      (0.131)         (0.030) 
Usual Care  0.466*** -0.434** -0.152 0.0647** 
       (0.098)      (0.209)      (0.131)         (0.030) 
Place of Residence      
     Metropolitan   -0.500*** 0.447* 0.411** -0.0541 
       (0.114)      (0.235)      (0.167)         (0.036) 
     Suburban   -0.403*** 0.305 0.339** -0.0342 
       (0.113)      (0.226)      (0.165)         (0.035) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 between the ages of 19 and 44 who are not 
currently pregnant, not relying on sterilization, have been sexually active at least 3 of the past 12 months, and have had 
private or public insurance or have been uninsured for the past 12 months. Greater than HS indicates woman has greater 
than a high school education, condition indicates woman has a condition that may benefit from hormonal contraception. 
Includes set of year controls. Base category for age is 24-28, zero for number of children, and rural for place of residence. 
Standard errors (clustered at woman-level) are in parentheses. * p<0.10, ** p<0.05, *** p<0.01  
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Being a device is estimated to have a negative effect on utility compared to not 
using a method. This effect is greater for older women compared to women ages 25-28. 
Women with higher incomes and who are married find less disutility from devices than 
other women. The coefficients on number of children (1, 2, or 3+ compared to none) are 
also positive.  
Again, the coefficient on the reduction of the risk of pregnancy is negative and 
significant. I have included women who are not currently contracepting in my main 
analytical sample as almost half of unintended pregnancies are among women who are 
not contracepting (Sonfield et al., 2014). However, among women who are not using a 
methods may be women who are ambivalent about pregnancy, actively trying to become 
pregnant, and not currently sexually active, and therefore gain no utility or perhaps some 
disutility from increased fertility control, which may explain the negative coefficient. 
Because of these concerns, I reestimate the model on the sample of women who are 
currently using a contraceptive. Table 28 reports these results. 
 
 
 
Table 28. Contraceptive Attributes Conditional Logistic Regression Results with Attribute-Characteristic Interactions 
Among Women Using Contraception 
 
Attributes Birth 
Control 
Price Hormonal Method Device 
Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of Use 
Interactions  
-0.127*** 
(0.010) 
 
-1.601** 
(0.678) 
-2.689*** 
(0.413) 
 26.14***  
(5.599) 
-0.339*** 
(0.113) 
Age       
     19-23  -0.238 -0.128 4.863* -0.0883* 
       (0.317)      (0.246)      (2.787)         (0.053) 
     29-33  0.0386 -0.538** -1.239 0.0723 
       (0.296)      (0.218)      (2.479)         (0.047) 
     34-38  -0.301 -0.660** 1.043 0.0273 
       (0.342)      (0.257)      (2.849)         (0.053) 
     39-44  -0.417 -0.309 -1.074 0.00107 
       (0.383)      (0.290)      (3.168)         (0.061) 
Black  -1.222*** -0.255 8.961*** -0.237*** 
       (0.262)      (0.207)      (2.286)         (0.042) 
Hispanic  -0.965*** 0.023 6.749*** -0.0987** 
       (0.261)      (0.194)      (2.223)         (0.041) 
Married  -0.424* 0.537*** -1.114 -0.057 
       (0.244)      (0.189)      (2.047)         (0.039) 
Working  1.021*** 0.674*** -7.515*** 0.119*** 
       (0.230)      (0.182)      (1.964)         (0.037) 
Great than HS  0.0971 0.00115 0.553 0.0358 
       (0.250)      (0.192)      (2.112)         (0.040) 
Income  0.0974** 0.0591** -0.578* 0.0129** 
       (0.039)      (0.029)      (0.330)         (0.006) 
Number of children      
     1  1.366*** 1.115*** -13.93*** 0.203*** 
       (0.288)      (0.224)      (2.449)         (0.047) 
     2  1.684*** 1.241*** -16.30*** 0.271*** 
       (0.316)      (0.241)      (2.642)         (0.051) 
      115 
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     3+  1.457*** 1.434*** -15.55*** 0.221*** 
       (0.379)      (0.289)      (3.143)         (0.061) 
Limiting fertility  0.171 0.136 0.92 0.0163 
       (0.256)      (0.183)      (2.108)         (0.040) 
Condition  0.44 0.745*** -4.492* -0.027 
       (0.286)      (0.211)      (2.388)         (0.046) 
Usual Care  0.139 -0.509** 3.127 0.0159 
       (0.267)      (0.227)      (2.273)         (0.044) 
Place of Residence      
     Metropolitan   0.235 0.700*** -6.578** 0.0465 
       (0.340)      (0.257)      (2.955)         (0.055) 
     Suburban Area  0.484 0.615** -8.068*** 0.0884 
       (0.339)      (0.250)      (2.936)         (0.054) 
Contracepting women only. Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 5,327 women 
between the ages of 19 - 44 who are not pregnant, not relying on sterilization, have been sexually active at least 3 of the 
past 12 months, and have had private or public insurance or have been uninsured during the past 12 months. Greater 
than HS indicates greater than high school education, condition indicates woman has a condition that may benefit from 
hormonal contraception. Includes set of year controls. Base category for age is 24-28, zero for number of children and 
rural for place of residence. Standard errors (clustered at woman-level) in parentheses. 
* p<0.10, ** p<0.05, *** p<0.01  
116 
 
117 
 
The contraceptive being a device and having a longer maximum duration of use 
both have negative effects on utility (which is less negative for women with children), 
however the sign on pregnancy risk reduction has now reversed and becomes quite a bit 
larger. Mothers place a lower value on effectiveness, which may reflect a higher cost for 
women transitioning into motherhood compared to having additional children. 
Interestingly, the main effect from the use of hormonal methods has become negative, 
though hormonal methods are now a better match for women with children.  
In Table 29 I present the average predicted probabilities by method for both of my 
models. Due to the inclusion of alternative-specific constants, the average predicted 
probabilities for the alternatives models perfectly match the distribution of observed 
choices (Cameron & Trivedi, 2009).  
 
Table 29. Average Predicted Probabilities of Contraceptive Choice 
 
Method 
Observed  
Percentage 
Predicted 
(Alternatives) 
Predicted 
(Attributes) 
LARC (Any) 16.36 16.36 16.36 
       Implant 2.93 2.93 5.05 
       Non-Hormonal IUD 3.82 3.82 4.66 
       Hormonal IUD 9.62 9.62 6.65 
SARC 28.33 28.33 29.17 
Condoms 17.60 17.60 11.92 
Traditional 8.86 8.86 13.97 
No Method 28.85 28.85 28.58 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 women between the 
ages of 19 and 44 who are not currently pregnant, not relying on sterilization, have been sexually active 
at least 3 of the past 12 months, and have had private or public insurance or have been uninsured for the 
past 12 months.  
* p<0.10, ** p<0.05, *** p<0.010                        
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For the attributes model, the average predicted probability of any LARC use 
matches the proportion of women who choose LARC, but the distribution of type of 
LARC differs. The predicted probabilities for implants and non-hormonal IUDs are 
higher than those observed, and the predicted probabilities for hormonal IUDs are low. 
The biggest differences between the predicted probabilities and the observed distribution 
of choices come from condoms and traditional methods, both being over 5 percentage 
points off, but in opposite directions.  
4.5.1 Sensitivity Analyses 
As is always the case, I made a number of choices and restrictions during my 
analysis. To assess the restrictiveness of these decisions, I estimated a series of models 
that change different assumptions. Specifically, I focus on the inclusion of the price 
variable, the decision to restrict the analysis to women who were sexually active at least 
25% of the year, possible differential use by women who have children, and the decision 
to use typical failure rates rather than perfect use failure rates. 
In my primary specification, I use the price variable I constructed based on 
average out-of-pocket expenditures in the literature and the woman’s insurance status. 
While the attributes of the contraceptives may account for some differences in prices 
between the methods (and thus there may be less of a concern about unobserved quality), 
it is possible that other factors may endogenize price. Examples of such factors could 
include attributes not considered (like STI protections), partner preferences, and supply-
side barriers and changes in access that may be related to the contraceptive method. In 
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order to check the robustness of my estimates, I reestimate my primary specifications for 
both the alternatives and the attributes, excluding price and adding insurance status as an 
individual characteristic. I present these results in Tables 30 and 31. In Table 30, the 
alternative-specific constants on LARC methods are negative, and the coefficients have 
increased in magnitude. In Table 31, the main effect of “device” is still statistically 
significantly negative and even larger than it was in the primary specification.  
Next, I explore the implication of my assumption to limit my sample to women 
who were sexually active at least 25% of the year. I test this assumption in two ways. 
First, by restricting the sample further to women who reported being sexually active the 
entire year, and second by relaxing the assumption and including all women regardless of 
reported sexual activity. Results from the alternative-specific model with characteristics 
for women who are sexually active the entire year and regardless of sexual activity are 
reported in Tables 32 and 33, respectively.
 
 
 
Table 30. Contraceptive Choice Logistic Regression Results with Women’s Characteristics: Insurance Status 
 
Price ($10) --      
       
Alternative Specific Constant Implant Non-hormonal IUD Hormonal IUD SARC Condoms Traditional 
 -3.475*** -3.736*** -3.300*** -0.091 -0.554** -1.783*** 
      (0.561)      (0.472)      (0.343)      (0.214)      (0.244)      (0.316) 
Individual  
Characteristics 
      
Age       
     19-23 0.764*** 0.212 0.16 0.453*** 0.217* 0.0898 
      (0.190)      (0.226)      (0.153)      (0.098)      (0.114)      (0.152) 
     29-33 -1.345*** -0.345* -0.528*** -0.364*** -0.283*** -0.203 
 -0.24 -0.184 -0.127 -0.0934 -0.104 -0.13 
     34-38 -2.221*** -0.893*** -1.350*** -0.775*** -0.565*** -0.568*** 
 (0.344) (0.214) (0.247) (0.107) (0.116) (0.147) 
     39-44 -2.192*** -1.350*** -1.663*** -1.335*** -0.895*** -0.601*** 
      (0.353)      (0.247)      (0.164)      (0.123)      (0.128)      (0.158) 
Black -0.14 -0.910*** -0.765*** -0.368*** -0.0617 -0.378*** 
      (0.180)      (0.197)      (0.126)      (0.081)      (0.089)      (0.122) 
Hispanic 0.2 0.221 -0.214* -0.379*** 0.013 -0.268** 
      (0.178)      (0.148)      (0.113)      (0.084)      (0.091)      (0.118) 
Married -0.463** -0.25 -0.326*** -0.461*** 0.073 0.234** 
      (0.202)      (0.159)      (0.113)      (0.080)      (0.082)      (0.105) 
Income 0.00703 0.0321 0.0376** 0.0458*** 0.014 0.0273 
      (0.030)      (0.025)      (0.018)      (0.013)      (0.014)      (0.018) 
Working 0.338** 0.202 0.400*** 0.121 -0.118 0.135 
      (0.159)      (0.147)      (0.110)      (0.075)      (0.081)      (0.103) 
Greater than HS -0.0329 0.457*** 0.449*** 0.337*** 0.303*** 0.086 
      (0.227)      (0.164)      (0.109)      (0.078)      (0.087)      (0.113) 
Number of children       
     1 0.839*** 0.969*** 1.176*** -0.126 -0.104 0.363*** 
      (0.214)      (0.214)      (0.140)      (0.086)      (0.098)      (0.124) 
     2 1.194*** 1.621*** 1.649*** 0.0718 0.0722 0.589*** 
      (0.242)      (0.222)      (0.151)      (0.099)      (0.110)      (0.135)  
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     3+ 1.392*** 1.532*** 1.553*** -0.118 0.00316 0.535*** 
      (0.271)      (0.242)      (0.163)      (0.108)      (0.121)      (0.151) 
Limiting fertility 0.691*** 0.849*** 1.075*** 0.679*** 0.606*** 0.263** 
      (0.186)      (0.152)      (0.108)      (0.083)      (0.090)      (0.109) 
Condition -0.209 -1.112*** -0.389*** -0.538*** -0.541*** -0.331*** 
      (0.202)      (0.228)      (0.118)      (0.082)      (0.095)      (0.116) 
Usual care 0.451** 0.318* 0.252* 0.424*** 0.0339 -0.230* 
      (0.204)      (0.191)      (0.132)      (0.093)      (0.096)      (0.119) 
Place of residence       
     Metropolitan  0.0121 0.282 0.213 -0.182* 0.18 0.547*** 
      (0.209)      (0.215)      (0.145)      (0.099)      (0.117)      (0.161) 
     Suburban  -0.337 0.181 0.250* -0.15 0.139 0.530*** 
      (0.218)      (0.212)      (0.142)      (0.097)      (0.116)      (0.159) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 between the ages of 19 and 44 who are not currently pregnant, not 
relying on sterilization, and have had private or public insurance or have been uninsured for the past 12 months. Greater than HS indicates woman has 
greater than a high school education, condition indicates woman has a condition that may benefit from hormonal contraception. Base alternative is no 
method use. Includes set of year controls. Base category for age is 24-28, zero for number of children and rural for place of residence. Standard errors 
(clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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Table 31. Contraceptive Attributes Conditional Logistic Regression Results with Attribute-Characteristic Interactions: 
Insurance Status 
 
Attribute Birth 
Control 
Price 
Hormonal Method Device Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of Use 
 __  0.724*** -2.594*** -1.308*** -0.0693 
Interactions       (0.242)      (0.378)         (0.339)            (0.066) 
Age      
     19-23  0.208** 0.135 0.330** -0.0315 
       (0.106)      (0.226)         (0.164)            (0.038) 
     29-33  -0.0602 -0.583*** -0.408*** 0.0572** 
       (0.102)      (0.192)         (0.148)            (0.029) 
     34-38  -0.126 -0.674*** -0.873*** -0.00632 
       (0.117)      (0.225)         (0.165)            (0.038) 
     39-44  -0.430*** -0.394 -1.196*** -0.00632 
       (0.132)      (0.256)         (0.180)            (0.038) 
Black  -0.236*** 0.328* -0.188 -0.110*** 
       (0.091)      (0.188)         (0.127)            (0.030) 
Hispanic  -0.290*** 0.305* -0.0978 -0.0978 
       (0.092)      (0.171)         (0.130)            (0.130) 
Married  -0.600*** 0.399** 0.211* -0.0846*** 
       (0.084)      (0.168)         (0.118)            (0.025) 
Working  0.199** 0.239 -0.098 0.00543 
       (0.081)      (0.161)         (0.115)            (0.024) 
Greater than HS  0.0671 -0.0933 0.360*** 0.0279 
       (0.086)      (0.166)         (0.125)            (0.025) 
Income  0.0222* -0.0129 0.0293 0.00164 
       (0.013)      (0.026)         (0.020)            (0.004) 
Number of children      
     1  -0.0838 1.242*** -0.0232 -0.0143 
       (0.097)      (0.216)         (0.138)            (0.034) 
     2  -0.077 1.382*** 0.244 0.0109 
       (0.107)      (0.230)         (0.155)            (0.035) 
     3+  -0.195 1.661*** 0.155 -0.0186 
       (0.132)      (0.272)         (0.184)            (0.041) 
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Limiting fertility  0.147* 0.199 0.725*** 0.0123 
       (0.087)      (0.162)         (0.129)            (0.024) 
Condition  0.0434 0.593*** -0.751*** 0.0123 
       (0.097)      (0.184)         (0.131)            (0.024) 
Usual care   0.445*** -0.315 -0.0677 0.0639** 
       (0.100)      (0.204)         (0.135)            (0.030) 
Area of residence      
     Metropolitan   -0.499*** 0.520** 0.438*** -0.0557 
       (0.115)      (0.222)         (0.167)            (0.035) 
     Suburban  -0.405*** 0.337 0.364** -0.0365 
       (0.113)      (0.214)         (0.165)            (0.034) 
Insurance      
     Private Insurance 0.630*** -0.530** -0.216 0.0978*** 
       (0.111)      (0.233)         (0.153)            (0.035) 
     Public Insurance 0.478*** -0.0996 -0.544*** 0.0407 
       (0.122)      (0.250)         (0.165)            (0.037) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 between the ages of 19 and 44 who 
are not currently pregnant, not relying on sterilization, have been sexually active at least 3 of the past 12 months, and 
have had private or public insurance or have been uninsured for the past 12 months. Greater than HS indicates woman 
has greater than a high school education, condition indicates woman has a condition that may benefit from hormonal 
contraception. Includes set of year controls. Base category for age is 24-28, zero for number of children, rural for 
place of residence, and no insurance in the last year for insurance. Standard errors (clustered at woman-level) are in 
parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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Table 32. Contraceptive Choice Logistic Regression Results with Women’s Characteristics: Sexually Active Women 
 
Price ($10) -0.157***      
      (0.016)      
Alternative Specific Constant Implant Non-hormonal IUD Hormonal IUD SARC Condoms Traditional 
 -1.168 -1.168 -0.988* -0.880* 0.716** -0.0391 
 (0.741)      (0.741)      (0.597)      (0.484)      (0.310)      (0.315) 
Individual  
Characteristics  
      
Age       
     19-23 0.906*** 0.315 0.0746 0.654*** 0.319* 0.17 
      (0.273)      (0.294)      (0.234)      (0.152)      (0.167)      (0.209) 
     29-33 -1.307*** -0.407* -0.639*** -0.429*** -0.290** -0.285* 
 -0.322 -0.241 -0.175 -0.133 -0.137 -0.166 
     34-38 -2.293*** -0.422 -1.357*** -0.750*** -0.551*** -0.682*** 
 (0.474) (0.270) (0.301) (0.150) (0.151) (0.186) 
     39-44 -2.259*** -1.357*** -1.694*** -1.668*** -1.203*** -1.006*** 
      (0.443)      (0.301)      (0.216)      (0.172)      (0.167)      (0.196) 
Black -0.323 -1.234*** -0.811*** -0.432*** -0.074 -0.611*** 
      (0.242)      (0.272)      (0.175)      (0.121)      (0.121)      (0.163) 
Hispanic 0.308 0.341* 0.109 -0.137 0.143 -0.166 
      (0.235)      (0.195)      (0.154)      (0.120)      (0.120)      (0.150) 
Married -0.658** -0.452** -0.353** -0.888*** -0.460*** -0.290** 
      (0.261)      (0.196)      (0.151)      (0.112)      (0.108)      (0.133) 
Income 0.0712* 0.133*** 0.134*** 0.0646*** 0.0163 0.0409* 
      (0.043)      (0.031)      (0.025)      (0.017)      (0.018)      (0.021) 
Working 0.720*** 0.27 0.597*** 0.199* -0.0571 0.249* 
      (0.229)      (0.190)      (0.147)      (0.105)      (0.106)      (0.129) 
Greater than HS 0.499* 0.779*** 0.923*** 0.627*** 0.579*** 0.331** 
      (0.299)      (0.219)      (0.155)      (0.107)      (0.111)      (0.139) 
Number of children       
     1 0.00449 0.31 0.557*** -0.156 -0.00923 0.493*** 
      (0.275)      (0.262)      (0.185)      (0.120)      (0.126)      (0.155) 
     2 0.680** 1.062*** 1.166*** 0.137 0.240* 0.744*** 
      (0.313)      (0.263)      (0.196)      (0.138)      (0.143)      (0.172)  
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     3+ 0.675* 0.689** 0.696*** -0.349** 0.0608 0.680*** 
      (0.363)      (0.312)      (0.233)      (0.169)      (0.165)      (0.193) 
Limiting fertility 1.200*** 1.111*** 1.599*** 1.209*** 1.056*** 0.713*** 
      (0.262)      (0.194)      (0.155)      (0.125)      (0.126)      (0.145) 
Condition -0.324 -1.136*** -0.604*** -0.708*** -0.646*** -0.476*** 
      (0.288)      (0.270)      (0.161)      (0.114)      (0.118)      (0.145) 
Usual care -0.216 0.047 0.324* 0.246* -0.108 -0.347** 
      (0.271)      (0.241)      (0.191)      (0.132)      (0.124)      (0.149) 
Place of residence       
     Metropolitan  0.314 0.271 0.215 -0.0339 0.266* 0.609*** 
      (0.328)      (0.280)      (0.206)      (0.141)      (0.152)      (0.195) 
     Suburban  0.0373 0.3 0.367* 0.0166 0.306** 0.558*** 
      (0.327)      (0.271)      (0.198)      (0.137)      (0.148)      (0.191) 
       
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 4,477 between the ages of 19 and 44 who are not currently pregnant or 
postpartum, not relying on sterilization, and have had private or public insurance or have been uninsured for the past 12 months. Greater than HS 
indicates woman has greater than a high school education, condition indicates woman has a condition that may benefit from hormonal contraception. 
Base alternative is no method use. Includes set of year controls. Base category for age is 24-28, zero for number of children, and rural for place of 
residence. Standard errors (clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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Table 33. Contraceptive Choice Logistic Regression Results with Women’s Characteristics: No Restrictions on Sexual 
Activity 
 
Price ($10) -0.130***      
      (0.011)      
Alternative Specific Constant Implant Non-hormonal IUD Hormonal IUD SARC Condoms Traditional 
 -2.568*** -2.903*** -2.331*** -0.549*** -1.498*** -2.859*** 
      (0.558)      (0.443)      (0.327)      (0.178)      (0.220)      (0.296) 
Individual  
Characteristics 
      
Age       
     19-23 -0.228 -0.878*** -0.848*** -0.305*** 0.0432 -0.293** 
      (0.162)      (0.181)      (0.115)      (0.068)      (0.081)      (0.117) 
     29-33 0.135 0.369*** -0.223** -0.403*** 0.00307 -0.254** 
      (0.168)      (0.141)      (0.106)      (0.073)      (0.082)      (0.112) 
     34-38 0.186 0.496*** 0.431*** 0.0889 0.726*** 0.901*** 
      (0.196)      (0.150)      (0.106)      (0.072)      (0.077)      (0.100) 
     39-44 0.0745*** 0.104*** 0.124*** 0.0623*** 0.0255** 0.0441*** 
      (0.027)      (0.023)      (0.017)      (0.010)      (0.012)      (0.016) 
Black 0.535*** 0.437*** 0.725*** 0.266*** -0.04 0.223** 
      (0.151)      (0.143)      (0.103)      (0.062)      (0.071)      (0.096) 
Hispanic -0.016 0.610*** 0.565*** 0.279*** 0.201*** -0.0025 
      (0.207)      (0.162)      (0.106)      (0.065)      (0.078)      (0.105) 
Married -0.228 -0.878*** -0.848*** -0.305*** 0.0432 -0.293** 
      (0.162)      (0.181)      (0.115)      (0.068)      (0.081)      (0.117) 
Income 0.135 0.369*** -0.223** -0.403*** 0.00307 -0.254** 
      (0.168)      (0.141)      (0.106)      (0.073)      (0.082)      (0.112) 
Working 0.186 0.496*** 0.431*** 0.0889 0.726*** 0.901*** 
      (0.196)      (0.150)      (0.106)      (0.072)      (0.077)      (0.100) 
Greater than HS 0.0745*** 0.104*** 0.124*** 0.0623*** 0.0255** 0.0441*** 
      (0.027)      (0.023)      (0.017)      (0.010)      (0.012)      (0.016) 
Number of children       
     1 0.679*** 0.905*** 1.008*** 0.183** 0.311*** 0.726*** 
      (0.196)      (0.201)      (0.128)      (0.073)      (0.091)      (0.119) 
     2 1.013*** 1.408*** 1.339*** 0.343*** 0.488*** 0.960*** 
      (0.226)      (0.205)      (0.137)      (0.086)      (0.101)      (0.128) 
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     3+ 1.133*** 1.261*** 1.203*** 0.229** 0.491*** 0.945*** 
      (0.271)      (0.242)      (0.163)      (0.108)      (0.121)      (0.151) 
Limiting fertility 0.636*** 0.793*** 1.019*** 0.677*** 0.606*** 0.256** 
 0.329* 0.590*** 0.744*** 0.367*** 0.304*** -0.00817 
Condition      (0.174)      (0.143)      (0.099)      (0.068)      (0.079)      (0.101) 
 -0.0175 -0.669*** -0.148 -0.184*** -0.335*** -0.131 
Usual care      (0.195)      (0.203)      (0.112)      (0.070)      (0.090)      (0.113) 
 0.109 0.211 0.191 0.422*** -0.00594 -0.287*** 
Place of residence       
     Metropolitan       (0.193)      (0.183)      (0.126)      (0.079)      (0.084)      (0.108) 
 -0.133 0.19 0.145 -0.148* 0.188* 0.531*** 
     Suburban      (0.200)      (0.210)      (0.139)      (0.084)      (0.108)      (0.156) 
 -0.534** 0.134 0.165 -0.162* 0.101 0.493*** 
      (0.208)      (0.206)      (0.135)      (0.083)      (0.107)      (0.154) 
Data from 201-2013, 2013-2015 and 2015-2017 NSFG. N = 9,594 between the ages of 19 and 44 who are not currently pregnant, not relying on 
sterilization, and have had private or public insurance or have been uninsured for the past 12 months. Greater than HS indicates woman has greater 
than a high school education, condition indicates woman has a condition that may benefit from hormonal contraception. Base alternative is no method 
use. Includes set of year controls. Base category for age is 24-28, zero for number of children, and rural for place of residence. Standard errors 
(clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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In Table 32, the alternative-specific constants of hormonal IUDs and SARCs are 
negative and statistically significant. The coefficients are negative for implants, 
non-hormonal IUDs, and traditional methods but the results are not precise. Condoms are 
now associated with a positive effect on utility. In Table 33, all alternative-specific 
constants are negative. In both tables, limiting fertility increases the utility of using any 
method.  
The results of the attributes with interactions for women who are sexually active 
the entire year and women regardless of sexual activity are in Tables 34 and 35, 
respectively. The main result—that being a device decreases the utility of a method—
remains regardless of sexual activity. Among women who are sexually active the entire 
year, the coefficient on the main effect of reduction in the risk of pregnancy is not 
statistically different from zero, with women who are young, more educated, and limiting 
fertility preferring methods with more protection. In both tables, having children 
increases the likeliness of using a contraceptive device.
 
 
 
Table 34. Contraceptive Attributes Conditional Logistic Regression Results with Attribute-Characteristic Interactions: 
Sexually Active Women 
 
Attributes Birth 
Control 
Price 
Hormonal Method Device Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of Use 
 -0.146*** 1.049*** -2.005*** -0.613 0.108 
Interactions (0.012) (0.297) (0.482) (0.455) (0.078) 
Age group      
    19-23  0.284** -0.111 0.503** -0.0108 
       (0.138)      (0.305)      (0.250)         (0.048) 
     29-33  -0.104 -0.527** -0.444** 0.0446 
       (0.126)      (0.243)      (0.201)         (0.035) 
     34-38  -0.119 -0.900*** -0.876*** 0.0967** 
       (0.142)      (0.286)      (0.221)         (0.040) 
     39-44  -0.380** -0.141 -1.719*** 0.00154 
       (0.162)      (0.311)      (0.240)         (0.044) 
Black  -0.191 0.26 -0.314* -0.111*** 
       (0.118)      (0.239)      (0.180)         (0.037) 
Hispanic  -0.186* 0.295 0.0816 -0.00182 
       (0.112)      (0.210)      (0.176)         (0.030) 
Married  -0.377*** 0.736*** -0.652*** -0.0615** 
       (0.103)      (0.205)      (0.160)         (0.029) 
Income  0.0368** 0.0387 0.0354 0.00673 
       (0.017)      (0.033)      (0.026)         (0.004) 
Working  0.196** 0.534*** 0.00817 -0.0226 
       (0.100)      (0.207)      (0.154)         (0.030) 
Greater than HS  0.0653 0.151 0.767*** 0.00851 
       (0.105)      (0.218)      (0.162)         (0.031) 
Number of children      
     1  -0.239** 0.546** 0.156 -0.0234 
       (0.118)      (0.267)      (0.183)         (0.041) 
     2  -0.188 0.767*** 0.494** -0.00027 
       (0.129)      (0.278)      (0.208)         (0.041) 
     3+  -0.510*** 1.152*** 0.303 -0.0609 
       (0.156)      (0.330)      (0.237)         (0.048) 129 
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Limiting fertility  0.17 0.192 1.415*** -0.0138 
       (0.111)      (0.207)      (0.183)         (0.029) 
Condition  0.00238 0.564** -0.926*** -0.0749** 
       (0.120)      (0.247)      (0.168)         (0.037) 
Usual Care  0.508*** -0.383 -0.332* 0.0785** 
       (0.123)      (0.272)      (0.181)         (0.038) 
Place of residence      
     Metropolitan   -0.448*** 0.463 0.574*** -0.0684 
       (0.142)      (0.292)      (0.222)         (0.043) 
     Suburban   -0.385*** 0.368 0.570*** -0.05 
       (0.139)      (0.278)      (0.216)         (0.041) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 4,477 between the ages of 19 and 44 who 
are not currently pregnant or postpartum, not relying on sterilization, and have had private or public insurance or have 
been uninsured for the past 12 months. Greater than HS indicates woman has greater than a high school education, 
condition indicates woman has a condition that may benefit from hormonal contraception. Includes set of year 
controls. Base category for age is 24-28, and zero for number of children and rural for place of residence. Standard 
errors (clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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Table 35. Contraceptive Attributes Conditional Logistic Regression Results with 
Attribute-Characteristic Interactions: No Restrictions on Sexual Activity 
 
Attributes 
Birth Control 
Price 
Hormonal 
Method Device 
Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of Use 
 -0.122*** 1.509*** -1.522*** -2.902*** 0.0428 
Interactions            (0.008)      (0.228)      (0.361)      (0.297)         (0.063) 
Age group      
    19-23  0.250** 0.0927 -0.00278 -0.0269 
       (0.104)      (0.228)      (0.143)         (0.038) 
     29-33  -0.0111 -0.436** -0.455*** 0.0479* 
       (0.100)      (0.191)      (0.136)         (0.029) 
     34-38  -0.0451 -0.437** -1.032*** 0.0517 
       (0.113)      (0.221)      (0.151)         (0.033) 
     39-44  -0.324** -0.136 -1.426*** 0.00932 
       (0.126)      (0.245)      (0.161)         (0.037) 
Black  -0.293*** 0.0796 -0.0246 -0.0970*** 
       (0.088)      (0.182)      (0.115)         (0.029) 
Hispanic  -0.340*** 0.23 -0.0842 0.0118 
       (0.089)      (0.169)      (0.115)         (0.025) 
Married  -0.825*** 0.634*** 1.237*** -0.115*** 
       (0.083)      (0.163)      (0.109)         (0.024) 
Income  0.0272** 0.0549** 0.0460*** 0.00184 
       (0.012)      (0.025)      (0.017)         (0.004) 
Working  0.253*** 0.370** 0.0223 0.00888 
       (0.076)      (0.160)      (0.100)         (0.024) 
Greater than HS  0.141* -0.0259 0.187* 0.0520** 
       (0.082)      (0.168)      (0.110)         (0.025) 
Number of 
children 
 
    
     1  -0.252*** 0.680*** 0.611*** -0.0133 
       (0.094)      (0.210)      (0.125)         (0.033) 
     2  -0.288*** 0.807*** 0.886*** -0.000584 
       (0.105)      (0.221)      (0.141)         (0.034) 
      131 
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     3+  -0.400*** 0.922*** 0.893*** -0.0266 
       (0.128)      (0.263)      (0.167)         (0.040) 
Limiting fertility  0.179** 0.123 0.269** 0.0292 
       (0.082)      (0.156)      (0.111)         (0.023) 
Condition  0.141 0.326* -0.427*** -0.0478* 
       (0.092)      (0.183)      (0.122)         (0.029) 
Usual Care  0.529*** -0.547*** -0.154 0.0859*** 
       (0.094)      (0.200)      (0.116)         (0.029) 
Area of residence      
     Metropolitan   -0.453*** 0.345 0.424*** -0.0428 
       (0.112)      (0.225)      (0.152)         (0.035) 
     Suburban   -0.364*** 0.147 0.291* -0.0159 
       (0.110)      (0.218)      (0.150)         (0.034) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 9,594 between the ages of 19 and 44 who 
are not currently pregnant, not relying on sterilization, and have had private or public insurance or have been 
uninsured for the past 12 months. Greater than HS indicates woman has greater than a high school education, 
condition indicates woman has a condition that may benefit from hormonal contraception. Includes set of year 
controls. Base category for age is 24-28, zero for number of children, and rural for area of residence. Standard errors 
(clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010 
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One barrier to the use of long-acting method among childless women is that 
providers sometimes believe that IUDs are not appropriate for women without children 
(Luchowski et al., 2014). The coefficients on having children are positive and statistically 
significant for LARC alternatives (with the exception of implants among women with 
one child), as are the effects of having children on the utility of using a contraceptive that 
is a device. Because it is possible that these results are picking up barriers to LARC use 
among women without children, I reestimate the primary specification for the alternative 
and attributes models using a sample of mothers. These results are reported in Tables 36 
and 37 and show that the main effects of devices and alternative-specific constants of 
LARC methods remain negative. 
Finally, it is possible that women consider the perfect use failure rate when 
choosing a contraceptive method rather than the typical use rate. To explore this, I 
estimated the attributes models using a reduction in risk of pregnancy calculated with 
perfect use failure rates. I only estimate these results for the attributes model, as I am 
changing the definition of one of the attributes. I also reestimate the model among 
contracepting women only. The results are reported in Table 38 and Table 39. The 
directions of the results are largely similar to those in primary specifications, though the 
magnitude on the coefficient of pregnancy risk reduction is much larger than in Table 28. 
There are also some differences in which variables are significant. For example, the 
coefficient on hormonal is negative, but no longer statistically different from zero. 
 
 
 
Table 36. Contraceptive Choice Logistic Regression Results with Women’s Characteristics: Mothers Only 
 
Price ($10) -0.103***      
      (0.012)      
Alternative Specific Constant Implant Non-hormonal IUD Hormonal IUD SARC Condoms Traditional 
 -1.564** -1.566*** -0.660* 0.384 -0.794*** -1.788*** 
      (0.677)      (0.515)      (0.370)      (0.267)      (0.304)      (0.379) 
Interactions       
Age       
     19-23 0.812*** 0.354 0.0856 0.406** 0.351* -0.0496 
      (0.231)      (0.271)      (0.209)      (0.161)      (0.181)      (0.248) 
     29-33 -1.195*** -0.189 -0.332** -0.230* -0.158 -0.106 
 -0.277 -0.21 -0.148 -0.122 -0.133 -0.161 
     34-38 -1.975*** -0.494** -0.914*** -0.438*** -0.419*** -0.371** 
 (0.395) (0.237) (0.271) (0.135) (0.145) (0.179) 
     39-44 -1.775*** -0.914*** -1.111*** -1.012*** -0.722*** -0.435** 
      (0.420)      (0.271)      (0.184)      (0.153)      (0.158)      (0.188) 
Black -0.119 -0.867*** -0.749*** -0.177* -0.11 -0.522*** 
      (0.208)      (0.216)      (0.141)      (0.107)      (0.116)      (0.152) 
Hispanic 0.537** 0.511*** 0.00246 -0.109 0.034 -0.227 
      (0.213)      (0.169)      (0.130)      (0.108)      (0.116)      (0.142) 
Married -0.0877 0.224 0.155 -0.171 0.307*** 0.454*** 
      (0.233)      (0.178)      (0.130)      (0.105)      (0.105)      (0.131) 
Income 0.0435 0.101*** 0.103*** 0.0617*** 0.0258 0.0427* 
      (0.041)      (0.029)      (0.022)      (0.018)      (0.019)      (0.022) 
Working 0.328* 0.337** 0.691*** 0.106 -0.14 0.0461 
      (0.188)      (0.165)      (0.123)      (0.093)      (0.098)      (0.118) 
Greater than HS -0.258 0.278 0.427*** 0.168 0.237** 0.08 
      (0.308)      (0.202)      (0.133)      (0.108)      (0.113)      (0.141) 
Number of children       
     2 0.377* 0.549*** 0.350*** 0.138 0.165 0.167 
      (0.216)      (0.182)      (0.124)      (0.100)      (0.109)      (0.130)  
     3+ 0.526** 0.304 0.128 -0.148 0.0941 0.0638 
      (0.257)      (0.222)      (0.150)      (0.121)      (0.128)      (0.153) 
Limiting fertility 0.350* 0.742*** 0.843*** 0.627*** 0.508*** 0.276** 
      (0.211)      (0.167)      (0.119)      (0.098)      (0.104)      (0.125) 134 
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Condition 0.0601 -1.125*** -0.323** -0.514*** -0.434*** -0.371** 
      (0.256)      (0.275)      (0.141)      (0.118)      (0.127)      (0.151) 
Usual care 0.0454 0.172 0.145 0.258** 0.00516 -0.0806 
      (0.252)      (0.219)      (0.160)      (0.126)      (0.124)      (0.152) 
Place of residence       
     Metropolitan -0.475* -0.045 -0.0877 -0.514*** 0.0549 0.515*** 
      (0.257)      (0.241)      (0.170)      (0.128)      (0.148)      (0.198) 
     Suburban -0.622** 0.054 0.178 -0.391*** 0.0901 0.558*** 
      (0.257)      (0.234)      (0.164)      (0.125)      (0.146)      (0.195) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 4,606 mothers between the ages of 19 and 44 who are not currently 
pregnant, not relying on sterilization, have been sexually active at least 3 of the past 12 months, and have had private or public insurance or have been 
uninsured during the past 12 months. Greater than HS indicates woman has greater than a high school education, condition indicates woman has a 
condition that may benefit from hormonal contraception. Base alternative is no method use. Includes set of year controls. Base category for age is 24-
28, one for number of children, and rural for place of residence. Standard errors (clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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Table 37. Contraceptive Attributes Conditional Logistic Regression Results with Attribute-Characteristic Interactions: 
Mothers Only 
 
Attributes Birth Control 
Price 
Hormonal Method Device Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of Use 
 -0.0998*** 1.509*** -1.285*** -1.698*** 0.0641 
Interactions            (0.010)      (0.294)      (0.398)      (0.415)         (0.069) 
Age group      
    19-23  0.0433 0.222 0.483* -0.0349 
       (0.172)      (0.301)      (0.260)         (0.047) 
     29-33  -0.0606 -0.619*** -0.222 0.0567* 
       (0.132)      (0.230)      (0.188)         (0.034) 
     34-38  -0.00313 -0.920*** -0.601*** 0.0742** 
       (0.147)      (0.261)      (0.206)         (0.038) 
     39-44  -0.329** -0.426 -0.908*** 0.00087 
       (0.162)      (0.294)      (0.220)         (0.043) 
Black  0.0246 -0.114 -0.305* -0.0495 
       (0.120)      (0.217)      (0.165)         (0.033) 
Hispanic  -0.0829 0.12 -0.0498 0.0352 
       (0.117)      (0.199)      (0.164)         (0.029) 
Married  -0.580*** 0.478** 0.572*** -0.0746*** 
       (0.108)      (0.196)      (0.151)         (0.028) 
Income  0.0227 0.0381 0.0476* 0.0175 
       (0.018)      (0.033)      (0.026)         (0.029) 
Working  0.272*** 0.412** -0.194 -0.031 
       (0.099)      (0.189)      (0.138)         (0.035) 
Greater than HS  -0.00533 0.196 0.255 -0.00103 
       (0.116)      (0.208)      (0.163)         (0.031) 
Number of children      
     2  -0.026 0.158 0.227 0.0175 
            (0.108)      (0.195)      (0.153)         (0.029) 
     3+  -0.220* -0.426 0.118 -0.031 
       (0.131)      (0.294)      (0.178)         (0.035) 
      
Limiting fertility  0.172* -0.0859 0.617*** 0.0374 
       (0.103)      (0.183)      (0.147)         (0.027) 
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Condition  -0.00357 0.818*** -0.645*** -0.112*** 
       (0.133)      (0.231)      (0.176)         (0.035) 
Usual Care  0.289** -0.306 -0.0544 0.0522 
       (0.133)      (0.251)      (0.175)         (0.036) 
Place of residence      
     Metropolitan  -0.689*** 0.626** 0.278 -0.0808** 
       (0.145)      (0.266)      (0.211)         (0.041) 
     Suburban  -0.575*** 0.580** 0.3 -0.0642* 
       (0.141)      (0.251)      (0.209)         (0.039) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 4,606 mothers between the ages of 19 and 
44 who are not currently pregnant, not relying on sterilization, have been sexually active at least 3 of the past 12 
months, and have had private or public insurance or have been uninsured during the past 12 months. Greater than HS 
indicates woman has greater than a high school education, condition indicates woman has a condition that may benefit 
from hormonal contraception. Base alternative is no method use. Includes set of year controls. Base category for age is 
24-28, one for number of children, and rural for place of residence. Standard errors (clustered at woman-level) are in 
parentheses.  
* p<0.10, ** p<0.05, *** p<0.010  
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Table 38. Contraceptive Attributes Conditional Logistic Regression Results with Attribute-Characteristic Interactions: 
Perfect Use Failure Rates 
 
Attributes Birth Control 
Price 
Hormonal Method Device Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of Use 
 -0.120*** 1.224*** -1.752*** -1.184*** 0.0333 
Interactions            (0.009)      (0.216)      (0.375)      (0.260)         (0.064) 
Age       
    19-23  0.240** 0.0946 0.234* -0.0295 
       (0.097)      (0.233)      (0.128)         (0.037) 
     29-33  -0.0887 -0.582*** -0.311*** 0.0547* 
       (0.094)      (0.198)      (0.115)         (0.029) 
     34-38  -0.182* -0.619*** -0.665*** 0.0426 
       (0.108)      (0.230)      (0.129)         (0.033) 
     39-44  -0.506*** -0.266 -0.909*** -0.0167 
       (0.123)      (0.261)      (0.140)         (0.038) 
Black  -0.272*** 0.159 -0.183* -0.111*** 
       (0.084)      (0.190)      (0.100)         (0.029) 
Hispanic  -0.301*** 0.324* -0.0474 -0.00304 
       (0.084)      (0.175)      (0.100)         (0.025) 
Married  -0.553*** 0.590*** 0.195** -0.0752*** 
       (0.078)      (0.169)      (0.092)         (0.024) 
Income  0.0361*** 0.0443* 0.0298** 0.00407 
       (0.012)      (0.026)      (0.015)         (0.004) 
Working  0.233*** 0.404** -0.0157 0.00529 
       (0.073)      (0.166)      (0.087)         (0.024) 
Greater than HS  0.142* 0.0158 0.295*** 0.0406 
       (0.078)      (0.175)      (0.095)         (0.025) 
Number of children     
     1  -0.147* 0.671*** -0.0434 -0.0116 
       (0.087)      (0.214)      (0.106)         (0.032) 
     2  -0.129 0.736*** 0.178 0.0152 
       (0.098)      (0.226)      (0.120)         (0.033) 
     3+  -0.273** 0.948*** 0.087 -0.0218 
       (0.121)      (0.272)      (0.141)         (0.039) 138 
 
 
 
Table 38 Continued 
    
Limiting fertility  0.215*** 0.16 0.567*** 0.0231 
       (0.080)      (0.166)      (0.101)         (0.024) 
Condition  -0.0291 0.625*** -0.577*** -0.0952*** 
       (0.089)      (0.191)      (0.102)         (0.029) 
Usual Care  0.454*** -0.439** -0.126 0.0630** 
       (0.091)      (0.209)      (0.102)         (0.030) 
Place of residence     
     Metropolitan   -0.467*** 0.464** 0.333** -0.0493 
       (0.105)      (0.234)      (0.130)         (0.035) 
     Suburban   -0.379*** 0.321 0.281** -0.0307 
       (0.103)      (0.226)      (0.129)         (0.034) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,487 between the ages of 19 and 44 who 
are not currently pregnant, not relying on sterilization, have been sexually active at least 3 of the past 12 months, and 
have had private or public insurance or have been uninsured during the past 12 months.  indicates woman has greater 
than a high school education, condition indicates woman has a condition that may benefit from hormonal 
contraception. Includes set of year controls. Base category for age is 24-28, zero for number of children, and rural for 
place of residence. Standard errors (clustered at woman-level) are in parentheses. * p<0.10, ** p<0.05, *** p<0.010                                         
 
  
139 
 
 
 
Table 39. Contraceptive Attributes Conditional Logistic Regression Results with 
Attribute-Characteristic Interactions Among Women Using Contraception: Perfect Use Failure Rates 
 
Attributes Birth Control 
Price 
Hormonal Method Device Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of Use 
 -0.129*** -0.714 -1.219*** 81.05*** -0.159** 
Interactions            (0.010)      (0.434)      (0.377)    (16.150)         (0.071) 
Age       
    19-23  0.00682 0.171 11.43 -0.0536 
       (0.203)      (0.227)      (7.570)         (0.040) 
     29-33  -0.0133 -0.593*** -3.484 0.0615* 
       (0.194)      (0.199)      (6.707)         (0.034) 
     34-38  -0.219 -0.613*** 1.204 0.0394 
       (0.223)      (0.232)      (7.670)         (0.038) 
     39-44  -0.317 -0.41 -9.103 0.00953 
       (0.252)      (0.266)      (8.501)         (0.044) 
Black  -0.770*** 0.238 21.45*** -0.164*** 
       (0.167)      (0.184)      (6.191)         (0.032) 
Hispanic  -0.636*** 0.389** 16.61*** -0.0429 
       (0.171)      (0.176)      (6.053)         (0.029) 
Married  -0.398** 0.466*** -6.291 -0.0580** 
       (0.159)      (0.172)      (5.475)         (0.028) 
Income  0.0633** 0.0292 -1.178 0.00756* 
       (0.025)      (0.027)      (0.889)         (0.004) 
Working  0.631*** 0.265 -17.51*** 0.0557** 
       (0.148)      (0.165)      (5.244)         (0.027) 
Greater than HS  0.0244 0.0752 5.59 0.0277 
       (0.161)      (0.175)      (5.677)         (0.029) 
Number of children      
     1  0.604*** 0.401* -31.07*** 0.0774** 
       (0.185)      (0.209)      (6.553)         (0.035) 
     2  0.780*** 0.420* -35.79*** 0.121*** 
       (0.208)      (0.226)      (7.163)         (0.038) 
     3+  0.584** 0.648** -33.62*** 0.0774* 
       (0.250)      (0.271)      (8.471)         (0.045) 140 
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Limiting fertility  0.038 0.25 9.723* 0.00225 
       (0.169)      (0.168)      (5.735)         (0.028) 
Condition  0.233 0.496*** -11.51* -0.0619* 
       (0.185)      (0.192)      (6.382)         (0.034) 
Usual Care  0.203 -0.31 11.37* 0.0312 
       (0.174)      (0.210)      (6.017)         (0.033) 
Place of residence      
     Metropolitan  -0.0383 0.346 -18.41** -0.0035 
       (0.219)      (0.231)      (8.150)         (0.040) 
     Suburban  0.13 0.177 -21.72*** 0.0257 
       (0.219)      (0.223)      (8.120)         (0.039) 
Unweighted data from 201-2013, 2013-2015 and 2015-2017 NSFG. N = 5,327 between the ages of 19 and 44 who are 
not currently pregnant, not relying on sterilization, have been sexually active at least 3 of the past 12 months, and have 
had private or public insurance or have been uninsured for the past 12 months. Greater than HS indicates woman has 
greater than a high school education, condition indicates woman has a condition that may benefit from hormonal 
contraception. Includes set of year controls. Base category for age is 24-28, zero for number of children, and rural for 
place of residence. Standard errors (clustered at woman-level) are in parentheses. * p<0.10, ** p<0.05, *** p<0.010                                         
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4.6 Discussion 
My results suggest that women prefer methods that do not require the insertion of 
a device, as seen in the results of both models with alternative-specific constants and with 
contraceptive attributes. This is true even when the attributes model is estimated among 
women who have decided to use contraception.  
Women with more children find LARC methods and attributes as a better match. 
It is possible that the coefficients on the device and number of children variables are 
picking up on barriers to LARC use for women without children. However, implants are 
also associated with a negative effect on utility of the method, though they would not be 
subject to the same concerns as IUDs regarding insertion in nulliparous patients. Further, 
the results of a set of sensitive analyses indicate that the negative effect is still present 
when the results are estimated only for mothers. 
In specifications that include women who choose to not use a contraceptive, more 
effective methods are associated with a negative effect on utility. The coefficients are 
also much smaller magnitude than the results for contracepting women only. It is possible 
that women have different preferences for the use of effective contraceptives, resulting in 
the negative effect. Some women (particularly those choosing to use contraception) place 
high importance on effectiveness, while others (such as women attempting to become 
pregnant) would find a great disutility from using contraception. Others might be 
ambivalent about pregnancy (Kaye et al., 2009).  
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Among contraceptive users, methods that provide greater protection are more 
attractive, however the fact that LARCs are devices may discourage women from using 
the most effective reversible methods. Additionally, duration of use also has a negative 
effect on utility when estimated among a group of contracepting women only. Thus, 
while increasing LARC access may be an important goal that will benefit some women, 
there are likely some women who would prefer to use more effective methods but will 
find LARCs as an unattractive option. A more effective woman-controlled contraceptive 
would likely be a better alternative for these women. 
There are a number of different possible reasons that the coefficients on the 
device attribute is negative. For example, some women may be uncomfortable having a 
device inserted into their bodies or do not like methods that they cannot easily 
discontinue if they want to become pregnant or if they experience side-effects. 
Addressing the first concern would require developing new methods, though concerns 
over having a device placed in the body could be potentially reduced by contraceptive 
counseling (Sundstrom et al., 2016). Providing instructions on self-removal of IUDs may 
be able to address the latter concern (Foster et al., 2012, 2014). 
In 2018, the FDA approved a contraceptive ring that could be used up to a year 
(U.S. Food & Drug Administration, 2018). The ring was developed to follow a 21-day-
on-7-day-off regimen which would still allow room for user error. If the ring can be used 
continuously (as women have been doing with the pill for many years), then such a ring 
may be a step in the direction of long-lasting contraception that does not require a 
doctor’s visit for discontinuation. 
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4.6.1 Limitations 
Train (2009) discusses three limitations of logit models, two of which are 
applicable to this paper. The first is the property of Independence from Irrelevant 
Alternatives (IIA) and the resulting substitution patterns. The IIA results from assuming 
that the error terms are distributed iid type I extreme value, which implies that the ratio of 
the log probabilities of two options does not depend on other available alternatives. If a 
model is not correctly specified such that utility is well represented, then the IIA may 
lead to unrealistic substitution patterns. By estimating logit models, I am assuming that 
the decision to choose one method compared to no method is unrelated to the other 
contraceptives available. It seems likely that the choice to use a contraceptive would be 
related to the availability other methods, particularly if those methods are very similar. 
For example, one could imagine that the availability of hormonal IUDs may have little 
influence the decision to use a traditional method, but that the choice of a hormonal 
method like the implant may depend on the availability of IUDs and SARCs. 
The second limitation of the logit model is that it cannot account for unobserved 
heterogeneity in taste preferences. My models assume that for a contraceptive (or set of 
attributes) the effects on utility are constant. While adding the characteristics and 
interactions can account for some observed taste preferences, it is possible that 
preferences for attributes vary by woman in ways that I cannot capture adequately.  
Beyond the restrictions of the model, the data I use create other limitations. 
Because the NSFG does not gather information on the out-of-pocket expenses paid for 
contraceptives, I use a price variable constructed from the literature which adds 
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measurement error. Because my approach to the price variable requires knowledge of a 
woman’s insurance status, I can only use the most recent (relative to the interview) 12 
months of data in the contraceptive histories. I also do not account for protection against 
sexually transmitted diseases due to multicollinearity. 
Finally, in order to interpret the results as effects on utility, it is necessary to 
control for barriers to use, such as supply-side factors. I included if a woman lives in a 
metropolitan, suburban or rural area, and indicator for if she has a usual place of care, and 
a set of year controls to control for such access issues. These variables may still not 
completely capture LARC-related barriers. A limitation of the National Survey of Family 
Growth is that the public use datasets do not include information on the state, county, or 
region of residence. Further analysis should be performed using regional or state-level 
data to ascertain that the negative effect of the method being a device is not due to 
supply-side barriers.  
4.7 Conclusion 
The rate of unplanned pregnancies in the United States is high, with as many as 
45% of pregnancies being unplanned. Forty-one percent of these pregnancies are among 
women who are using contraceptives, but not using their method consistently. Long-
acting reversible contraceptives have been advocated as a way to decrease the rate of 
unintended pregnancies as they do not rely on user compliance, however LARC specific 
attributes—such as being a device that is inserted in the body—may make LARCs an 
unattractive option for many women. 
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It is likely that barriers to access have slowed the adoption of LARCs. It is also 
likely that the attributes of LARCs themselves inhibit their uptake. Thus, policies should 
be implemented to both increase LARC access and to encourage research and 
development of contraceptives that better fit the needs of women. 
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CHAPTER V 
CONCLUSION 
 
 
In this dissertation I used a variety of econometric techniques and data from the 
National Survey of Family Growth to assess the duration, effect on pregnancies, and 
decision to use long-acting reversible contraception. Using duration analysis including a 
competing risk model, I find that LARC methods are used longer than other reversible 
methods, but that spells of contraceptives that are more sensitive to user error are not 
more at risk of ending due to a switch to LARC use. Using an instrumental variables 
approach using variation from the release of provider recommendations to account for 
selection into LARC use, I find that LARCs decrease the probability of becoming 
pregnant in the current and subsequent year, at least among young mothers affected by 
the recommendation. I also find evidence of selection into LARC use by women who 
would have otherwise been more likely to become pregnant in the following year.  
LARC methods have the potential to positively affect women’s welfare by 
reducing the possibility of user error, but some women may find long-acting methods as 
unattractive alternatives. In my third essay, I find that being a physical device may reduce 
the utility of LARC methods and may prevent some women from choosing a LARC. 
Thus, to help women have greater control over their fertility, it is essential to both 
decrease barriers to access for LARC methods and to invest in the development of other 
effective methods that better fit women’s needs. 
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APPENDIX A 
CHAPTER II CONTRACEPTIVE SPELL CONSTRUCTION 
 
 
For the data used in Chapter II, the 2006-2010, 2011-2013, and 2013-2015 NSFG 
datasets were combined resulting in a dataset with 23,579 observations, each representing 
one female respondent. Additionally, the three corresponding pregnancy interval files 
were combined resulting in a pregnancy-level dataset with information on 14,517 
pregnancies. 
The NSFG questionnaire is completed using a life-table calendar to record 
contraceptive methods and sexual activity month by month; this information was 
exploited to create longitudinal data. The calendars begin in January of three years before 
the survey and ask a woman about her contraceptive use that month (up to four methods) 
and whether she was sexually active for every month up to when the survey was 
administered. At a maximum, a woman contributed 48 months of data if she were 
surveyed in December, though the months of data contributed were on average 42.2. The 
start and end dates for marriages and pregnancies and dates of births of children are also 
recorded, but not in a question-per-month fashion. The dates from these variables were 
matched up to corresponding months in the calendar to build a more detailed longitudinal 
dataset consisting of contraceptive use, marriage spells, sexual activity, and childbirth.  
The contraceptive questions allowed for a range of detailed responses (e.g., pills, 
patches, rings and shots were listed separately), which were grouped into contraceptive 
types during data cleaning (e.g., pills, patches, rings, or shots were all in the “short-acting 
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reversible contraceptives (SARC)” category). The categories of methods are listed in 
Table A.1 below. 
 
Table A.1 Categories of Contraceptives 
 
Category Method in Questionnaire 
No method No method used (current); no method used (ever)1 
  
Emergency 
Contraception  
Emergency contraception (EC) 
  
Traditional Method Withdrawal/pulling out; rhythm or safe period by calendar; safe 
period by temperature or cervical mucous, natural family planning 
  
Barrier Method Condoms (male or female); diaphragm, foam; jelly or cream; 
suppository or insert 
  
Short-Acting 
Reversible 
Contraception (SARC) 
Birth control pills; patches; rings; injectables 
  
Long-Acting 
Reversible 
Contraception (LARC) 
Intrauterine device (IUD), coil, or loop; hormonal implant  
  
Male Sterilization Partner’s vasectomy 
  
Female Sterilization Female sterilizing operation, such as tubal sterilization and 
hysterectomy  
  
Other Method Other method; male sterility; female sterility2 
1A woman who never used a method and was not sexually active was not within the NSFG’s universe for 
the contraceptive calendar and was simply recorded as a missing value; during data construction these 
women were included into the calendar and grouped into “no method”. 
2Non-contraceptive sterility was not included as part of the sterilization methods because it is presumably 
not chosen and is thus fundamentally different.  
 
 
After assigning the NSFG responses each month to a category, binary variables 
that indicated whether a type of method was used across any of the four mentions were 
created. Because a woman may use more than one method each month, these indicator 
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variables were used to construct a “main method” variable which reported the most 
effective method or longest acting method used in that month. The hierarchy for 
constructing the main method variable is as follows: 
 
1. Female sterilization 
2. Male sterilization 
3. LARC method 
4. SARC method 
5. Barrier method 
6. Traditional method 
7. Other method 
8. Emergency contraception 
9. No method 
 
 
If a woman listed female sterilization across any of her mentions, it was recorded 
as her main method; if not, then the next category (male sterilization) was checked and 
recorded as the main method if listed; if male sterilization was not listed, then the next 
method checked was LARC. If a LARC method was not listed, then the next category 
was considered. This continued until the options were exhausted. 
While constructing the panel data, some observations were missing necessary 
information and thus needed to be edited or excluded. Some women had missing 
information regarding her contraceptive use during months within the calendar. If the 
same method was used on either side of the missing month, the value was imputed to the 
value from surrounding months. If the missing value was at the end of the calendar, the 
data for that woman was removed from the sample.33  
 
33 In practice this resulted in the exclusion of one observation. 
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If women did not know or refused to provide information on their first month of 
contraceptive use, they were assigned a starting month of contraceptive use before the 
start of the survey, so that they could still be included in the calendar.34 As the month of 
first method use is not included in my analysis (unless it occurred within the calendar), 
this did nothing more than to allow women who did not remember this date to remain in 
the data during the data cleaning process. Women who replied that they did not know or 
refused information on contraceptive use or sexual activity for any month within the 
calendar were removed from the sample.  
For all but the very first year of the 2006-2010 NSFG, the sexual activity calendar 
applied to all respondents; during that first year, however, there were 36 individuals who 
were not in the universe for the sexual activity calendar, and 43 individuals without 
information on the reference month for the calendar entry. Observations of individuals 
who fell into these groups were excluded. Additionally, if women reported not knowing 
the beginning and end dates of their marriages, or if they reported sterilization or LARC 
use within the calendar but claimed to have never been sterilized or to never have used a 
LARC, the observations were removed.35 A total of 377 women were excluded, leaving 
 
34 Century months (CM) are used in the NSFG and the earliest century month in any calendar is 1237; 
century months can be calculated using the following formula: CM= 12(year – 1900) + month. 
(https://demographicestimation.iussp.org/content/dhs-century-month-codes ). I imputed a calendar month 
before this date.  
 
35 The NSFG contains “perturbed data” in order to keep the respondents unidentifiable; while the 
documentation assures that the changes were done in such a way that it would not affect descriptive 
statistics or coefficient estimates, the lack of detail on the process of perturbing the data resulted in the need 
for particularly aggressive data cleaning.  
 
170 
 
23,202 women who contributed 979,896 women-months in the dataset.36 After making 
these exclusions, I removed spells of use that were left censored, and women who were 
adolescents (<20 years old).  
In Table A.2, I report descriptive statistics of the NSFG before excluding 
teenagers and women with left censored spells. The proportion of women relying on 
female sterilization is greater than it is after removing left censored spells (13% versus 
8.2%), though this proportion is still lower than results reported in Kavanaugh and 
Jerman (2018). This difference is likely due to Kavanaugh and Jerman (2018) using 
weights to adjust for the oversampling of young women who are unlikely to be sterilized. 
The mean number of spells is also lower compared to the results after removing left 
censored spells, likely because left censored spells are likely to be long spells. 
 
  
 
36 Initially, 380 women were excluded. After reviewing the data, I was able to determine enough 
information on 3 women to keep them in the sample.  
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Table A.2 Descriptive Statistics of National Survey of Family Growth at Time of 
Survey 
 
Variable Mean 
     Age during calendar month 28.628 
     Under 20 years old 0.185 
     Respondent is Black 0.226 
     Respondent is Hispanic 0.236 
     Currently married 0.314 
     Has children 0.544 
          Number of children (among mothers) 2.156 
     Currently working 0.622 
     Household income is below the poverty level 0.306 
     Respondent is insured 0.799 
     Less than high school education 0.253 
     Has high school diploma or equivalent 0.459 
     Greater than high school education (any level) 0.289 
     Number of spells 3.349  
Unweighted data from the 2006-2010, 2011-2013, and 2013-2015 NSFG. N = 23,202 (12,616 mothers) 
ages 20-45.  
 
 
In Table A.3, I summarize how spells are censored by method for women who are 
over the age of 19 at the start of the spell. Over two thirds of sterilization spells are left 
censored or both left and right censored.  
 
Table A.3 How Spells are Censored by Method 
 
Method 
Only Left 
Censored 
Only Right 
Censored 
Both Left 
and Right 
Censored Uncensored Total 
Sterilization (F) 2 934 2,187 0 3,123 
LARC 318 828 460 334 1,940 
SARC 2,427 1,882 1,482 2,954 8,745 
Barrier 1,514 1,593 481 7,869 11,457 
Traditional 577 698 207 2,999 4,481 
Sterilization (M) 26 538 563 14 1,141 
Other method 13 26 9 185 233 
EC 3 5 0 155 163 
No method 3,255 3,393 1,602 11,355 19,605 
Pregnancy 1,132 917 0 4,974 7,023 
Total 9,267 10,814 6,991 30,839 57,911 
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APPENDIX B 
CHAPTER II KAPLAN-MEIER AND COMPETING RISK ANALYSIS WITH 
WEIGHTS 
 
 
In Chapter II, I make the choice to not use the weights provided in the NSFG. The 
weights for each wave were constructed to adjust for the sampling scheme and 
nonresponse in order to make the cross-sectional data from the time of the survey 
representative of the US at the midpoint of the respective waves. Since I am using panel 
data rather than cross-section data, these weights are not correct for my analysis. There 
may, however, be value in using these weights, even though that are not designed for my 
purposes. As a robustness check, I reestimate selected models using the survey weights 
provided in the NSFG.  
The first set of results I present are the Kaplan-Meier survival probabilities. As 
seen in Table B.1, the results with weights tend to be a few percentage points higher than 
the unweighted results, at the exception of for IUD (and LARCs overall) starting at 24 
months. While there are gaps between the weighted and unweighted results ranging from 
less than one percentage point to over 5 percentage points, the same general patterns 
hold. LARCs spells have higher rates of continuation than SARCs.  
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Table B.1 Kaplan-Meier Survival Probabilities of Long-Acting Reversible 
Contraceptives with Weights 
 
Method 6 months 12 months 18 months 24 months 30 months  36 months 
All LARC 87.68 77.64 71.72 63.85 60.83 53.80 
     IUD 86.77 77.23 71.04 63.98 61.86 55.00 
     Implant 93.19 79.89 76.07 62.54 52.80 45.26 
SARC 67.41 50.08 40.81 34.45 29.31 23.35 
Data from the 2006-2010, 2011-2013, and 2013-2015 National Survey of Family Growth. 
Results are weighted using the survey weights provided by the NSFG. Survival probabilities are 
estimated using the Kaplan-Meier Survival curve.  
 
 
I also reestimate the competing risk model from Table 9 with weights. When 
using the weights, there is no significant difference in the baseline hazards of a spell 
ending due to LARC use for SARC and barrier methods during the 4-6 month interval or 
during the first six months of traditional method spells. Traditional method spells have a 
statistically significantly lower hazard of switching into LARC use compared to SARC 
methods after the first nine months. The overall conclusion that spells of less effective 
methods do not have a greater hazard for switching into LARC use remains. 
 
Table B.2 Competing Risk Contraceptive Spell Exit Results: Time-Method 
Interactions with Weights 
 
 (1) (2) (3) (4) (5) 
Variable LARC 
No 
Method 
Other 
Flexible 
Method Pregnancy Sterilization 
      
Baseline 
hazard (SARC 
use) month 
     
     1 - 3 -6.600*** -2.675*** -4.510*** -5.245*** -6.429*** 
      (0.596)      (0.123)      (0.230)      (0.389)      (0.573) 
     4 - 6 -6.218*** -3.431*** -5.160*** -5.543*** -7.166*** 
      (0.457)      (0.164)      (0.250)      (0.404)      (0.551) 
     7 - 9 -7.531*** -3.357*** -5.341*** -5.979*** -6.995*** 
      (0.592)      (0.172)      (0.268)      (0.423)      (0.695) 
     10 - 12 -6.437*** -3.312*** -5.223*** -5.676*** -7.395*** 
      (0.546)      (0.217)      (0.288)      (0.441)      (0.667) 
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Table B.2 Continued 
    
     13 - 18 -6.450*** -3.540*** -5.736*** -5.832*** -6.626*** 
      (0.542)      (0.178)      (0.269)      (0.415)      (0.576) 
     19 - 24 -6.839*** -4.310*** -5.783*** -6.015*** -7.201*** 
      (0.734)      (0.211)      (0.322)      (0.455)      (0.625) 
     25 + -8.185*** -4.000*** -5.840*** -6.366*** -7.810*** 
      (0.674)      (0.242)      (0.366)      (0.482)      (0.838) 
      
Barrier  
×Time  
months 
     
     1 - 3 0.798** 1.537*** 0.488*** 0.869** 0.0345 
      (0.382)      (0.095)      (0.112)      (0.348)      (0.341) 
     4 -6 -0.521 1.278*** -0.0702 0.812*** 0.794* 
      (0.437)      (0.138)      (0.156)      (0.228)      (0.448) 
     7 - 9 0.198 0.609*** -0.0542 1.017*** 0.0838 
      (0.577)      (0.174)      (0.248)      (0.283)      (0.654) 
     10 - 12 -0.254 0.447** -0.0343 0.801** 0.134 
      (0.541)      (0.219)      (0.270)      (0.341)      (0.703) 
     13 - 18 -0.916 0.333* -0.143 0.724** 0.171 
      (0.560)      (0.174)      (0.272)      (0.304)      (0.702) 
     19 - 24 -0.629 0.764*** -0.532 0.721* 0.933 
      (0.818)      (0.265)      (0.337)      (0.391)      (0.803) 
     25 + -0.459 0.603** -1.108* 1.023** 0.206 
      (1.129)      (0.287)      (0.575)      (0.460)      (0.956) 
      
Traditional 
×Time 
months 
     
     1 - 3 0.529 1.329*** 0.389*** 1.432*** -0.235 
      (0.477)      (0.121)      (0.141)      (0.355)      (0.443) 
      
Table B.2 Continued     
     4 - 6 0.49 0.724*** 0.580*** 1.129*** 0.607 
      (0.650)      (0.152)      (0.176)      (0.278)      (0.540) 
     7 - 9 1.054 0.0152 -0.321 1.350*** -0.914 
      (0.785)      (0.217)      (0.308)      (0.303)      (0.789) 
     10 - 12 -1.342* -0.0157 -0.0893 1.255*** 1.404* 
      (0.686)      (0.264)      (0.338)      (0.390)      (0.788) 
     13 - 18 -25.86*** 0.108 0.161 1.319*** -0.855 
      (0.363)      (0.262)      (0.350)      (0.307)      (0.860) 
     19 - 24 -1.907* 0.747** -0.526 1.752*** 0.428 
      (1.150)      (0.310)      (0.487)      (0.421)      (0.891) 
     25 + -24.26*** 0.308 0.0514 1.947*** -1.058 
      (0.559)      (0.442)      (0.475)      (0.522)      (1.054) 
      
Black -0.551** 0.285*** 0.074 0.325*** -0.581** 
      (0.228)      (0.059)      (0.106)      (0.094)      (0.255) 
Hispanic -0.144 0.0213 0.239* 0.0775 -0.994*** 
      (0.245)      (0.076)      (0.134)      (0.095)      (0.256) 
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Table B.2 Continued     
Age Group      
     20-24 -0.235 0.00521 0.116 0.0979 -0.177 
      (0.238)      (0.061)      (0.091)      (0.101)      (0.342) 
     25-29 Omitted Omitted Omitted Omitted Omitted 
      
     30-34 0.0336 0.218*** -0.132 0.019 -0.242 
      (0.273)      (0.075)      (0.123)      (0.152)      (0.279) 
     35-39 0.0577 0.643*** -0.181 -0.417** 0.479* 
      (0.375)      (0.103)      (0.175)      (0.176)      (0.282) 
     40-45 -1.444** 0.755*** 0.383 -1.070*** 0.998*** 
      (0.607)      (0.129)      (0.276)      (0.343)      (0.369) 
      
Parity      
     0 Omitted Omitted Omitted Omitted Omitted 
      
     1  0.816*** -0.165** -0.115 0.361** 0.626 
      (0.294)      (0.066)      (0.115)      (0.147)      (0.384) 
     2  1.232*** -0.413*** -0.178 0.274 1.732*** 
      (0.299)      (0.096)      (0.119)      (0.172)      (0.324) 
     3+  1.028*** -0.427*** -0.0543 0.372** 2.279*** 
      (0.362)      (0.110)      (0.203)      (0.176)      (0.345) 
      
Marriage 
duration in 
years 
     
     Not married Omitted Omitted Omitted Omitted Omitted 
      
     1-3 years 0.078 -0.470*** -0.440*** 0.521*** -0.247 
      (0.277)      (0.079)      (0.110)      (0.133)      (0.402) 
     4-6 years -6.218*** -3.431*** -5.160*** -5.543*** -7.166*** 
      (0.457)      (0.164)      (0.250)      (0.404)      (0.551) 
     7+ years -7.531*** -3.357*** -5.341*** -5.979*** -6.995*** 
      (0.592)      (0.172)      (0.268)      (0.423)      (0.695) 
Postpartum 1.115*** -0.943*** -0.375** 0.045 -0.373 
      (0.325)      (0.150)      (0.181)      (0.215)      (0.399) 
Sexually 
active 0.0533 -0.220** 1.490*** 0.2 -0.281 
      (0.350)      (0.107)      (0.208)      (0.378)      (0.351) 
Unweighted data from 2006-2010, 2011-2013, and 2013-2015 NSFG. Includes 120,485 months of data 
from spells of SARCs, barrier, or traditional method use. “Other flexible” includes SARCs, barrier, and 
traditional. Also includes a set of year controls. Standard errors are in parenthesis and clustered at the 
woman-level. * p<.10, ** p<.05, *** p<.01 
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APPENDIX C 
CHAPTER III DATA 
 
 
Table C. 1 Main Method Hierarchy 
 
Method 
(1) Sterilization 
(2) Implant or IUD 
(3) Male Sterilization 
(4) SARC  
(5) Male Condom 
(6) Other Barrier 
(7) Traditional 
(8) Emergency Contraception 
(9) Other 
(10) No Method 
 
 
Table C.2 Proportion of Contraceptive Spells Initiated by Month (Non-Survey 
Years Only) 
 
Month % of contraceptive spells 
January 13.48 
February 6.76 
March 7.06 
April  7.93 
May 8.08 
June 8.63 
July 8.04 
August 8.41 
September 7.99 
October 8.32 
November 7.63 
December 7.67 
 
 
 
 
APPENDIX D 
CHAPTER III FULL RESULTS FOR FIRST STAGE, REDUCED FORM, AND MAIN ANALYSIS 
 
 
Table D.1 Difference-in-Differences Results: The Effect of CO450 on LARC Use 
 
 (1) (2) (3) (4) (5) (6) (7) 
 Any 
Contraceptives LARC SARC Condoms Traditional 
LARC  
(Non-survey years) 
LARC  
(Probit)a 
Any contraceptive 
status 
       
PostxTreatment -0.021 0.078*** -0.060** -0.053** -0.032 0.071*** 0.060** 
 (0.025) (0.020) (0.029) (0.026) (0.021) (0.022) (0.025) 
Black -0.037** -0.037*** -0.016 0.082*** -0.037*** -0.033** -0.036*** 
 (0.015) (0.013) (0.018) (0.016) (0.012) (0.014) (0.013) 
Hispanic -0.017 0.021 -0.031* 0.032* -0.022 0.027* 0.020 
 (0.016) (0.014) (0.018) (0.017) (0.013) (0.015) (0.014) 
Less than HS -0.082*** -0.052*** -0.099*** 0.011 0.010 -0.049*** -0.051*** 
 (0.020) (0.014) (0.020) (0.020) (0.016) (0.015) (0.014) 
Married -0.063*** -0.007 -0.050*** -0.037*** 0.006 -0.003 -0.005 
 (0.013) (0.012) (0.016) (0.014) (0.011) (0.013) (0.012) 
Sexually active 0.525*** 0.033*** 0.151*** 0.278*** 0.123*** 0.023 0.036*** 
 (0.023) (0.013) (0.020) (0.009) (0.007) (0.015) (0.013) 
Age        
     22 -0.036** -0.016 -0.016 -0.016 -0.020 -0.011 -0.017 
 (0.018) (0.013) (0.021) (0.020) (0.015) (0.016) (0.013) 
     23 0.002 -0.033* 0.002 0.024 -0.023 -0.025 -0.031* 
 (0.019) (0.017) (0.025) (0.023) (0.017) (0.020) (0.016) 
     24 -0.015 -0.033* -0.002 -0.008 -0.035** -0.027 -0.031* 
 (0.020) (0.018) (0.026) (0.023) (0.017) (0.021) (0.018) 
     25 -0.017 -0.036* -0.032 -0.002 -0.006 -0.027 -0.035* 
 (0.021) (0.019) (0.026) (0.024) (0.018) (0.021) (0.018) 
     26 0.001 -0.028 -0.039 0.010 -0.022 -0.036* -0.027 
 (0.020) (0.019) (0.026) (0.024) (0.018) (0.021) (0.018) 
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     27 -0.018 -0.053*** -0.068*** 0.025 -0.012 -0.037* -0.050*** 
 (0.021) (0.019) (0.026) (0.024) (0.018) (0.021) (0.018) 
     31 -0.055** -0.037* -0.103*** -0.040 -0.026 -0.030   -0.039* 
 (0.025) (0.020) (0.030) (0.027) (0.021) (0.022) (0.023) 
     32 -0.054** -0.036* -0.115*** -0.057** -0.025 -0.028 -0.037 
 (0.026) (0.020) (0.031) (0.027) (0.021) (0.022) (0.023) 
     33 -0.074*** -0.045** -0.114*** -0.059** -0.025 -0.042** -0.049** 
 (0.026) (0.020) (0.030) (0.027) (0.021) (0.021) (0.023) 
     34 -0.065** -0.045** -0.130*** -0.038 -0.036* -0.045** -0.049** 
 (0.026) (0.020) (0.030) (0.028) (0.021) (0.021) (0.023) 
     35 -0.060** -0.056*** -0.152*** -0.052* -0.040* -0.049** -0.060*** 
 (0.027) (0.020) (0.030) (0.028) (0.021) (0.022) (0.023) 
Year        
     2005 -0.022 -0.077*** 0.059** -0.025 0.009 -0.063*** -0.088*** 
 (0.020) (0.014) (0.025) (0.022) (0.016) (0.016) (0.017) 
     2006 -0.024 -0.070*** 0.045** -0.012 0.007 -0.054*** -0.082*** 
 (0.018) (0.013) (0.022) (0.020) (0.014) (0.016) (0.015) 
     2007 -0.033* -0.048*** 0.007 -0.016 0.003 -0.030* -0.055*** 
 (0.018) (0.013) (0.021) (0.019) (0.014) (0.016) (0.015) 
     2008 -0.030* -0.018 -0.024 0.016 -0.003 -0.004 -0.020 
 (0.017) (0.012) (0.020) (0.018) (0.013) (0.017) (0.013) 
     2010 -0.008 -0.032* 0.017 -0.015 0.047** -0.006 -0.027 
 (0.024) (0.018) (0.027) (0.024) (0.019) (0.020) (0.021) 
     2011 0.006 -0.018 0.014 -0.001 0.045** 0.004 -0.015 
 (0.025) (0.019) (0.028) (0.026) (0.020) (0.021) (0.023) 
     2012 -0.004 -0.011 0.004 -0.009 0.056*** 0.007 -0.009 
 (0.025) (0.019) (0.028) (0.026) (0.020) (0.023) (0.024) 
     2013 0.014 0.002 -0.003 -0.016 0.060*** 0.018 0.001 
 (0.026) (0.021) (0.029) (0.027) (0.022) (0.026) (0.025) 
N 7,628 (3,647) 7,628 (3,647) 5,891(3,261) 7,628 (3,647) 
Contraceptive users 
only 
       
PostxTreatment  0.096*** -0.069* -0.055 -0.039 0.089*** 0.083*** 
  (0.026) (0.036) (0.033) (0.027) (0.028) (0.031) 
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Black  -0.043** -0.002 0.121*** -0.042*** -0.037** -0.042** 
  (0.017) (0.022) (0.021) (0.015) (0.017) (0.017) 
Hispanic  0.030 -0.032 0.050** -0.025 0.035* 0.029 
  (0.018) (0.023) (0.021) (0.017) (0.019) (0.018) 
Less than HS  -0.057*** -0.089*** 0.056** 0.030 -0.054*** -0.056*** 
  (0.019) (0.027) (0.027) (0.022) (0.020) (0.019) 
Married  0.003 -0.032* -0.022 0.021 0.006 0.006 
  (0.016) (0.019) (0.018) (0.015) (0.016) (0.015) 
Sexually active  -0.103*** -0.235*** 0.326*** 0.148*** -0.133*** -0.103*** 
  (0.035) (0.041) (0.013) (0.011) (0.043) (0.035) 
Age        
     22  -0.009 0.002 -0.008 -0.020 -0.011 -0.010 
  (0.016) (0.024) (0.023) (0.018) (0.020) (0.016) 
     23  -0.039* -0.001 0.030 -0.028 -0.032 -0.037* 
  (0.021) (0.028) (0.027) (0.021) (0.024) (0.020) 
     24  -0.037* 0.009 -0.003 -0.042** -0.030 -0.034 
  (0.022) (0.030) (0.028) (0.021) (0.025) (0.022) 
     25  -0.041* -0.028 0.003 -0.005 -0.037 -0.039* 
  (0.023) (0.030) (0.029) (0.023) (0.025) (0.022) 
     26  -0.035 -0.045 0.013 -0.030 -0.048* -0.034 
  (0.023) (0.030) (0.028) (0.022) (0.025) (0.022) 
     27  -0.062*** -0.070** 0.034 -0.015 -0.043* -0.058*** 
  (0.023) (0.030) (0.029) (0.023) (0.026) (0.022) 
     31  -0.039 -0.102*** -0.026 -0.025 -0.034 -0.038 
  (0.025) (0.036) (0.033) (0.027) (0.027) (0.028) 
     32  -0.038 -0.121*** -0.048 -0.024 -0.030 -0.036 
  (0.025) (0.037) (0.034) (0.027) (0.028) (0.029) 
     33  -0.048* -0.106*** -0.046 -0.020 -0.046* -0.048* 
  (0.025) (0.037) (0.035) (0.027) (0.027) (0.029) 
     34  -0.049* -0.132*** -0.019 -0.038 -0.055** -0.050* 
  (0.025) (0.037) (0.035) (0.027) (0.027) (0.029) 
     35  -0.064** -0.169*** -0.039 -0.046* -0.058** -0.065** 
  (0.026) (0.037) (0.035) (0.028) (0.028) (0.029) 
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Year        
     2005  -0.096*** 0.097*** -0.026 0.012 -0.074*** -0.110*** 
  (0.018) (0.030) (0.028) (0.021) (0.020) (0.021) 
     2006  -0.087*** 0.079*** -0.007 0.011 -0.062*** -0.101*** 
  (0.017) (0.026) (0.025) (0.018) (0.020) (0.019) 
     2007  -0.057*** 0.032 -0.006 0.008 -0.030 -0.066*** 
  (0.016) (0.025) (0.024) (0.018) (0.020) (0.018) 
     2008  -0.017 -0.010 0.033 -0.002 0.003 -0.019 
  (0.016) (0.024) (0.022) (0.017) (0.021) (0.017) 
     2010  -0.035 0.034 -0.020 0.062** 0.002 -0.032 
  (0.023) (0.034) (0.032) (0.026) (0.026) (0.027) 
     2011  -0.023 0.020 -0.002 0.059** 0.009 -0.023 
  (0.025) (0.035) (0.033) (0.026) (0.027) (0.029) 
     2012  -0.008 0.012 -0.008 0.076*** 0.011 -0.010 
  (0.025) (0.035) (0.033) (0.027) (0.029) (0.030) 
     2013  0.002 -0.005 -0.025 0.077*** 0.018 -0.001 
  (0.027) (0.036) (0.034) (0.028) (0.032) (0.032) 
N 5,832 (2,958) 5,832 (2,958) 4,552 (2,629) 5,832 (2,958) 
Number of woman-years (number of women). Unweighted data. Pre-period is 2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-
27 with one child while control group includes women ages 31-35 with one child. Standard errors are clustered on the woman level. *, **, and *** 
indicate significance at the 0.10, 0.05, and 0.01 levels, respectively. 
a Average marginal effect. 
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Table D.2 Reduced Form Results: The Effect of CO450 on Pregnancies 
 
 (1) (2) (3) 
 Pregnant This 
Year 
Pregnant next 
year 
Birth next year 
 (OLS) (OLS) (OLS) 
PostxTreatment -0.052*** -0.052*** -0.039** 
 (0.018) (0.020) (0.018) 
Black 0.015 0.013 0.006 
 (0.011) (0.013) (0.011) 
Hispanic -0.020* 0.001 0.013 
 (0.012) (0.013) (0.012) 
Less than HS 0.053*** 0.026 0.031** 
 (0.015) (0.017) (0.016) 
Married 0.058*** 0.038*** 0.061*** 
 (0.010) (0.011) (0.010) 
Sexually active 0.094*** 0.032 0.076*** 
 (0.014) (0.027) (0.012) 
Age    
     22 -0.024 -0.032 0.042* 
 (0.024) (0.026) (0.024) 
     23 -0.057** 0.011 0.004 
 (0.024) (0.027) (0.023) 
     24 -0.058** -0.011 -0.006 
 (0.023) (0.027) (0.023) 
     25 -0.060** -0.056** -0.009 
 (0.024) (0.026) (0.023) 
     26 -0.076*** -0.057** -0.020 
 (0.023) (0.025) (0.022) 
     27 -0.088*** -0.071*** -0.021 
 (0.023) (0.025) (0.022) 
     31 -0.135*** -0.117*** -0.058** 
 (0.024) (0.027) (0.025) 
     32 -0.145*** -0.116*** -0.065*** 
 (0.025) (0.028) (0.024) 
     33 -0.165*** -0.094*** -0.095*** 
 (0.024) (0.029) (0.023) 
     34 -0.167*** -0.160*** -0.089*** 
 (0.024) (0.026) (0.024) 
     35 -0.169*** -0.135*** -0.100*** 
 (0.024) (0.028) (0.023) 
Year    
     2005 0.004 0.001 0.019 
 (0.021) (0.024) (0.021) 
     2006 0.024 -0.012 0.029 
 (0.019) (0.023) (0.020) 
     2007 -0.015 0.029 0.010 
 (0.018) (0.024) (0.020) 
     2008 0.012 -0.051** 0.008 
 (0.020) (0.024) (0.021) 
     2010 0.035 0.059** 0.037 
 (0.022) (0.028) (0.024) 
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     2011 0.072*** 0.007 0.040* 
 (0.022) (0.025) (0.022) 
     2012 0.023 0.009 0.028 
 (0.021) (0.025) (0.022) 
     2013 0.031 0.010 0.038 
 (0.021) (0.027) (0.024) 
Constant 0.099*** 0.155*** 0.018 
 (0.026) (0.038) (0.025) 
N 5,832 (2,958) 4,552 (2,629) 4,552 (2,629) 
Number of woman-years (number of women). Unweighted data. Contraceptive users 
only. N indicates the number of woman-years (number of women). Pre-period is 
2005-2009; post-period is 2010-2013. Columns 2 and 3 do not include observations 
from the survey year. Treatment indicates women ages 21-27 while control group 
includes women ages 31-35. Standard errors are clustered on the woman-level. 
 *, **, and *** indicate significance at the 0.10, 0.05, and 0.01 levels, respectively. 
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Table D.3 Instrumental Variables Results: The Effect of LARC Use on Pregnancies  
 
Pregnant This Year 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate 
Probita  
PostxTreatment -0.106*** -0.536** -0.389** -0.104*** -0.240*** 
 (0.010) (0.226) (0.160) (0.009) (0.061) 
Black 0.011 -0.007 -0.001 0.013 -0.008 
 (0.011) (0.017) (0.014) (0.011) (0.021) 
Hispanic -0.017 -0.004 -0.008 -0.016 -0.001 
 (0.011) (0.016) (0.014) (0.011) (0.019) 
Less than HS 0.048*** 0.023 0.031* 0.049*** 0.017 
 (0.015) (0.022) (0.019) (0.015) (0.031) 
Married 0.059*** 0.060*** 0.060*** 0.062*** 0.063*** 
 (0.010) (0.012) (0.011) (0.010) (0.015) 
Sexually active 0.083*** 0.039 0.054** 0.107*** 0.089 
 (0.014) (0.032) (0.025) (0.016) (0.060) 
Age      
     22 -0.025 -0.029 -0.028 -0.028 -0.030 
 (0.024) (0.024) (0.024) (0.025) (0.024) 
     23 -0.062*** -0.078*** -0.073*** -0.066*** -0.080*** 
 (0.024) (0.026) (0.025) (0.024) (0.025) 
     24 -0.062*** -0.078*** -0.072*** -0.068*** -0.080*** 
 (0.023) (0.026) (0.025) (0.024) (0.025) 
     25 -0.064*** -0.081*** -0.075*** -0.068*** -0.083*** 
 (0.023) (0.027) (0.025) (0.024) (0.025) 
     26 -0.080*** -0.095*** -0.090*** -0.085*** -0.097*** 
 (0.023) (0.026) (0.024) (0.024) (0.026) 
     27 -0.095*** -0.121*** -0.112*** -0.100*** -0.124*** 
 (0.023) (0.028) (0.026) (0.023) (0.025) 
     31 -0.121*** -0.156*** -0.144*** -0.126*** -0.160*** 
 (0.023) (0.030) (0.027) (0.023) (0.025) 
     32 -0.130*** -0.165*** -0.153*** -0.134*** -0.168*** 
 (0.024) (0.031) (0.028) (0.024) (0.026) 
     33 -0.151*** -0.190*** -0.177*** -0.152*** -0.192*** 
 (0.023) (0.032) (0.028) (0.023) (0.026) 
     34 -0.153*** -0.193*** -0.179*** -0.156*** -0.196*** 
 (0.023) (0.032) (0.028) (0.023) (0.025) 
     35 -0.158*** -0.204*** -0.188*** -0.160*** -0.207*** 
 (0.023) (0.035) (0.030) (0.023) (0.028) 
Year      
     2005 -0.006 -0.047 -0.033 -0.005 -0.052 
 (0.021) (0.031) (0.026) (0.020) (0.039) 
     2006 0.015 -0.023 -0.010 0.015 -0.029 
 (0.019) (0.028) (0.024) (0.018) (0.038) 
     2007 -0.022 -0.046** -0.037* -0.019 -0.046* 
 (0.018) (0.023) (0.020) (0.017) (0.025) 
     2008 0.011 0.003 0.006 0.010 0.002 
 (0.020) (0.021) (0.020) (0.019) (0.022) 
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     2010 0.003 0.016 0.012 0.007 0.023 
 (0.019) (0.021) (0.020) (0.020) (0.023) 
     2011 0.042** 0.060*** 0.054*** 0.046** 0.066*** 
 (0.019) (0.022) (0.021) (0.020) (0.021) 
     2012 -0.005 0.019 0.011 -0.004 0.024 
 (0.018) (0.023) (0.020) (0.018) (0.028) 
     2013 0.004 0.032 0.022 0.004 0.036 
 (0.019) (0.025) (0.022) (0.020) (0.030) 
Pregnant Next Year 
PostxTreatment -0.075*** -0.587** -0.395** -0.074*** -0.080 
 (0.012) (0.278) (0.186) (0.012) (0.164) 
Black 0.010 -0.009 -0.002 0.009 0.009 
 (0.012) (0.018) (0.015) (0.013) (0.015) 
Hispanic 0.003 0.021 0.015 0.005 0.005 
 (0.013) (0.019) (0.015) (0.013) (0.015) 
Less than HS 0.022 -0.005 0.005 0.023 0.022 
 (0.017) (0.025) (0.020) (0.016) (0.021) 
Married 0.039*** 0.042*** 0.041*** 0.041*** 0.041*** 
 (0.011) (0.014) (0.012) (0.011) (0.012) 
Sexually active 0.022 -0.045 -0.020 0.028 0.027 
 (0.028) (0.053) (0.042) (0.032) (0.043) 
Age      
     22 -0.034 -0.039 -0.037 -0.035 -0.035 
 (0.026) (0.028) (0.027) (0.027) (0.028) 
     23 0.008 -0.007 -0.002 0.007 0.006 
 (0.027) (0.030) (0.028) (0.027) (0.029) 
     24 -0.014 -0.029 -0.023 -0.016 -0.016 
 (0.027) (0.031) (0.028) (0.027) (0.029) 
     25 -0.059** -0.078*** -0.071** -0.062** -0.062** 
 (0.025) (0.030) (0.028) (0.026) (0.029) 
     26 -0.060** -0.085*** -0.076*** -0.062** -0.063** 
 (0.025) (0.031) (0.028) (0.026) (0.030) 
     27 -0.074*** -0.096*** -0.088*** -0.076*** -0.077*** 
 (0.025) (0.031) (0.028) (0.026) (0.030) 
     31 -0.099*** -0.137*** -0.123*** -0.102*** -0.102*** 
 (0.025) (0.035) (0.030) (0.026) (0.034) 
     32 -0.097*** -0.134*** -0.120*** -0.098*** -0.099*** 
 (0.026) (0.035) (0.031) (0.027) (0.034) 
     33 -0.077*** -0.121*** -0.105*** -0.081*** -0.082** 
 (0.027) (0.038) (0.033) (0.027) (0.036) 
     34 -0.143*** -0.193*** -0.174*** -0.144*** -0.145*** 
 (0.024) (0.038) (0.031) (0.024) (0.035) 
     35 -0.119*** -0.170*** -0.151*** -0.120*** -0.121*** 
 (0.026) (0.040) (0.033) (0.026) (0.037) 
Year      
     2005 -0.005 -0.042 -0.028 -0.008 -0.009 
 (0.024) (0.032) (0.028) (0.023) (0.029) 
     2006 -0.018 -0.048* -0.037 -0.019 -0.020 
 (0.022) (0.029) (0.025) (0.022) (0.026) 
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     2007 0.026 0.012 0.017 0.023 0.023 
 (0.024) (0.027) (0.025) (0.024) (0.025) 
     2008 -0.051** -0.049* -0.050** -0.052** -0.052** 
 (0.024) (0.026) (0.025) (0.023) (0.023) 
     2010 0.028 0.061* 0.048* 0.028 0.029 
 (0.024) (0.031) (0.028) (0.024) (0.031) 
     2011 -0.024 0.012 -0.002 -0.025 -0.025 
 (0.022) (0.030) (0.025) (0.022) (0.027) 
     2012 -0.021 0.015 0.002 -0.021 -0.021 
 (0.022) (0.031) (0.026) (0.022) (0.028) 
     2013 -0.019 0.021 0.006 -0.019 -0.018 
 (0.024) (0.034) (0.029) (0.025) (0.031) 
Birth Next Year 
PostxTreatment -0.069*** -0.443* -0.246 -0.067*** -0.043 
 (0.011) (0.241) (0.156) (0.010) (0.203) 
Black 0.003 -0.011 -0.003 0.004 0.005 
 (0.011) (0.015) (0.013) (0.011) (0.014) 
Hispanic 0.015 0.029* 0.022 0.016 0.015 
 (0.012) (0.017) (0.014) (0.012) (0.015) 
Less than HS 0.028* 0.008 0.018 0.028* 0.030 
 (0.016) (0.022) (0.018) (0.015) (0.020) 
Married 0.061*** 0.064*** 0.062*** 0.064*** 0.064*** 
 (0.010) (0.012) (0.011) (0.011) (0.011) 
Sexually active 0.066*** 0.017 0.043* 0.092*** 0.092*** 
 (0.012) (0.039) (0.026) (0.015) (0.015) 
Age      
     22 0.040* 0.037 0.039 0.044* 0.044* 
 (0.024) (0.024) (0.024) (0.025) (0.025) 
     23 0.002 -0.010 -0.004 0.002 0.003 
 (0.023) (0.025) (0.024) (0.024) (0.025) 
     24 -0.009 -0.020 -0.014 -0.008 -0.007 
 (0.023) (0.025) (0.024) (0.024) (0.025) 
     25 -0.012 -0.026 -0.019 -0.011 -0.010 
 (0.023) (0.026) (0.024) (0.024) (0.026) 
     26 -0.023 -0.041 -0.031 -0.024 -0.022 
 (0.022) (0.026) (0.024) (0.023) (0.026) 
     27 -0.025 -0.040 -0.032 -0.026 -0.024 
 (0.022) (0.026) (0.024) (0.023) (0.026) 
     31 -0.046** -0.074** -0.059** -0.047** -0.044 
 (0.023) (0.030) (0.026) (0.023) (0.030) 
     32 -0.052** -0.079*** -0.065** -0.053** -0.051* 
 (0.023) (0.029) (0.026) (0.023) (0.029) 
     33 -0.083*** -0.115*** -0.098*** -0.081*** -0.079*** 
 (0.022) (0.031) (0.026) (0.022) (0.028) 
     34 -0.078*** -0.114*** -0.095*** -0.077*** -0.074** 
 (0.022) (0.033) (0.027) (0.022) (0.030) 
     35 -0.090*** -0.126*** -0.107*** -0.087*** -0.084*** 
 (0.022) (0.033) (0.027) (0.022) (0.029) 
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Year      
     2005 0.014 -0.014 0.001 0.011 0.013 
 (0.021) (0.028) (0.024) (0.020) (0.025) 
     2006 0.024 0.002 0.014 0.022 0.024 
 (0.020) (0.025) (0.022) (0.019) (0.024) 
     2007 0.007 -0.004 0.002 0.005 0.006 
 (0.020) (0.023) (0.021) (0.020) (0.020) 
     2008 0.007 0.009 0.008 0.004 0.004 
 (0.021) (0.023) (0.022) (0.021) (0.021) 
     2010 0.014 0.037 0.025 0.013 0.011 
 (0.021) (0.026) (0.023) (0.021) (0.025) 
     2011 0.018 0.044* 0.030 0.016 0.014 
 (0.019) (0.026) (0.022) (0.019) (0.026) 
     2012 0.007 0.033 0.019 0.006 0.003 
 (0.019) (0.026) (0.022) (0.019) (0.026) 
     2013 0.017 0.046 0.031 0.013 0.011 
 (0.022) (0.029) (0.024) (0.022) (0.029) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one 
child. Pre-period is 2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while 
control group includes women ages 31-35. Less than HS indicates less than high school education. 
Standard errors are clustered on the woman-level. 
N: 5,832 woman-years from 2,958 women (top panel) and 4,552 woman-years from 2,629 women 
(bottom two panels)  
F-stats for 2SLS first stage (column 2): 13.32 (top panel); 9.86 (bottom two panels) 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. Standard 
a Average marginal effects 
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Table D.4 Instrumental Variables Results: The Effect of LARC Use on Pregnancies 
Among Women Who Use Contraception 9+ Months 
 
Pregnant This Year 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate 
Probita  
PostxTreatment -0.064*** -0.484** -0.226* -0.062*** -0.117*** 
 (0.009) (0.239) (0.131) (0.008) (0.031) 
Black 0.015 -0.008 0.006 0.013 0.006 
 (0.012) (0.020) (0.015) (0.011) (0.015) 
Hispanic -0.019* -0.002 -0.012 -0.016 -0.013 
 (0.011) (0.019) (0.013) (0.010) (0.014) 
Less than HS 0.038** 0.005 0.025 0.036** 0.027 
 (0.017) (0.028) (0.020) (0.016) (0.019) 
Married 0.007 0.004 0.006 0.009 0.009 
 (0.010) (0.014) (0.011) (0.010) (0.012) 
Sexually active 0.046*** 0.012 0.033** 0.059*** 0.073*** 
 (0.010) (0.030) (0.016) (0.011) (0.022) 
Age      
     22 -0.002 -0.024 -0.010 -0.005 -0.017 
 (0.027) (0.031) (0.027) (0.027) (0.033) 
     23 -0.040 -0.063** -0.049* -0.045* -0.064* 
 (0.025) (0.031) (0.026) (0.026) (0.033) 
     24 -0.026 -0.059* -0.039 -0.028 -0.048 
 (0.026) (0.036) (0.029) (0.027) (0.034) 
     25 -0.057** -0.087*** -0.068*** -0.059** -0.084** 
 (0.024) (0.033) (0.026) (0.025) (0.033) 
     26 -0.034 -0.075** -0.050* -0.037 -0.062* 
 (0.025) (0.038) (0.029) (0.026) (0.034) 
     27 -0.039 -0.078** -0.054* -0.042 -0.067** 
 (0.025) (0.036) (0.029) (0.026) (0.034) 
     31 -0.039 -0.098** -0.062* -0.042 -0.075** 
 (0.026) (0.044) (0.032) (0.026) (0.036) 
     32 -0.077*** -0.131*** -0.098*** -0.078*** -0.116*** 
 (0.024) (0.041) (0.030) (0.025) (0.036) 
     33 -0.089*** -0.155*** -0.114*** -0.090*** -0.134*** 
 (0.023) (0.045) (0.031) (0.024) (0.037) 
     34 -0.094*** -0.154*** -0.117*** -0.096*** -0.140*** 
 (0.022) (0.042) (0.029) (0.023) (0.038) 
     35 -0.096*** -0.169*** -0.124*** -0.098*** -0.146*** 
 (0.023) (0.050) (0.033) (0.040) (0.023) 
Year      
     2005 -0.024 -0.071** -0.042 -0.021 -0.042 
 (0.021) (0.036) (0.027) (0.019) (0.026) 
     2006 -0.008 -0.050 -0.024 -0.010 -0.028 
 (0.020) (0.032) (0.024) (0.018) (0.025) 
     2007 -0.021 -0.039* -0.028 -0.021 -0.032 
 (0.018) (0.024) (0.020) (0.017) (0.022) 
     2008 0.014 0.016 0.015 0.012 0.014 
 (0.023) (0.026) (0.024) (0.022) (0.026) 
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     2010 0.012 0.029 0.018 0.012 0.022 
 (0.022) (0.026) (0.023) (0.022) (0.027) 
     2011 0.000 0.026 0.010 0.003 0.015 
 (0.019) (0.026) (0.021) (0.020) (0.025) 
     2012 -0.014 0.020 -0.001 -0.014 -0.004 
 (0.019) (0.029) (0.021) (0.019) (0.025) 
     2013 0.001 0.037 0.015 0.001 0.016 
 (0.021) (0.032) (0.024) (0.022) (0.029) 
Pregnant Next Year 
PostxTreatment -0.064*** -0.484** -0.226* -0.062*** -0.117*** 
 (0.009) (0.239) (0.131) (0.008) (0.031) 
Black 0.015 -0.008 0.006 0.013 0.006 
 (0.012) (0.020) (0.015) (0.011) (0.015) 
Hispanic -0.019* -0.002 -0.012 -0.016 -0.013 
 (0.011) (0.019) (0.013) (0.010) (0.014) 
Less than HS 0.038** 0.005 0.025 0.036** 0.027 
 (0.017) (0.028) (0.020) (0.016) (0.019) 
Married 0.007 0.004 0.006 0.009 0.009 
 (0.010) (0.014) (0.011) (0.010) (0.012) 
Sexually active 0.046*** 0.012 0.033** 0.059*** 0.073*** 
 (0.010) (0.030) (0.016) (0.011) (0.022) 
Age      
     22 -0.002 -0.024 -0.010 -0.005 -0.017 
 (0.027) (0.031) (0.027) (0.027) (0.033) 
     23 -0.040 -0.063** -0.049* -0.045* -0.064* 
 (0.025) (0.031) (0.026) (0.026) (0.033) 
     24 -0.026 -0.059* -0.039 -0.028 -0.048 
 (0.026) (0.036) (0.029) (0.027) (0.034) 
     25 -0.057** -0.087*** -0.068*** -0.059** -0.084** 
 (0.024) (0.033) (0.026) (0.025) (0.033) 
     26 -0.034 -0.075** -0.050* -0.037 -0.062* 
 (0.025) (0.038) (0.029) (0.026) (0.034) 
     27 -0.039 -0.078** -0.054* -0.042 -0.067** 
 (0.025) (0.036) (0.029) (0.026) (0.034) 
     31 -0.039 -0.098** -0.062* -0.042 -0.075** 
 (0.026) (0.044) (0.032) (0.026) (0.036) 
     32 -0.077*** -0.131*** -0.098*** -0.078*** -0.116*** 
 (0.024) (0.041) (0.030) (0.025) (0.036) 
     33 -0.089*** -0.155*** -0.114*** -0.090*** -0.134*** 
 (0.023) (0.045) (0.031) (0.024) (0.037) 
     34 -0.094*** -0.154*** -0.117*** -0.096*** -0.140*** 
 (0.022) (0.042) (0.029) (0.023) (0.038) 
     35 -0.096*** -0.169*** -0.124*** -0.098*** -0.146*** 
 (0.023) (0.050) (0.033) (0.023) (0.040) 
Year      
     2005 -0.024 -0.071** -0.042 -0.021 -0.042 
 (0.021) (0.036) (0.027) (0.019) (0.026) 
     2006 -0.008 -0.050 -0.024 -0.010 -0.028 
 (0.020) (0.032) (0.024) (0.018) (0.025) 
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     2007 -0.021 -0.039* -0.028 -0.021 -0.032 
 (0.018) (0.024) (0.020) (0.017) (0.022) 
     2008 0.014 0.016 0.015 0.012 0.014 
 (0.023) (0.026) (0.024) (0.022) (0.026) 
     2010 0.012 0.029 0.018 0.012 0.022 
 (0.022) (0.026) (0.023) (0.022) (0.027) 
     2011 0.000 0.026 0.010 0.003 0.015 
 (0.019) (0.026) (0.021) (0.020) (0.025) 
     2012 -0.014 0.020 -0.001 -0.014 -0.004 
 (0.019) (0.029) (0.021) (0.019) (0.025) 
     2013 0.001 0.037 0.015 0.001 0.016 
 (0.021) (0.032) (0.024) (0.022) (0.029) 
Birth Next Year 
PostxTreatment -0.064*** -0.484** -0.226* -0.062*** -0.117*** 
 (0.009) (0.239) (0.131) (0.008) (0.031) 
Black 0.015 -0.008 0.006 0.013 0.006 
 (0.012) (0.020) (0.015) (0.011) (0.015) 
Hispanic -0.019* -0.002 -0.012 -0.016 -0.013 
 (0.011) (0.019) (0.013) (0.010) (0.014) 
Less than HS 0.038** 0.005 0.025 0.036** 0.027 
 (0.017) (0.028) (0.020) (0.016) (0.019) 
Married 0.007 0.004 0.006 0.009 0.009 
 (0.010) (0.014) (0.011) (0.010) (0.012) 
Sexually active 0.046*** 0.012 0.033** 0.059*** 0.073*** 
 (0.010) (0.030) (0.016) (0.011) (0.022) 
Age      
     22 -0.002 -0.024 -0.010 -0.005 -0.017 
 (0.027) (0.031) (0.027) (0.027) (0.033) 
     23 -0.040 -0.063** -0.049* -0.045* -0.064* 
 (0.025) (0.031) (0.026) (0.026) (0.033) 
     24 -0.026 -0.059* -0.039 -0.028 -0.048 
 (0.026) (0.036) (0.029) (0.027) (0.034) 
     25 -0.057** -0.087*** -0.068*** -0.059** -0.084** 
 (0.024) (0.033) (0.026) (0.025) (0.033) 
     26 -0.034 -0.075** -0.050* -0.037 -0.062* 
 (0.025) (0.038) (0.029) (0.026) (0.034) 
     27 -0.039 -0.078** -0.054* -0.042 -0.067** 
 (0.025) (0.036) (0.029) (0.026) (0.034) 
     31 -0.039 -0.098** -0.062* -0.042 -0.075** 
 (0.026) (0.044) (0.032) (0.026) (0.036) 
     32 -0.077*** -0.131*** -0.098*** -0.078*** -0.116*** 
 (0.024) (0.041) (0.030) (0.025) (0.036) 
     33 -0.089*** -0.155*** -0.114*** -0.090*** -0.134*** 
 (0.023) (0.045) (0.031) (0.024) (0.037) 
     34 -0.094*** -0.154*** -0.117*** -0.096*** -0.140*** 
 (0.022) (0.042) (0.029) (0.023) (0.038) 
     35 -0.096*** -0.169*** -0.124*** -0.098*** -0.146*** 
 (0.023) (0.050) (0.033) (0.023) (0.040) 
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Year      
     2005 -0.024 -0.071** -0.042 -0.021 -0.042 
 (0.021) (0.036) (0.027) (0.019) (0.026) 
     2006 -0.008 -0.050 -0.024 -0.010 -0.028 
 (0.020) (0.032) (0.024) (0.018) (0.025) 
     2007 -0.021 -0.039* -0.028 -0.021 -0.032 
 (0.018) (0.024) (0.020) (0.017) (0.022) 
     2008 0.014 0.016 0.015 0.012 0.014 
 (0.023) (0.026) (0.024) (0.022) (0.026) 
     2010 0.012 0.029 0.018 0.012 0.022 
 (0.022) (0.026) (0.023) (0.022) (0.027) 
     2011 0.000 0.026 0.010 0.003 0.015 
 (0.019) (0.026) (0.021) (0.020) (0.025) 
     2012 -0.014 0.020 -0.001 -0.014 -0.004 
 (0.019) (0.029) (0.021) (0.019) (0.025) 
     2013 0.001 0.037 0.015 0.001 0.016 
 (0.021) (0.032) (0.024) (0.022) (0.029) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one 
child who have used contraception for at least 9 months of a year. Pre-period is 2005-2009; post-period is 
2010-2013. Treatment indicates women ages 21-27 while control group includes women ages 31-35. All 
models include indicators for if the woman is Black, Hispanic, married, sexually active, has less than a 
high school education and year and age controls. Standard errors are clustered on the woman-level.  
N: 3,121 woman-years from 1,816 women (row 1); 2,877 woman-years from 1,734 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 7.29 (row 1); 6.76 (rows 2 and 3) 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
a Average marginal effects 
 
 
 
 
Table D.5 Control Function Results: The Effect of LARC Use on Pregnancies 
 
 (1) (2) (3) (4) (5) (6) 
 Pregnant this 
year  
Pregnant this 
year  
Pregnant next 
year (CF) 
Pregnant next 
year  
Birth next year  Birth Next Year  
LARC -0.313*** -0.349*** -0.123 -0.268* -0.106 -0.190 
 (0.117) (0.131) (0.136) (0.156) (0.124) (0.142) 
?̂? 0.115* 0.180 0.027 0.274* 0.020 0.164 
 (0.065) (0.125) (0.075) (0.151) (0.068) (0.137) 
LARC× ?̂?  -0.056  -0.202*  -0.117 
  (0.091)  (0.107)  (0.097) 
Black 0.002 -0.002 0.009 -0.004 0.002 -0.006 
 (0.012) (0.014) (0.013) (0.015) (0.012) (0.014) 
Hispanic -0.011 -0.008 0.005 0.017 0.017 0.024* 
 (0.012) (0.012) (0.014) (0.015) (0.012) (0.014) 
Less than HS 0.036** 0.030* 0.020 0.001 0.026* 0.015 
 (0.015) (0.017) (0.017) (0.020) (0.016) (0.018) 
Married 0.060*** 0.060*** 0.039*** 0.042*** 0.061*** 0.063*** 
 (0.010) (0.010) (0.011) (0.011) (0.010) (0.010) 
Sexually active 0.062** 0.054* 0.016 -0.023 0.061** 0.039 
 (0.027) (0.030) (0.034) (0.040) (0.031) (0.036) 
Age       
     22 -0.027 -0.028 -0.034 -0.038 0.040* 0.038* 
 (0.021) (0.021) (0.024) (0.024) (0.021) (0.022) 
     23 -0.070*** -0.073*** 0.007 -0.002 0.001 -0.005 
 (0.021) (0.022) (0.024) (0.024) (0.022) (0.022) 
     24 -0.070*** -0.072*** -0.015 -0.023 -0.010 -0.014 
 (0.021) (0.022) (0.024) (0.024) (0.022) (0.022) 
     25 -0.072*** -0.076*** -0.061** -0.071*** -0.014 -0.020 
 (0.021) (0.022) (0.024) (0.025) (0.022) (0.023) 
     26 -0.087*** -0.090*** -0.063** -0.078*** -0.025 -0.033 
 (0.021) (0.022) (0.024) (0.026) (0.022) (0.023) 
     27 -0.107*** -0.112*** -0.076*** -0.089*** -0.026 -0.033 
 (0.022) (0.024) (0.025) (0.025) (0.022) (0.023) 
     31 -0.138*** -0.144*** -0.103*** -0.126*** -0.049* -0.062** 
 (0.024) (0.027) (0.027) (0.030) (0.025) (0.027) 
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     32 -0.147*** -0.153*** -0.101*** -0.122*** -0.054** -0.067** 
 (0.025) (0.027) (0.028) (0.030) (0.026) (0.028) 
     33 -0.170*** -0.177*** -0.081*** -0.109*** -0.086*** -0.102*** 
 (0.026) (0.028) (0.029) (0.032) (0.026) (0.029) 
     34 -0.172*** -0.180*** -0.148*** -0.179*** -0.081*** -0.099*** 
 (0.026) (0.029) (0.029) (0.033) (0.026) (0.030) 
     35 -0.180*** -0.189*** -0.124*** -0.155*** -0.093*** -0.111*** 
 (0.027) (0.031) (0.030) (0.034) (0.027) (0.031) 
Year       
     2005 -0.026 -0.036 -0.009 -0.039 0.011 -0.006 
 (0.023) (0.029) (0.025) (0.029) (0.023) (0.027) 
     2006 -0.003 -0.013 -0.021 -0.045* 0.022 0.008 
 (0.021) (0.026) (0.023) (0.027) (0.021) (0.024) 
     2007 -0.033* -0.039* 0.025 0.013 0.006 -0.001 
 (0.020) (0.022) (0.023) (0.024) (0.021) (0.022) 
     2008 0.007 0.006 -0.051** -0.049** 0.007 0.008 
 (0.020) (0.020) (0.024) (0.024) (0.022) (0.022) 
     2010 0.009 0.012 0.031 0.052* 0.016 0.028 
 (0.020) (0.021) (0.025) (0.027) (0.022) (0.025) 
     2011 0.051*** 0.054*** -0.020 0.002 0.021 0.033 
 (0.020) (0.020) (0.024) (0.026) (0.022) (0.024) 
     2012 0.006 0.011 -0.017 0.005 0.010 0.022 
 (0.020) (0.021) (0.024) (0.027) (0.022) (0.024) 
     2013 0.017 0.022 -0.015 0.009 0.020 0.034 
 (0.021) (0.023) (0.026) (0.029) (0.024) (0.027) 
Unweighted data. Contraceptive users only. N = 5,832 woman-years from 2,958 women with one child (columns 1 and 2); N = 4,552 woman-years 
from 2,629 women with one child (columns 3 through 6). Pre-period is 2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-
27 while control group includes women ages 31-35. ν indicates generalized residuals. All specifications include indicators for if the woman is 
Black, Hispanic, married, sexually active, has less than a high school education and year and age controls.  
*, **, and *** indicate significance at the 0.10 ,0.05 and 0.01 levels, respectively.  
Bootstrap standard errors forthcoming. 
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CHAPTER III INTRUMENTAL VARIABLES ROBUSTNESS CHECKS 
 
 
Table E.1 Instrumental Variables Results: The Effect of LARC Use on Pregnancies Among Contracepting  
and Non-Contracepting Women 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.132*** -0.384* -0.315* -0.124*** -0.196*** 
 (0.010) (0.227) (0.171) (0.009) (0.047) 
Pregnant next year      
LARC use -0.080*** -0.611** -0.408** -0.077*** -0.090 
 (0.012) (0.298) (0.205) (0.011) (0.100) 
Birth next year      
LARC use -0.084*** -0.516* -0.344* -0.080*** -0.093 
 (0.010) (0.275) (0.189) (0.010) (0.118) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Mothers of one child only. Pre-period is 2005-2009; post-
period is 2010-2013. Treatment indicates women ages 21-27 while control group includes women ages 31-35. All models include 
indicators for if the woman is Black, Hispanic, married, sexually active, has less than a high school education and year and age 
controls. Standard errors are clustered on the woman-level. 
N: 7,628 woman-years from 3,647 women (row 1) and 5,891 woman-years from 3,261 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 14.53 (row 1); 10.40 (row 2 and 3) 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
a Average marginal effects 
 
193 
 
 
 
Table E.2 Instrumental Variables Results: The Effect of LARC Use on Pregnancies 
Among Sexually Active Women 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate Probit a 
Pregnant this year      
LARC use -0.110*** -0.501** -0.378** -0.138*** -0.440*** 
 (0.011) (0.213) (0.168) (0.017) (0.129) 
Pregnant next year      
LARC use -0.078*** -0.510** -0.340* -0.090*** -0.085 
 (0.013) (0.252) (0.193) (0.017) (0.222) 
Birth next year      
LARC use -0.073*** -0.407* -0.251 -0.088*** -0.118 
 (0.011) (0.225) (0.175) (0.017) (0.511) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-period is 
2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while control group includes women ages 31-35. 
All models include indicators for if the woman is Black, Hispanic, married, has less than a high school education and year and 
age controls. Standard errors are clustered on the woman-level. 
N: 5,612 woman-years from 2,897 women (row 1) and 4,403 woman-years from 2,582 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 15.13 (row 1); 11.27 (row 2 and 3) 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively 
a Average marginal effects 
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Table E.3 Instrumental Variables Results: The Effect of LARC Use on Pregnancies (Women Ages 18-27 vs. 31-38) 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.483** -0.358*** -0.483** -0.358*** -0.483** 
 (0.232) (0.128) (0.232) (0.128) (0.232) 
Pregnant next year      
LARC use -0.084*** -0.529* -0.243* -0.079*** -0.056 
 (0.010) (0.310) (0.139) (0.010) (0.095) 
Birth next year      
LARC use -0.075*** -0.396 -0.196 -0.072*** -0.012 
 (0.009) (0.269) (0.123) (0.008) (0.111) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-period is 
2005-2009; post-period is 2010-2013. Treatment indicates women ages 18-27 while control group includes women ages 31-38. 
All models include indicators for if the woman is Black, Hispanic, married, sexually active, has less than a high school 
education and year and age controls. Standard errors are clustered on the woman-level.  
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
N: 7,847 woman-years from 3,718 women (row 1) and 6,145 woman-years from 3,401 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 11.86 (row 1); 7.43 (row 2 and 3) 
a Average marginal effects 
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Table E.4 Instrumental Variables Results: The Effect of LARC Use on Pregnancies (Women Ages 23-27 vs. 31-35) 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.098*** -0.659** -0.474* -0.096*** -0.253*** 
 (0.011) (0.318) (0.243) (0.010) (0.008) 
Pregnant next year      
LARC use -0.071*** -0.235 -0.090 -0.068*** 0.075 
 (0.014) (0.334) (0.266) (0.013) (0.189) 
Birth next year      
LARC use -0.056*** -0.491 -0.210 -0.055*** 0.228 
 (0.012) (0.357) (0.239) (0.011) (0.223) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-period is 
2005-2009; post-period is 2010-2013. Treatment indicates women ages 23-27 while control group includes women ages 31-35. 
All models include indicators for if the woman is Black, Hispanic, married, sexually active, has less than a high school 
education and year and age controls. Standard errors are clustered on the woman-level. 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
N: 4,761 woman-years from 2,491 women (row 1) and 3,713 woman-years from 2,183 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 8.08 (row 1); 4.86 (row 2 and 3) 
a Average marginal effects 
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Table E.5 Instrumental Variables Results: The Effect of LARC Use on Pregnancies (Women Ages 23-28 vs 32-36) 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.098*** -0.407* -0.333** -0.096*** -0.235 
 (0.010) (0.215) (0.155) (0.009) (0.663) 
Pregnant next year      
LARC use -0.082*** -0.483** -0.335** -0.080*** -0.049 
 (0.012) (0.246) (0.167) (0.011) (0.164) 
Birth next year      
LARC use -0.073*** -0.375* -0.239* -0.071*** -0.041 
 (0.010) (0.212) (0.144) (0.009) (0.203) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-period is 
2005-2009; post-period is 2010-2013. Treatment indicates women ages 23-28 while control group includes women ages 32-36. 
All models include indicators for if the woman is Black, Hispanic, married, sexually active, has less than a high school 
education and year and age controls. Standard errors are clustered on the woman-level. 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
N: 5,168 woman-years from 2,616 women (row 1) and 4,031 woman-years from 2,312 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 7.42 (row 1); 6.07 (row 2 and 3) 
a Average marginal effects 
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Table E.6 Instrumental Variables Results: The Effect of LARCs on Pregnancy Using 
Non-Survey Years Only 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS Direct 2SLS Probit 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.122*** -0.563** -0.365* -0.119*** -0.284*** 
 (0.012) (0.285) (0.188) (0.011) (0.009) 
Pregnant next year      
LARC use -0.075*** -0.587** -0.395** -0.074*** -0.080 
 (0.012) (0.278) (0.186) (0.012) (0.164) 
Birth next year      
LARC use -0.069*** -0.443* -0.246 -0.067*** -0.043 
 (0.011) (0.241) (0.156) (0.010) (0.203) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-period is 
2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while control group includes women ages 31-35. 
All models include indicators for if the woman is Black, Hispanic, married, sexually active, has less than a high school 
education and year and age controls. Standard errors are clustered on the woman-level. 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively 
N: 4,552 woman-years from 2,629 women  
F-stats for 2SLS first stage (column 2): 9.86 
a Average marginal effects 
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Table E.7 Instrumental Variables Results: The Effect of LARC Use on Pregnancies Using NSFG Weights 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS 2SLS 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.130*** -0.567* -0.468** -0.123*** -0.246*** 
 (0.014) (0.342) (0.204) (0.012) (0.033) 
Pregnant next year      
LARC use -0.062*** -0.821* -0.644*** -0.061*** -0.260*** 
 (0.022) (0.477) (0.240) (0.021) (0.014) 
Birth next year      
LARC use -0.066*** -0.551 -0.417* -0.063*** N/Ab 
 (0.016) (0.411) (0.217) (0.015)  
Weighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-period is 
2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while control group includes women ages 31-35. 
All models include indicators for if the woman is Black, Hispanic, married, sexually active, has less than a high school 
education and year and age controls. Standard errors are clustered on the woman-level. 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively 
N: 5,832 woman-years from 2,958 women (row 1) and 4,552 woman-years from 2,629 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 13.32 (row 1); 9.86 (row 2 and 3) 
a Average marginal effects 
b Bivariate probit results unavailable as model did not converge. 
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Table E.8 Instrumental Variables Results: The Effect of LARC Use on Pregnancies Including Income and Insurance 
Controls 
 
 (1) 
LARC use 
(2) 
LARC use 
(3) 
LARC use 
(4) 
LARC use 
(5) 
LARC use 
 OLS 2SLS 2SLS Probit a Bivariate probit a 
Pregnant this year      
LARC use -0.106*** -0.527** -0.376** -0.104*** -0.223*** 
 (0.010) (0.220) (0.162) (0.009) (0.044) 
Pregnant next year      
LARC use -0.075*** -0.552** -0.396** -0.073*** -0.037 
 (0.012) (0.261) (0.187) (0.012) (0.216) 
Birth next year      
LARC use -0.069*** -0.423* -0.258 -0.067*** -0.035 
 (0.011) (0.229) (0.160) (0.010) (0.204) 
Unweighted data from the 2006-2010, 2011-2013, 2013-2015 NSFG. Contraceptive users only with one child. Pre-period is 
2005-2009; post-period is 2010-2013. Treatment indicates women ages 21-27 while control group includes women ages 31-35. 
All models include indicators for if the woman used private insurance in the survey year, if the woman used public insurance 
in the survey year, and controls for her total income level. Each model also includes indicators of if the woman is Black, 
Hispanic, married, sexually active, has less than a high school education and year and age controls. Standard errors are 
clustered on the woman-level. 
*, **, and *** indicate significance at the 0.10, 0.05 and 0.01 levels, respectively. 
N: 5, woman-years from 2,958 women (row 1) and 4,552 woman-years from 2,629 women (rows 2 and 3)  
F-stats for 2SLS first stage (column 2): 3.93 (row 1); 3.60 (row 2 and 3) 
a Average marginal effects 
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APPENDIX F 
CHAPTER IV CONTRACEPTIVE ATTRIBUTES CONDITIONAL LOGISTIC 
REGRESSION RESULTS INCLUDING STERILIZATION ALTERNATIVES 
 
 
In my main analysis, I do not include women who choose to rely on sterilization 
(either male or female) as very few women choose sterilization during the 12 months 
when I observe them. However, as sterilization is a popular contraceptive option, I 
reestimate the results for the attributes specification allowing women to choose between 9 
contraceptive options: no method, female sterilization, male sterilization, the 
contraceptive implant, hormonal IUD, non-hormonal IUD, SARCs, condoms, or 
traditional methods.  
In Tables F.1 and F.2 I report the cost data and attributes data including 
information on sterilization outcomes. In Table F.3, I report the results of the attributes 
model including sterilization options. I also estimate the attribute specification among 
contracepting women only and report the results in F.4. In both tables, the utility of using 
a longer lasting method is negative. This may reflect how infrequently sterilization 
(which is much longer lasting that other methods) is chosen. The main effect of device is 
negative in both tables, though the coefficient on device is less negative in Table F.3. 
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Table F.1. Summary of Contraceptive Out-Of-Pocket Costs Including 
Sterilization Alternatives 
 
 
Uninsured  
($) 
Public  
($) 
Private 
(Pre-ACA)  
($) 
Private 
(Post-ACA) 
($) 
Female Sterilization 2912a 0h 582.4f 174.72f, g 
Implant 749.45a 0h 320.31c 91.01c 
Non-Hormonal IUD 718a 0h 262.38c 84.3c 
Hormonal IUD 844a 0h 262.38c 84.3c 
Male Sterilization 707.97a 0h 141.59f 141.59f, d 
SARC 52.81a 0h 16.37c, e 10.19c, e 
Condoms 9a, g 9a, g 9a, g 9a, g 
Traditional 0 0 0 0 
No Method 0 0 0 0 
a Source: Trussell et al (2010); Source: bTrussell et al. (2009). c  Source: Becker and Polsky (2015); the 
authors note that the out-of-pocket expenses reported from their data are sometimes women filling 2-3 
month prescriptions(Becker & Polsky, 2015), thus I have divided the amount reported by 2; the resulting 
number is in line with 2010 and 2013 estimates from Kim and Look (2018) (Kim & Look, 2018) ; d 
Expenses for 1 month of condoms, assuming couple purchases one 12-count box a month, or uses 9 
condoms a month at a price of $1 each as in Trussell et al. e Family planning expenses are generally 
covered by Medicaid; thus, I have assumed $0 out-of-pocket expenses for all methods other than 
condoms. However, there is variation by state in family planning coverage by state (Walls et al., 2016.). 
Since the NSFG does not release state identifiers in their public-use files, I cannot account for these 
state-by-state differences. f Using “Uninsured” price and assuming 20% co-insurance rate. f Assuming 
female sterilization experienced a similar percentage fall in price as LARCs (~ 70 percentage points). 
g Male sterilization is not covered by the ACA contraceptive mandate.  
 
 
Table F.2 Contraceptive Attribute Data Summary Including Sterilization 
Alternatives 
 
Alternative 
Price* 
($) Hormonal Device 
Reduction of 
Pregnancy 
Risk x 100 
Maximum 
Duration of 
Use (Years) 
Female Sterilization 0 - 2,912 No No 84.5 30 
Implant 0- 749.45 Yes Yes 84.95 3 
Non-Hormonal IUD 0 - 718 No Yes 84.2 10 
Hormonal IUD 0 - 844 Yes Yes 84.8 5 
Male Sterilization 0- 707.97 No No 84.85 30 
SARC 0 - 52.81 Yes No 76 0.083 
Condoms 9 No No 67 0.003 
Traditional 0 No No 62 0.003 
No Method 0 No No 0 0 
*Price varies by insurance status (see Table F.1) 
 
 
 
Table F.3 Contraceptive Attributes Conditional Logistic Regression Results with Attribute-Characteristic Interactions 
Including Sterilization Alternatives 
 
Attributes Birth Control 
Price 
Hormonal 
Method 
Device Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of 
Use 
 -0.114*** 1.364*** -0.733*** -1.531*** -0.114*** 
Interactions            (0.009)      (0.234)      (0.224)      (0.327)         (0.032) 
Age group      
    19-23  0.239** -0.0898 0.293* -0.0112 
       (0.105)      (0.120)      (0.161)         (0.011) 
     29-33  -0.0986 -0.189* -0.375*** 0.000769 
       (0.100)      (0.106)      (0.143)         (0.008) 
     34-38  -0.116 -0.270** -0.859*** 0.00553 
       (0.114)      (0.127)      (0.159)         (0.010) 
     39-44  -0.340*** -0.233* -1.239*** 0.0111 
       (0.129)      (0.139)      (0.174)         (0.011) 
Black  -0.13 -0.298*** -0.325*** -0.0281*** 
       (0.090)      (0.105)      (0.125)         (0.009) 
Hispanic  -0.362*** 0.397*** -0.0364 0.00138 
       (0.089)      (0.093)      (0.123)         (0.007) 
Married  -0.511*** 0.267*** 0.168 -0.0118* 
       (0.083)      (0.093)      (0.114)         (0.007) 
Income  0.0320** 0.0441*** 0.0397** 0.00247** 
       (0.013)      (0.015)      (0.019)         (0.001) 
Working  0.217*** 0.320*** -0.00985 0.0174*** 
       (0.078)      (0.090)      (0.109)         (0.007) 
Greater than 
HS 
 
0.071 0.107 0.419*** 0.0179** 
       (0.083)      (0.096)      (0.118)         (0.008) 
One child  -0.246*** 0.617*** -0.00503 0.0139 
       (0.094)      (0.110)      (0.132)         (0.009) 
Two children  -0.344*** 0.791*** 0.333** 0.0235** 
       (0.103)      (0.120)      (0.149)         (0.009) 
Three children  -0.433*** 0.798*** 0.17 0.0285*** 
       (0.127)      (0.144)      (0.175)         (0.011) 
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Table F.3 Continued 
    
Limiting 
fertility 
 
0.0931 0.11 0.782*** 0.0184*** 
       (0.085)      (0.090)      (0.125)         (0.006) 
Condition  0.137 0.0995 -0.823*** 0.00822 
       (0.094)      (0.107)      (0.127)         (0.010) 
Usual Care  0.412*** -0.137 -0.0843 0.00373 
       (0.096)      (0.116)      (0.128)         (0.010) 
Metropolitan 
Area 
 
-0.499*** 0.239** 0.388** -0.00251 
       (0.113)      (0.120)      (0.161)         (0.009) 
Suburban Area  -0.407*** 0.172 0.324** 0.00401 
       (0.111)      (0.117)      (0.159)         (0.009) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,509 between the ages of 19 
and 44 who are not currently pregnant, not relying on sterilization as of 12 months before survey date, 
have been sexually active at least 3 of the past 12 months, and have had private or public insurance or 
have been uninsured for the past 12 months. GTHS indicates woman has greater than a high school 
education, condition indicates woman has a condition that may benefit from hormonal contraception. 
Includes set of year controls. Base category for age is 24-28, and zero for number of children. Standard 
errors (clustered at woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010                                          
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Table F.4 Contraceptive Attributes Conditional Logistic Regression Results with 
Attribute-Characteristic Interactions Among Women Using Contraception Including Sterilization Alternatives 
 
Attributes Birth Control 
Price 
Hormonal 
Method 
Device Reduction in 
Risk of 
Pregnancy 
Maximum 
Duration of 
Use 
 -0.122*** -1.052** -2.596*** 21.80*** -0.268*** 
Interactions            (0.011)      (0.531)      (0.397)      (4.553)         (0.049) 
Age group      
    19-23  -0.124 -0.26 3.932 -0.0464* 
       (0.271)      (0.235)      (2.508)         (0.026) 
     29-33  -0.218 -0.299 0.74 -0.00555 
       (0.238)      (0.209)      (2.177)         (0.019) 
     34-38  -0.376 -0.483* 1.598 -0.00991 
       (0.274)      (0.248)      (2.497)         (0.022) 
     39-44  -0.255 -0.213 -2.502 0.0207 
       (0.307)      (0.271)      (2.764)         (0.024) 
Black  -0.572*** -0.622*** 3.847* -0.0651*** 
       (0.221)      (0.199)      (2.041)         (0.021) 
Hispanic  -0.790*** -0.111 5.326*** -0.0375** 
       (0.205)      (0.189)      (1.919)         (0.017) 
Married  -0.131 0.482*** -3.613** 0.00651 
       (0.199)      (0.179)      (1.815)         (0.016) 
Income  0.0693** 0.0716** -0.357 0.00525** 
       (0.032)      (0.028)      (0.290)         (0.003) 
Working  0.766*** 0.756*** -5.610*** 0.0619*** 
       (0.188)      (0.173)      (1.735)         (0.016) 
Greater than 
HS 
 
-0.0411 0.00765 1.703 0.012 
       (0.206)      (0.183)      (1.879)         (0.017) 
One child  0.870*** 1.306*** -10.26*** 0.0949*** 
       (0.240)      (0.210)      (2.186)         (0.020) 
Two children  0.879*** 1.488*** -10.36*** 0.111*** 
       (0.253)      (0.228)      (2.314)         (0.022) 
Three children  0.932*** 1.559*** -11.75*** 0.127*** 
       (0.299)      (0.273)      (2.714)         (0.025) 205 
 
 
 
Table F.4 Continued 
    
Limiting 
fertility 
 
0.0782 0.0414 1.672 0.0181 
       (0.199)      (0.178)      (1.809)         (0.015) 
Condition  0.756*** 0.566*** -7.089*** 0.0536*** 
       (0.235)      (0.201)      (2.079)         (0.019) 
Usual Care  -0.0754 -0.460** 5.006** -0.0339* 
       (0.222)      (0.208)      (2.018)         (0.019) 
Metropolitan 
Area 
 
0.25 0.732*** -6.905*** 0.0500** 
       (0.286)      (0.251)      (2.678)         (0.023) 
Suburban Area  0.407 0.723*** -7.697*** 0.0648*** 
       (0.283)      (0.247)      (2.652)         (0.022) 
Unweighted data from 2011-2013, 2013-2015 and 2015-2017 NSFG. N = 7,509 between the ages of 19 and 
44 who are not currently pregnant, not relying on sterilization as of 12 months before survey date, have been 
sexually active at least 3 of the past 12 months, and have had private or public insurance or have been 
uninsured for the past 12 months. GTHS indicates woman has greater than a high school education, 
condition indicates woman has a condition that may benefit from hormonal contraception. Includes set of 
year controls. Base category for age is 24-28, and zero for number of children. Standard errors (clustered at 
woman-level) are in parentheses.  
* p<0.10, ** p<0.05, *** p<0.010 
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